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Abstract 
Mitochondria are of increasing interest in pharmaceutical and medical research since it has 
been reported that dysfunction of these organelles contributes to several diseases with a 
great diversity of clinical appearance. By the fact that mitochondria are located inside the cell 
and, in turn, origins of mitochondrial diseases or targets of drugs are located inside 
mitochondria, a drug molecule has to cross several barriers. This is a severe drawback for 
the selective accumulation of drug molecules in mitochondria. Therefore, targeting strategies 
such as direct drug modification or encapsulation into nanocarriers have to be applied to 
achieve an accumulation of drug molecules in these organelles. In this review, it will be 
demonstrated how properties and dysfunctions of mitochondria are generating a need for the 
development of mitochondria specific therapies. Furthermore, intracellular targets of 
mitochondrial diseases, strategies to utilize mitochondrial specificities and targeting 
approaches will be discussed. Finally, techniques to investigate mitochondrial characteristics 
and functionality are reviewed.    
 
Graphical abstract 
 
Mitochondria are important for cellular functionality but they are also involved in diseases. Therefore, they are of 
increasing interest in targeted drug therapy. 
 
Key words 
intracellular targeting; mitochondria; drug delivery; targeting strategies; nanocarriers; 
mitochondrial diseases  
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Introduction 
Mitochondria are intriguing cellular organelles that exhibit numerous structural and functional 
specificities. They are highly mobile and so are able to distribute the energy that they 
produce throughout the cell [1]. The production of energy is essential for the maintenance of 
the functionality of all important cellular processes [2]. In contrast to that, dysfunctions of 
mitochondria cause disorders. These mitochondrial dysfunctions are mainly related to 
degenerative diseases affecting tissues that are highly energy dependent on the one hand 
[3] or malignant diseases on the other hand [4].  
It is challenging to treat the cause of a disorder if it is located inside mitochondria, including 
changes of mitochondrial DNA, mitochondrial proteins or metabolic pathways. Although 
several substances are known to act on mitochondria [5–7], it is necessary to utilize and 
develop specific strategies to target them selectively to mitochondria, as this is their site of 
action. 
In general, the physicochemical properties of a drug substance may not be appropriate to 
overcome biochemical, anatomical or immunological barriers to reach its target [8]. If the 
target of a substance is located inside of an intracellular compartment such as a 
mitochondrion, the drug molecule has to penetrate several membranes to find its final 
destination. The molecule would require very specific physicochemical properties to cross 
the different barriers. Changing the physicochemical properties of drug molecules is one 
approach toward overcoming these limitations. D’Souza et al. commented in their review 
about mitochondria-targeted processes to cancer therapy [9]. They distinguish two processes 
of targeting in drug therapy: On the one hand the selective interaction between the drug 
molecule and its target and on the other hand the accumulation of a drug due to its 
physicochemical properties. Thereby, it can well be that a drug could exert a potent 
therapeutic effect upon binding to its molecular target but does not exhibit the necessary 
physicochemical properties to find its way to it. With the help of delivery strategies and 
delivery technology, such drugs could be better distributed to their site of action [9]. It is thus 
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possible that the application of targeting strategies could provide us with new applications for 
the use of well-established drugs.  
Over the years, the fields of prodrugs and drug carriers as strategies toward site specific 
drug delivery have also evolved. There is a number of examples that drugs can be changed 
to prodrugs with superior physicochemical properties which allow for better site specific 
delivery. These molecules are then transformed into the active entity at their site of action 
[10,11]. However, modifications of low molecular weight drug substances to achieve a higher 
accumulation at their targeted site may also lead to a loss of activity [12].  
The idea to synthesize drug carriers that transport the drug molecule to the desired target 
site evolved more than over 30 years ago. Targeting of a drug substance means to trade the 
physicochemical properties of drug molecules against that of a carrier to obtain other 
physicochemical properties that allow for the specific accumulation at the target site. 
Ringsdorf developed a model for a carrier system that comprises several features. It is based 
on a polymer that contains different units to influence solubility, to bind a pharmacologically 
active drug and a transport system that delivers this macromolecule specifically to its site of 
action by recognizing specific features at the target site (Figure 1.1) [12].  
 
Figure 1.1: Concept of a model drug carrier system according to Ringsdorf [12]. 
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The use of polymers as drug carriers was one of the first approaches toward targeted drug 
delivery. Over the years, several other drug carriers such as liposomes [13,14], nanoparticles 
[15,16], and modified polymers such as dendrimers [15,16], polymeric micelles [15–17] or 
polyplexes  [18]  followed. Also today, an increasing number of multifunctional nanocarriers 
that unite targeting, sensing, signaling and drug release properties are emerging [8]. 
However, the traditional blue print of these carriers suffers from a number of disadvantages. 
Considering that several barriers may need to be crossed to reach the final site, it may not be 
sufficient that a carrier system contains only one transport and recognition unit according to 
the genuine approach by Ringsdorf [12]. Such carrier systems may require several molecular 
transport and recognition motifs that need to become active, depending on the barrier to be 
crossed. The more barriers to be overcome, the more transport and recognition moieties 
would be required, acting one after the other depending on the next type of barrier to be 
crossed. It is obvious that such a carrier system has a high level of complexity and is, 
therefore, not easy to develop at all. It also has to be considered that drug carrier systems 
will undergo the same transformation reactions in the body as low molecular weight 
substances and that these reactions could change the physicochemical properties and hence 
the targeting properties of the nanocarriers [8]. If the first targeting moiety is inactivated, for 
example due to protein adsorption in the blood [8], all subsequent transport and recognition 
systems will fail, and the drug molecule will not be delivered to its targeted site of action. 
In summary, strategies toward targeting are on the one hand highly promising since adverse 
physicochemical drug properties can be compensated but are on the other hand not simple 
to realize. This is also true for targeting drugs to mitochondria. Therefore, targeting strategies 
in drug delivery that have evolved over the years will be reviewed in the following chapter. 
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General targeting strategies in medical and pharmaceutical research 
Advantages of drug targeting 
Targeted drug delivery systems may facilitate a better therapeutic outcome as they are 
supposed to overcome limitations of conventional drug application such as unfavorable 
biodistribution, low bioavailability, lack of water solubility, low therapeutic response despite 
high dosages, side effects, drug resistance, toxicity and barriers in the body such as the 
blood brain barrier [19,20]. Various targeting approaches for the therapy of cancer [21], 
neurodegenerative diseases e.g. Alzheimer’s disease [22], infectious diseases e.g. 
tuberculosis [23], autoimmune diseases [24] and several other disorders were reported. 
Thereby, numerous definitions of “targeting” exist in several areas of research. An overview 
will show how versatile the use of the term targeting is.  
 
Active and passive targeting 
At first, active and passive targeting can be distinguished. Active targeting is defined as the 
specific recognition of a molecular structure by a target. Passive targeting describes the 
recognition of a molecule by the reticuloendothelial system (RES or mononuclear phagocyte 
system) [25] or makes use of the enhanced permeability and retention effect (EPR-effect) in 
tumor tissue [26]. Passive targeting is achieved when a drug carrier is administered 
systemically into the blood circulation and gets trapped inside the body on the tissue level 
mainly based on its size. In fact, it is not feasible to reach targets inside cells like 
mitochondria by passive targeting [27]. Hence, active targeting strategies such as the 
recognition by receptors on the surface of the cell [28] and subsequently the targeting of 
specific structures inside the cell or on intracellular organelles are required to deliver a 
molecule to its site of action. Active strategies to accomplish an uptake into the cell are 
mainly studied in cell culture [29–31]. The question remains whether these systems can 
achieve the same outcome when they are administered in vivo. 
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As only active targeting is a reasonable strategy to reach mitochondria, passive targeting will 
not be considered in more detail, but rather the uptake into the cell as well as approaches to 
intracellular delivery.   
 
Therapy and diagnostics 
Beside the therapeutic approach, targeting is also used in diagnostics [32]. Some 
approaches combine targeted drug therapy and diagnostics, termed theragnostics or 
theranostics [33]. Thereby, a diagnostic test that is linked to the application of a specific 
targeted therapy is supposed to identify responding and non-responding patients [33].   
 
Chemical modification of drugs and encapsulation into nanocarriers 
In approaches toward targeting, the chemical modification of a drug or the encapsulation into 
a drug carrier can be distinguished and will be described in more detail below.  
The term “targeting” is used to describe a molecule to which ligands are covalently bound. 
These ligands such as antibodies [34] or peptides [35] are known to actively bind to a desired 
target site. Besides this, pure specific antibodies without modification, for which an antigen 
exhibits a target, are considered targeted therapeutics [36]. It has to be considered that 
chemical modifications affect the physicochemical properties of the drugs and may also 
change their pharmacokinetic and pharmacodynamic behavior.  
Alternatively, the term “targeting” is used in the context of nanocarriers including liposomes 
[13], micelles, nanoparticles or dendrimers for the delivery of drug molecules or nucleic acids 
[15,16]. Liposomes are capable of hosting water soluble drugs in their core or lipophilic drugs 
in their membrane layers. Micelles are mainly used for the delivery of poorly soluble drugs 
[14]. An advantage of carriers over chemically modified drugs is that molecules can be 
encapsulated without changing their molecular structure. Thus, only alterations in 
pharmacokinetics but not in pharmacodynamics of the respective drug are to be expected. 
Such nano-sized delivery systems are used to transport low molecular weight substances, 
peptides, proteins, DNA or siRNA [37–40]. They can be additionally functionalized with 
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antibodies or receptor specific ligands that recognize a target. Nanocarriers and low 
molecular weight substances can also be modified by polymers such as polyethylene glycol 
which is widely used to prolong the blood circulation time. Pharmaceutical nanocarriers are 
used to increase the stability of the administered drug, to protect it from degradation or 
inactivation, to improve efficacy and to decrease undesired side effects [8,14]. Another 
advantage is that they allow for the sustained release of drugs which can improve therapy 
and compliance. In case of applying a drug without a drug carrier, active control of tissue 
distribution, uptake into cells and intracellular trafficking may not be sufficient to exhibit a 
therapeutic activity [41]. 
 
“Targeting” specified 
To specify a scientific or therapeutic approach, targeting is very often defined more precisely 
by adding a second term which describes a disease (e.g. cancer), an organ or tissue (e.g. 
brain) or a structure on the molecular or cellular level (e.g. proteins, genes, receptors and 
organelles). The latter also involves intracellular targeting which the following will focus on. 
Nature offers a prominent example for this, a virus which is taken up by selected cells via 
endocytosis. They release their genome into the cytosol and are able to target their DNA to 
the nucleus as an organelle. This is an excellent example of intracellular targeting.  
 
Intracellular targeting – interpretations of the term, motivation and challenges 
Most approaches of intracellular delivery focus on crossing the cellular membrane without 
defining a specific intracellular target or controlling the distribution of the drug inside the cell 
[17,42,43]. In many cases, delivery into the cytosol is hoped to be sufficient, and it is 
assumed that the drug molecule will find its final subcellular target by simple diffusion and 
interaction with various structures of the cell. While this may be appropriate for siRNA 
therapy, an increasing body of evidence has emerged indicating that these simple 
mechanisms are not sufficient for the majority of targeted drug delivery approaches [17]. It is 
possible that the dysfunction of a molecular structure which is located inside of an organelle 
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contributes to a disease and therefore exhibits a target. It is also known that many drugs act 
on a subcellular localization. Considering this, it is desirable not only to target specific organs 
or cells but also to efficiently deliver drugs to inner cell compartments and to define this 
intracellular target specifically. An example is paclitaxel, which directly acts on mitochondria, 
triggering apoptosis. Mitochondria play a key role in this process [44] but the capacity to 
induce apoptosis is frequently deficient in cancer cells [45]. Hence, mitochondria exhibit a 
target for disease and drug action. Other intracellular compartments that can be focused on 
include mRNA in the cytosol, transgene induction in the nucleus, stimulation or inhibition of 
apoptosis in mitochondria and in the cytosol, modulation of protein synthesis in the 
endoplasmic reticulum and Golgi apparatus, certain types of enzyme replacement therapies 
in endosomes and lysosomes for the therapy of lysosomal storage diseases [46].  
Nevertheless, targeting of organelles is extremely challenging as barriers for instance the cell 
membrane and membrane(s) of organelles have to be penetrated, if the target is located in 
intracellular compartments. In addition, it is essential to locate intracellular disease related 
targets, to determine drugs which can act on these targets and to develop suitable methods 
for the detection of subcellular accumulation. 
It is also conceivable to exploit advantages of nanocarriers for intracellular targeting. Such 
drug delivery systems can be conjugated with organelle specific targeting moieties to deliver 
an encapsulated drug to a desired subcellular compartment. Targeting moieties for this 
purpose included peptide sequences that can be recognized by the endoplasmatic reticulum, 
the nucleus or mitochondria as well as non-peptide molecules that interact with membranes 
of organelles, in particular mitochondria [47,48]. Considering the challenges that affect 
intracellular targeting, a major limiting step of nanocarries for intracellular delivery is to 
escape from endosomes after endocystosis. A drug delivery system decorated with targeting 
moieties will not be able to target a drug to an organelle of interest if it resides inside an 
endosome and is not released into the cytosol. Only a small fraction of endosomes degrade 
spontaneously while the majority of endocytosed material is degraded and not able to reach 
the cytosol and subsequently the target organelle. Hence, even the delivery into the cytosol 
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comprises not only the step of cell membrane transfer. Another limitation of intracellular 
targeting that affects targeting efficiency, is dependent on processes such as the mobility of 
the system in the cytosol because of the high concentrations of dissolved macromolecules 
which limit diffusion, the rate of degradation in the cytosol and the rate of uptake into the 
targeted organelle [17,48]. Therefore, targeting of organelles with nanocarriers is a multi-step 
process, exhibiting numerous barriers that have to be crossed. Despite all these obstacles, it 
should become a major goal to develop drug delivery systems which reach subcellular 
targets specifically to make therapy more efficient and to minimize non-specific side effects.  
 
Targeting drugs to mitochondria – motivation and definitions 
Mitochondrial dysfunctions contribute to several diseases that will be considered later in this 
review, and reaching mitochondrial targets is challenging due to several specifics that will 
also be reflected in subsequent sections. This review will focus on mitochondria as 
intracellular targets and specific, active targeting strategies toward mitochondria. Thereby, 
the term “targeting” will be used to describe the specific, active delivery of drug molecules or 
drug carriers to the intracellular mitochondrial targets, accomplished by low molecular weight 
molecules, peptides or nanocarriers with a specific “affinity” to mitochondria. The term 
“target” will be used as synonym for the specific site of action of drug molecules, 
mitochondrial metabolic processes and mitochondria, respectively. “Intracellular targeting” 
will be used in order to describe strategies that overcome intracellular barriers such as 
mitochondrial membranes to reach a target inside mitochondria. 
 
Mitochondria: functions and properties of a potential target 
Before considering mitochondria in relation to diseases, drug therapy and drug targeting, 
important mitochondrial characteristics and functions are outlined in the following section to 
provide pertinent insights into this fascinating organelle.  
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Mitochondrial morphology 
Mitochondria exhibit some unique ultrastructural features (Figure 1.2) that differ from other 
organelles as they are enclosed by a double membrane with an unusual lipid composition 
[49]. The inner membrane is folded into cristae in order to increase the surface area [50], 
they have a high membrane potential of 180–200 mV [14,51] and contain their own genome 
that offers specific characteristics compared to the nuclear genome [50]. The facts, that 
mitochondria are self-replicating organelles, that they have a lipid composition which is 
similar to those found in prokaryotes, and that they contain their own DNA and protein 
synthesis machinery, led to the endosymbiotic hypothesis in the evolution of mitochondria. 
According to this theory, prokaryotes have been taken up by eukaryotes to form a symbiotic 
association. Even though this theory is well recognized, and mitochondria and prokaryotes 
actually share many common features, it is still controversially discussed whether or not 
mitochondria are indeed originally derived from endosymbiotic prokaryotes [52–54]. 
 
Figure 1.2: Ultrastructure of mitochondria; mitochondrial DNA (mtDNA). 
 
Mitochondria reside in all eukaryotic cells, but the abundance per individual cell depends on 
the specific energy requirements of the cell and varies dependent on cell type, cell-cycle 
stage, proliferative state and dysfunction in diseases [55]. Metabolically active organs such 
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as liver, brain, cardiac and skeletal muscle tissues contain up to several thousands of 
mitochondria per cell while somatic tissues with low energy demands contain only a few 
dozen mitochondria [56]. Human oocytes contain up to 100,000 mitochondria while 
spermatozoa have a constant number of 16 mitochondria which are located in the tail that is 
cleaved and degraded after fertilization [56]. This phenomenon causes maternal inheritance 
of these organelles [57]. Mitochondria cannot be formed de novo. During the processes of 
growth and division of preexisting mitochondria, newly synthesized components such as 
lipids and proteins have to be introduced into preformed structures [58]. 
The traditional view on mitochondria as round shaped organelles that produce and supply 
energy (ATP) has changed [59] since it appeared that they form a network via dynamic 
processes like fusion and fission, and active transport along microtubules and actin filaments 
mediated by myosin, dyneins and kinesins to subcellular localization [1,60]. Mitochondrial 
transport is required to distribute mitochondria throughout the cell. While they move along the 
cytoskeleton, they can encounter each other and undergo fusion (Figure 1.3), mediated by 
GTP-dependent fusion proteins in the mitochondrial membranes [61], resulting in the 
exchange of mitochondrial content. Therefore, mitochondria should not be considered 
autonomous and static organelles. Shape, length, size and number of mitochondria in a cell 
are highly variable and can range from small, individual spheres, short rods to long tubules 
and complex, interconnected, network like structures [50]. Fusion is a protective mechanism 
that allows mitochondria to tolerate high levels of pathogenic mitochondrial DNA (mtDNA) 
and is necessary to maintain mtDNA stability and mitochondrial function [62]. 
 
Figure 1.3: Mitochondrial fusion mediated by mitochondrial fusion proteins. 
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Mitochondrial functionality 
Besides the morphological diversity, mitochondria play an essential role in maintaining 
cellular homeostasis. They exhibit various important functions and metabolic pathways 
(Figure 1.4) including calcium homeostasis and signaling, thermogenesis, gluconeogenesis, 
the citric acid cycle, the β-oxidation of fatty acids, the synthesis of heme, amino acids, steroid 
hormones and Fe-S-clusters, the urea cycle, and the electron transport chain and oxidative 
phosphorylation (OXPHOS) that end in the production of ATP [2].  
 
Figure 1.4: Mitochondrial functions and metabolic pathways. 
 
ATP-synthesis is important for all cellular processes but also generates reactive oxygen 
species (ROS) as byproducts. Early publications suggest that about 2–5 % of oxygen is 
metabolized into the highly reactive superoxide anion and other radicals [2] whereas more 
recent studies provide evidence that mitochondria produce one or two orders lower amounts 
of ROS under normal physiological conditions [63]. Besides this, it is known that an 
increased calcium influx in mitochondria can lead to the production of reactive oxygen 
species [64]. ROS play a significant role in the regulation of cell-signaling processes, in 
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cytoprotection and thus are needed for the survival of the cell [2]. But they are also related to 
pathological processes when produced in excess. There are mitochondrial and cytosolic 
enzymes that scavenge ROS [59] as well as non-enzymatic antioxidants, such as glutathione 
(GSH), vitamin E, vitamin C and ubiquinone to limit the cytotoxicity of reactive oxygen 
species [63]. But when these cellular antioxidants are depleted, lipid peroxidation, mtDNA 
damage, OXPHOS dysfunction and damage of Fe-S-containing enzymes occur. The critical 
limit for the positive and necessary effects of ROS is yet not known, and excessive oxidative 
stress to nuclear or mitochondrial DNA can cause cellular and mitochondrial dysfunction, 
mutagenesis and carcinogenesis [2]. These negative and potentially damaging effects of 
ROS were originally described in the “free radical theory” over 50 years ago. This theory 
suggested that aging and neurodegenerative diseases could be attributed to the effects of 
free radicals [65]. Besides the implication in neurodegenerative diseases, it is nowadays 
discussed that oxidative stress is also related to atherosclerosis, pulmonary fibrosis and 
cancer [66]. The causes and effects of ROS and ROS related diseases are summarized in 
Figure 1.5. 
Even though mitochondria contain their own genome, the vast majority of mitochondrial 
proteins are encoded by the nuclear DNA (nDNA). They are synthesized in the cytosol and 
imported into mitochondria via translocase protein import complexes, the translocase of the 
outer mitochondrial membrane (TOM-complex) and the translocase of the inner 
mitochondrial membrane (TIM-complex). These protein import pores recognize specific, 
positively charged amino-terminal or internal mitochondrial targeting sequences that are also 
often termed MLS (mitochondrial localization or leading sequence). MLS are short peptide 
sequences attached to the protein and cleaved after translocation into the mitochondrial 
matrix or mitochondrial membranes [67]. Mitochondrial DNA itself encodes only 13 of the 
more than 1000 mitochondrial proteins. All of them are proteins of the respiratory chain [67–
69].  
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Figure 1.5: Causes and effects of reactive oxygen species (ROS) and ROS related disorders; mitochondrial DNA 
(mtDNA). 
 
There are some differences between mitochondrial and nuclear DNA. The mitochondrial 
genetic code differs in four codons from the universal code [70]. Compared to the nuclear 
genome, mitochondrial DNA lacks histone protection, has no introns and only a weak repair 
capacity. This in combination with the fact that ROS are generated in mitochondria makes 
mitochondrial DNA prone to mutations [71]. The fusion and fission machinery allows for the 
exchange of mutated and wild-type mitochondrial DNA. Mitochondrial DNA copies are 
organized in protein-associated nucleoids that are motile and can interact with each other. 
Thereby, recombination of mtDNA has been documented [50]. The exchange of mutated and 
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wild-type mtDNA as well as recombination prevents the crossing of a critical threshold before 
a cell expresses a mitochondrial defect. Cells are able to tolerate 70–90 % mutated mtDNA, 
the so-called “threshold-effect”. The precise value varies from mutation to mutation and from 
tissue to tissue [3]. But if mutations exceed the critical limit, defects appear even 
phenotypically [72].  
In summary, mitochondrial genetics differ from Mendelian genetics comprising of maternal 
inheritance, heteroplasmy, the threshold effect and mitotic segregation. Mitochondrial DNA is 
only inherited maternally because sperm mtDNA is degraded after fertilization. Molecules of 
mtDNA exist in hundreds or thousands of copies in each cell (polyploid), whereas nuclear 
genes consist of only one maternal and one paternal allele (diploid). Mutations of mtDNA 
often do not affect all molecules, and thus, cells may harbor wild-type and mutant mtDNA, an 
effect called heteroplasmy. A critical number of mutant mtDNA copies must be present 
before dysfunctions appear phenotypically, termed threshold-effect. The phenomenon mitotic 
segregation explains the manifestation of different mitochondrial diseases at different stages 
of patient’s lives: the proportion of mutant mtDNAs in daughter cells can shift which means if 
the pathogenic threshold is crossed, the phenotype may also change [57,73]. 
Mitochondria also play a crucial role in the viability of a cell. Various cases of apoptosis are 
initiated by mitochondria via formation of the mitochondrial permeability transition pore 
complex (mPTPC) in response to energy deficiency, oxidative stress, increased calcium and 
other stimuli [2,63]. Apoptosis depends on the release of apoptotic proteins from 
mitochondria, the disruption of ATP-synthesis and the modification of the cellular redox 
potential [59]. It is also known that mitochondrial fission plays an important role in apoptosis 
and can be the onset of the programmed cell death [61]. The mechanisms of all processes 
that result in apoptosis are not completely understood yet [59].  
Last but not least, a particular mitochondrial protein species, so-called sirtuins show 
intriguing activities. Sirtuins or silent information regulator (Sir) proteins act as key metabolic 
sensors that directly link environmental signals, such as calorie restriction or cellular stress to 
metabolic homeostasis and stress response [74]. The field of sirtuin research is quite young, 
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but it emerges that they play a pivotal role in mitochondrial functionality. A total of seven 
sirtuins in mammalian cells have been identified. They are localized in diverse cellular 
compartments, three of them can be found in the nucleus, one is located in the cytosol and 
another three ones are located in mitochondria. Sirtuins possess a NAD+-dependent 
enzymatic activity, catalyzing histone deacetylation and ADP-ribosylation reactions, and 
targeting multiple substrates. Metabolites of these reactions may be important regulators in 
physiology. Sirtuins are also involved in various cellular functions, such as metabolism, cell 
cycle, cell survival, thermogenesis and insulin secretion. They are able to extend replicative 
lifespan through the delay of mitosis in model organisms like flies, worms and yeast. To this 
date, it is not clear whether the data gathered regarding the life span of these organisms can 
be transferred to mammalian organisms. Nevertheless, it is also known that sirtuins enable 
DNA repair, are involved in chromosome fidelity during meiosis and generally have positive 
and protective effects in the cell [75]. Several studies revealed a direct linkage between 
nutrition and activity of sirtuins. The activity of sirtuins is upregulated under calorie restriction 
and fasting conditions. Calorie restriction also has an increasing effect on mitochondrial 
function, and it induces the endothelial nitric oxide synthase that results in the activation of 
mitochondrial biogenesis. Moreover, stress treatments such as heat shock or oxidative 
damage cause increased sirtuin activity [52,75]. 
The mitochondrial localization of sirtuins is particularly intriguing because mitochondrial 
dysfunction is related to aging and diseases. An overexpression of mitochondrial sirtuins 
increases respiration, while it decreases the production of reactive oxygen species. 
Furthermore, they affect mitochondrial metabolism, comprising of the citric acid cycle and the 
synthesis of cholesterol and fatty acids. Sirtuins also regulate the amino-acid stimulated 
insulin secretion in pancreatic cells [75]. 
Nuclear sirtuins are considered to act as guardians against cellular oxidative stress and DNA 
damage. Therefore, they also have an impact on mitochondrial functionality. Nuclear sirtuins 
regulate physiological and metabolic processes, like insulin secretion, lipolysis, 
gluconeogenesis, DNA repair and growth via promotion of rRNA transcription. They are 
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linked to neuronal survival, protection against neurodegenerative disorders such as 
Alzheimer’s disease or Parkinson’s disease. In case of neuronal protection, they may act as 
antiapoptotic factors through the down regulation of proapoptotic factors. Nuclear sirtuins 
also repress transcription of mitochondrial uncoupling proteins. These uncoupling proteins 
separate mitochondrial respiration from ATP-production and reduce the proton gradient 
across the mitochondrial membrane. By preventing this process, sirtuins promote a more 
efficient energy production [75]. Intracellular levels of ATP are a determinant for apoptosis 
[76]. 
The functionality of mitochondria determines cell life, cell death and cellular dysfunction [2]. 
Therefore, all described features of mitochondria should not be considered independently. In 
fact, they are closely linked, and an alteration in one function can cause a change of another 
function or may start a viscous cycle. For example, calcium homeostasis is connected to 
increased ATP-production followed by the activation of calcium sensitive citric acid cycle 
enzymes, ROS production, opening of the mitochondrial transition pore and loss of 
membrane potential which causes apoptosis [5,63,77]. Increased ROS-production can also 
be generated as a byproduct of the electron transport chain and ATP-production as well as 
by the dysfunction of these processes. Excessive ROS-production causes mtDNA damage, 
mitochondrial dysfunction and in turn apoptosis. An imbalance in fusion and fission leads to 
mitochondrial dysfunction, fragmentation, increased production of ROS and ATP, followed by 
a decreased membrane potential that can be the starting point of apoptosis [63]. Controlled 
activity of these processes such as the production of reactive oxygen species, calcium 
uptake, apoptosis and thermogenesis serves as protective mechanisms against infection and 
other damages to the cell. Overshooting or alterations of these processes and the resulting 
dysfunctions of mitochondria are related to aging, senescence and disorders [2,77] that will 
be reflected in more detail as follows. 
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Mitochondrial dysfunction and related disorders 
By convention, mitochondrial diseases include any disorders that are related to defects or 
absence of proteins that are localized in mitochondria, independent from their gene locus 
(nuclear or mitochondrial DNA, mitochondrial tRNAs or rRNAs) [73]. A minimum of about 1 in 
8500 individuals is affected by such a disorder [78]. 
Dysfunctions caused by mutations of nuclear or mitochondrial DNA, inherited or not, mainly 
affect proteins of the respiratory chain and consequently energy production. This can lead to 
severe diseases. The group of mitochondrial diseases is highly heterogeneous and includes 
various clinical appearances [73]. Although mitochondrial function is essential for all cells, 
mitochondrial disorders do not affect every tissue in the body, tissues and organs that are 
highly dependent on energy are primarily impaired [3]. Such disorders often exhibit 
myopathic (“ragged-red fibers”) and neurological characteristics [73,79] comprising of ataxia, 
seizures, stroke-like episodes, dementia, muscle weakness, sensory neuropathy and 
developmental delay [78,80]. Deafness, exercise intolerance, cardiomyopathy, optic atrophy, 
lactic acidosis and diabetes mellitus are also well-recognized common clinical phenotypes of 
mitochondrial diseases [78]. A recent study reported on an inherited mitochondrial disease 
that causes dysfunction of the mitochondrial lipid metabolism and disturbance of the lipid 
membranes. The study concluded that this, in turn, impairs mitochondrial energy production 
and leads to cardiomyopathy, myopathy and lactic acidosis in the phenotypical appearance, 
mostly without neurological manifestation [81]. Additionally, it is also possible that different 
mutations have the same clinical phenotype and that the same genetic defect can cause very 
different clinical phenotypes. Some disorders only affect a single organ, whereas others 
involve multiple organ systems [3]. Mitochondrial disorders may develop at any age. Until 
recently, it was generally thought that nuclear DNA abnormalities appear in childhood and 
mtDNA abnormalities (primary or secondary to a nuclear DNA abnormality) appear in late 
childhood, or adult life. Recent advances have shown that many mtDNA disorders appear in 
childhood, and many nuclear genetic mitochondrial disorders appear in adult life [78]. 
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However, disorders, affecting nuclear DNA, often show severe clinical phenotypes that are 
rapidly progressive, leading to neonatal or infantile death [68]. 
The transport of mitochondrial proteins that are synthesized in the cytosol and contain 
specific targeting sequences requires an import machinery consisting of docking proteins, 
chaperonins that are a class of molecules belonging to chaperones, translocases and 
proteases to translocate the protein to the right compartment of the mitochondrion and also 
involves unfolding and refolding processes. Several mutations in targeting sequences have 
been documented to prevent proteins from being translocated to their desired destination 
leading to defects related to the function of the protein or the associated protein complex. 
Only a few genetic defects are known to date that affect the general import machinery 
because this would impair mitochondrial function severely and would not be compatible with 
life. At least two disorders have been associated with mutations in components of the 
transport machinery resulting in neurological and deafness syndromes [73]. 
The dynamic processes fusion and fission are essential for mammalian development and 
defects in mitochondrial dynamics cause diseases [50]. The morphology of mitochondria 
depends on the balance between fusion and fission. Unbalanced fission leads to 
fragmentation, whereas unbalanced fusion leads to elongation. In normal development, the 
control of these processes can change the shape of mitochondria to suit a particular 
developmental or bioenergetic function [61]. In cells that lack fusion proteins or that have 
defective fusion proteins, mitochondrial function is impaired. Mitochondria become 
autonomous and cannot exchange mtDNA or proteins to maintain their function [61]. Affected 
cells grow much more slowly, show heterogeneity in mitochondrial membrane potential and a 
decreased cellular respiration. Mutations of mitochondrial fusion proteins are mainly related 
to neurodegenerative diseases such as Alzheimer’s disease [61,82]. The other dynamic 
process, mitochondrial fission, is related to apoptosis. Fragmentation of mitochondria is a 
proapoptotic phenomenon in cell death, whereas mitochondrial fusion seems to protect from 
cell death. Mitochondrial fusion is reduced following induction of apoptosis and 
overexpression of fusion proteins can reduce the apoptotic capacity [61]. 
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Mitochondrial transport, closely related to the process of mitochondrial fusion, is important to 
meet the energy requirements of the cell, particularly in cells with high energy demands such 
as neurons. Mitochondria are rapidly transported to areas of high energy demand, and 
therefore, this process is important for the development, function and stability of synapses 
and dendritic spines. Impaired mitochondrial trafficking has been implicated in 
neurodegenerative disorders including Huntington’s disease, Parkinson’s disease, 
Alzheimer’s disease and amyotrophic lateral sclerosis [83]. 
In case of critical illnesses, such as trauma, surgery or sepsis, mitochondria are initially 
activated. They respond to stress mediators like glucocorticoids or catecholamines by 
modulating the expression and activity of certain OXPHOS subunits or by increasing their 
size and number to maintain the increased energy demands of the cell. But prolonged stress 
and a stress-induced hyperglycemia can then increase the mortality risk by impairing the 
function of mitochondria caused by cell toxic glucose levels. This leads to disturbance in 
oxygen use and hence cytopathic hypoxia [2].  
The mPTPC is involved in the pathogenesis of necrotic cell death following ischemia-
reperfusion. All cellular conditions that promote the formation of the mPTPC such as calcium 
overload, high phosphate concentrations and oxidative stress also appear during ischemia-
reperfusion [56]. 
It is assumed that alterations in nuclear or mitochondrial DNA and excessive caloric intake 
contribute to the metabolic syndrome (including visceral obesity, insulin resistance, 
dyslipidemia, hypertension, proinflammatory and prothrombic syndrome). This leads to an 
imbalance and to failure of energy metabolism. In turn, the mentioned cardiovascular risk 
factors accompany with low aerobic capacity and reduced expression of genes that are 
required for the biogenesis of mitochondria. Caloric restriction reduces the workload of the 
respiratory chain, improves energy output and decreased oxidative stress [2]. 
Defects in mitochondrial fatty acid oxidation can lead to the accumulation of metabolites that 
disrupt insulin signaling and maybe also secretion, causing insulin resistance and hence, 
type 2 diabetes [2]. 
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Cardiolipin, the major lipid component of the inner mitochondrial membrane, is rich in 
unsaturated fatty acids and therefore, susceptible to damage caused by ROS. Alterations in 
the cardiolipin composition can affect the function of the respiratory chain and may also 
cause disorders [84]. 
An increased calcium uptake into mitochondria leads to the production of reactive oxygen 
species and thus is related to neurodegenerative diseases [85]. 
Dysfunction of mitochondria is also related to cancer. There are differences between normal 
cells and cancer cells regarding the structure and function of their mitochondria. These 
differences include metabolic activity, molecular composition and mtDNA sequence [4]. The 
first association between mitochondrial dysfunction and cancer was made in the 1930s by 
Otto Warburg. He hypothesized that cancer cells mainly produce ATP by glycolysis as a 
consequence of impaired mitochondrial respiratory capacity or low oxygen concentrations in 
tumors. This phenomenon has been called the Warburg-effect. It has been shown that 
mitochondria in carcinoma cells have a significantly higher membrane potential which is 
another characteristic that distinguishes them from normal cells. Besides this, numerous 
other metabolic and functional alterations have been observed in cancer cells, such as 
acidification caused by the conversion of pyruvate to lactate instead of entering the citric acid 
cycle [4,6]. Mutations of mtDNA have been reported in a variety of cancers [4]. Dysfunction 
of programmed cell death caused by mutations in oncogenes or a mutated tumor suppressor 
gene is another profound characteristic of tumor cells [45,63]. Possible causes of 
mitochondrial diseases, their effects on the cellular level, affected tissues and clinical 
appearances are summarized in Table 1.1. 
        
Chapter 1 – Introduction 
 
- 27 - 
 
 
 
 
 
 C
a
u
s
e
 o
f 
 
m
it
o
c
h
o
n
d
ri
a
l 
d
is
e
a
s
e
 
E
ff
e
c
t 
o
n
 c
e
ll
u
la
r 
le
v
e
l 
A
ff
e
c
te
d
 t
is
s
u
e
s
 
C
li
n
ic
a
l 
a
p
p
e
a
ra
n
c
e
 
g
e
n
e
ti
c
 a
lt
e
ra
ti
o
n
s
 o
f 
n
D
N
A
 o
r 
m
tD
N
A
 
(i
n
h
e
ri
te
d
 /
 a
c
q
u
ir
e
d
) 
d
y
s
fu
n
c
ti
o
n
 o
f 
re
s
p
ir
a
to
ry
 c
h
a
in
 
 r
e
d
u
c
e
d
 e
n
e
rg
y
 
p
ro
d
u
c
ti
o
n
 
n
e
u
ro
n
a
l 
s
y
s
te
m
, 
m
y
o
c
a
rd
ia
l 
m
u
s
c
le
 
a
ta
x
ia
, 
s
e
iz
u
re
s
, 
s
tr
o
k
e
-l
ik
e
 e
p
is
o
d
e
s
, 
d
e
m
e
n
ti
a
, 
m
u
s
c
le
 w
e
a
k
n
e
s
s
, 
s
e
n
s
o
ry
 
n
e
u
ro
p
a
th
y
, 
d
e
v
e
lo
p
m
e
n
ta
l 
d
e
la
y
, 
d
e
a
fn
e
s
s
, 
o
p
ti
c
 a
tr
o
p
h
y
, 
la
c
ti
c
 a
c
id
o
s
is
, 
d
ia
b
e
te
s
 m
e
lli
tu
s
 
d
y
s
fu
n
c
ti
o
n
 o
f 
lip
id
 m
e
ta
b
o
lis
m
 
 r
e
d
u
c
e
d
 e
n
e
rg
y
 
p
ro
d
u
c
ti
o
n
 
m
y
o
c
a
rd
ia
l 
m
u
s
c
le
 
la
c
ti
c
 a
c
id
o
s
is
, 
m
y
o
p
a
th
y
 
m
u
ta
te
d
 M
L
S
 o
r 
tr
a
n
s
lo
c
a
s
e
s
  

 m
a
lt
ra
n
s
lo
c
a
ti
o
n
 
o
f 
p
ro
te
in
s
  
n
e
u
ro
n
a
l 
s
y
s
te
m
 
d
e
a
fn
e
s
s
, 
n
e
u
ro
lo
g
ic
a
l 
s
y
m
p
to
m
s
 
a
lt
e
re
d
 m
e
ta
b
o
lic
 a
c
ti
v
it
y
 (
A
T
P
 p
ro
d
u
c
ti
o
n
 b
y
 
g
ly
c
o
ly
s
is
, 
a
c
id
if
ic
a
ti
o
n
) 

 i
m
p
a
ir
e
d
 r
e
s
p
ir
a
ti
o
n
, 
im
p
a
ir
e
d
 a
p
o
p
to
s
is
  
a
ll 
ti
s
s
u
e
s
 
c
a
n
c
e
r 
d
y
s
fu
n
c
ti
o
n
 o
f 
m
it
o
c
h
o
n
d
ri
a
l 
 f
u
s
io
n
, 
fi
s
s
io
n
 a
n
d
 
tr
a
n
s
p
o
rt
 
 a
lt
e
re
d
 m
it
o
c
h
o
n
d
ri
a
l 
m
e
m
b
ra
n
e
 
p
o
te
n
ti
a
l,
 r
e
d
u
c
e
d
 e
n
e
rg
y
 p
ro
d
u
c
ti
o
n
, 
a
lt
e
ra
ti
o
n
s
 i
n
 
a
p
o
p
to
s
is
  
n
e
u
ro
n
a
l 
s
y
s
te
m
 
n
e
u
ro
d
e
g
e
n
e
ra
ti
v
e
 d
is
e
a
s
e
s
 (
A
lz
h
e
im
e
r´
s
 
d
is
e
a
s
e
s
, 
H
u
n
ti
n
g
to
n
´s
 d
is
e
a
s
e
, 
P
a
rk
in
s
o
n
´s
 
d
is
e
a
s
e
, 
a
m
y
o
tr
o
p
h
ic
 l
a
te
ra
l 
s
c
le
ro
s
is
) 
g
e
n
e
ti
c
 a
lt
e
ra
ti
o
n
s
 a
n
d
 
e
x
c
e
s
s
iv
e
 c
a
lo
ri
c
 i
n
ta
k
e
 
im
b
a
la
n
c
e
 a
n
d
 f
a
ilu
re
 o
f 
e
n
e
rg
y
 m
e
ta
b
o
lis
m
, 
o
x
id
a
ti
v
e
 s
tr
e
s
s
 
c
a
rd
io
v
a
s
c
u
la
r 
s
y
s
te
m
 
m
e
ta
b
o
lic
 s
y
n
d
ro
m
e
  
s
tr
e
s
s
 (
tr
a
u
m
a
, 
s
u
rg
e
ry
, 
s
e
p
s
is
) 
s
tr
e
s
s
 m
e
d
ia
to
rs
 (
g
lu
c
o
c
o
rt
ic
o
id
s
, 
c
a
te
c
h
o
la
m
in
e
s
) 
a
c
ti
v
a
te
 m
it
o
c
h
o
n
d
ri
a
 (
s
iz
e
, 
n
u
m
b
e
r,
 e
n
e
rg
y
 
p
ro
d
u
c
ti
o
n
);
 
s
tr
e
s
s
 i
n
d
u
c
e
d
 h
y
p
e
rg
ly
c
e
m
ia
 i
n
d
u
c
e
s
 g
lu
c
o
s
e
 
to
x
ic
it
y
 
a
ll 
ti
s
s
u
e
s
 
c
y
to
p
a
th
ic
 h
y
p
o
x
ia
 
c
a
lc
iu
m
 o
v
e
rl
o
a
d
, 
h
ig
h
 
p
h
o
s
p
h
a
te
 c
o
n
c
e
n
tr
a
ti
o
n
s
, 
o
x
id
a
ti
v
e
 s
tr
e
s
s
 
m
P
T
P
C
 f
o
rm
a
ti
o
n
 
 a
p
o
p
to
s
is
; 
o
x
id
a
ti
o
n
 o
f 
m
e
m
b
ra
n
e
 l
ip
id
s
 
 r
e
d
u
c
e
d
 e
n
e
rg
y
 
p
ro
d
u
c
ti
o
n
 
n
e
u
ro
n
a
l 
s
y
s
te
m
, 
m
y
o
c
a
rd
ia
l 
m
u
s
c
le
 
n
e
c
ro
ti
c
 c
e
ll 
d
e
a
th
 a
ft
e
r 
is
c
h
e
m
ia
 r
e
p
e
rf
u
s
io
n
, 
n
e
u
ro
d
e
g
e
n
e
ra
ti
v
e
 d
is
e
a
s
e
s
 
d
e
fe
c
ts
 i
n
 f
a
tt
y
 a
c
id
 
o
x
id
a
ti
o
n
 
a
c
c
u
m
u
la
ti
o
n
 o
f 
m
e
ta
b
o
lit
e
s
 t
h
a
t 
d
is
ru
p
t 
in
s
u
lin
 
s
ig
n
a
lin
g
 a
n
d
 s
e
c
re
ti
o
n
  
a
ll 
ti
s
s
u
e
s
 
d
ia
b
e
te
s
 t
y
p
e
 2
 
 T
a
b
le
 1
.1
: 
C
a
u
s
e
s
 o
f 
m
it
o
c
h
o
n
d
ri
a
l 
d
is
e
a
s
e
s
, 
th
e
ir
 e
ff
e
c
ts
 o
n
 t
h
e
 c
e
llu
la
r 
le
v
e
l,
 a
ff
e
c
te
d
 t
is
s
u
e
s
 a
n
d
 c
lin
ic
a
l 
a
p
p
e
a
ra
n
c
e
s
; 
n
u
c
le
a
r 
D
N
A
 (
n
D
N
A
),
 m
it
o
c
h
o
n
d
ri
a
l 
D
N
A
 (
m
tD
N
A
),
  
m
it
o
c
h
o
n
d
ri
a
l 
le
a
d
in
g
 s
e
q
u
e
n
c
e
 (
M
L
S
),
 m
it
o
c
h
o
n
d
ri
a
l 
p
e
rm
e
a
b
ili
ty
 t
ra
n
s
it
io
n
 p
o
re
 c
o
m
p
le
x
 (
m
P
T
P
C
).
 
 
Chapter 1 – Introduction 
- 28 - 
 
The role of mitochondrial dysfunction in aging considers a vicious cycle consisting of 
accumulation of mtDNA mutations with increasing age and impairment of the respiratory 
chain, therefore increased production of ROS and further damage of mtDNA and proteins. It 
is also possible to explain late onset neurodegenerative diseases, such as Parkinson’s 
disease, Huntington’s disease and Alzheimer’s disease with the age-related increase in ROS 
[84]. Neurodegenerative diseases are associated with neuronal death and progressive loss 
of synapses in brain and spinal cord [63]. Additionally, the number of mitochondria is 
decreased in neurons of patients with Alzheimer’s disease [82]. The major effects of 
neurodegenerative disorders are memory loss, emotional alterations, problems with 
imbalance and movements [63]. 
As a result of their physiological functions and their localization in mitochondria, sirtuins and 
dysfunction in the regulation of the expression of these protective proteins may play a role in 
aging and certain (age-related) diseases, including cancer, neurodegenerative diseases e.g. 
Alzheimer’s and Parkinson’s disease, and metabolic disorders e.g. diabetes and adipositas 
[75]. 
The diagnosis of mitochondrial disorders is quite challenging when only one symptom is 
present. Diagnosis is easier when two or more apparently unrelated symptoms involving 
more than one organ system are present. If it is possible to identify a known pathogenic 
mtDNA mutation, investigations can be straightforward [78]. MtDNA or nDNA studies should 
be accomplished when a classical maternally inherited mitochondrial syndrome or a nuclear 
DNA-inherited syndrome is present. Difficulties arise when no mtDNA defect is detectable or 
when the clinical appearance is complex and not easily match those of more common 
mitochondrial disorders [78]. If the clinical appearance is uncertain but highly suggestive to a 
mitochondrial disorder, measurement of plasma or cerebrospinal fluid lactic acid 
concentration, ketone bodies, plasma acylcarnitines, and urinary organic acids should 
proceed [78]. If these results are abnormal, muscle biopsy and assessment of the respiratory 
chain enzymes should follow. Neuroimaging (CT or MRI) is indicated in patients with a 
suspected disease of the central nervous system, electroencephalography (EEG) is indicated 
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at suspected encephalopathy or seizures, electromyography (EMG) may show myopathic 
features and nerve conduction velocity (NCV) may show polyneuropathy. 
Electrocardiography and echocardiography may indicate cardiac involvement [78]. 
Therapeutic options for mitochondrial dysfunction are currently limited [2], no effective 
disease-modifying therapy is available, and a careful clinical management is necessary to 
minimize symptoms of the diseases. The treatment of manifestations and management of 
mitochondrial disease is largely supportive and may include early diagnosis and treatment of 
diabetes mellitus, cardiac pacing, ptosis correction, and intraocular lens replacement for 
cataracts to prevent complications and unnecessary morbidity and mortality [78]. Individuals 
with complex I and/or complex II deficiency may benefit from oral administration of riboflavin 
[78]. Food supplements such as ubiquinone are generally well tolerated, and some 
individuals report a subjective benefit on treatment [78]. Supplementation of other 
antioxidants, such as vitamins and co-factors, are also usual treatments, but data from 
controlled clinical studies are absent [86]. Due to the unsatisfying therapeutic options in the 
treatment of mitochondrial diseases, there is a need for mitochondria-targeted therapies. 
 
Intracellular targets of mitochondrial diseases 
At first, it is necessary to identify causes and potential targets that are related to 
mitochondrial dysfunction. This includes functional alterations in metabolic pathways, 
proteins and other molecular compositions compared to normal cells. Some mitochondria 
related diseases exhibit various alterations in function, and it is not possible to treat all 
causes of the disease. An example is diabetes type 2 that is related to dysfunction of 
mitochondrial fatty acid oxidation, defects of mitochondrial oxidative phosphorylation and 
alterations of the mitochondrial genome [2]. 
Mutations in the mitochondrial or nuclear genome are the cause for most mitochondria-
related disorders including respiratory chain defects, mitochondrial fusion defects and 
malfunction of the protein import machinery. Hence, an overall aim is to reduce the fraction of 
mutated mtDNA to subthreshold levels. This could be achieved by adding synthetic wild-type 
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mtDNA, by removing or selective inhibition of mutated mtDNA [3,18]. The mitochondrial 
genome itself as a target is challenging to influence. To date, it is not possible to treat 
inherited diseases causally, but it is possible to prevent age-related mutations caused by 
reactive oxygen species. Scavenging of ROS that are produced in excess is therefore a 
possible strategy. This also prevents oxidation of cardiolipin in the inner mitochondrial 
membrane that is related to the function of the respiratory chain [84]. Another option to 
prevent the accumulation of mtDNA mutations is to increase the DNA repair capacity in 
mitochondria by transfecting cells with recombinant enzymes that are known to be involved 
in the repair of oxidative damage to mtDNA [18]. Beyond that, it is conceivable to choose an 
indirect approach to mitochondria gene therapy also known as allotopic expression. The 
strategy is to deliver a wild-type mitochondrial gene fused to a sequence that encodes a 
mitochondrial targeting sequence into the nucleus followed by cytosolic expression and 
import of the protein into mitochondria [18]. Finally, mitochondrial gene therapy is a 
promising but challenging approach, and its development is still at an early stage [14]. 
A target in carcinoma cell mitochondria is the defective programmed cell death due to the 
overexpression of antiapoptotic proteins contributing to the development and progression of 
tumors [87]. Induction of apoptosis is a powerful approach in treating malignant diseases 
[88]. Therefore, mitochondria are nowadays regarded as prime targets for cancer therapy 
[89]. Other alterations in cancer cells, for example decreased activity of OXPHOS enzymes, 
modified composition of membrane lipids, alterations in gene expression and mtDNA 
mutations that differ between the various cancer types, the higher membrane potential 
compared to normal mitochondria due to metabolic changes, glycolysis, and other metabolic 
alterations are potential targets although some of them are difficult to manipulate [6,54].  
It is also thinkable that calcium signaling can be a target. The increase of mitochondrial 
calcium concentration can lead to formation of the mitochondrial permeability transition pore 
complex (mPTPC), loss of membrane potential and hence, apoptosis [61]. The inhibition of 
calcium channels and reduced calcium influx into tumor cells suppresses tumor cell 
proliferation, respectively [14,90]. An increased calcium influx also contributes to the 
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generation of reactive oxygen species and is associated with neurodegenerative diseases 
[64,84]. Mitochondrial calcium homeostasis is closely related to the mitochondrial membrane 
potential which is in turn regulated by potassium channels. Mitochondrial potassium 
channels, therefore, are also a target in therapy [91]. 
The mPTPC itself plays a central role in apoptosis and presents a target for cytoprotective 
and cytotoxic therapies [56]. 
The peripheral benzodiazepine receptor (PBR) that is localized primarily in mitochondrial 
membranes is thought to be a component or a regulator of mPTPC in apoptosis and 
therefore exhibits a target for cytotoxicity and cytoprotection [5,6]. 
The activity of uncoupling proteins in the inner mitochondrial membrane acts in the storage of 
triglycerides in adipose tissue. Targeting of these proteins may offer new treatment strategies 
in obesity [56]. 
Even though the field of sirtuin research is quite young, most studies rely on microorganisms 
and in spite of the controversial discussion whether sirtuins can really extend lifespan in 
mammals or not, they seem to be an attractive target in mammals. Due to the correlation of 
calorie restriction and activation of sirtuin activity, it is possible that in future, new 
pharmacological agents target and activate sirtuins by mimicking calorie restriction. This may 
prevent neurodegenerative or metabolic diseases or helps to treat cancer [75]. It has already 
been shown that the natural product resveratrol can activate sirtuins upon oral administration 
leading to antidiabetic effects such as improved insulin sensitivity and glucose tolerance as 
well as decreased fasting glucose levels [92].  
Since it is known that mitochondrial fusion has a protective effect on mitochondrial 
functionality and excessive mitochondrial fragmentation contributes to programmed cell 
death [61] it is thinkable that the manipulation of mitochondrial dynamics might be a 
promising therapeutic strategy to improve mitochondrial functionality. Feasible approaches 
may be the enhancement of mitochondrial fusion or the prevention of mitochondrial fission in 
cells that exhibit a disequilibrium of both processes. If fragmentation of the mitochondrial 
network is a consequence of mitochondrial dysfunction, an effective therapeutic approach 
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cannot be expected by an enhancement of mitochondrial fusion. In contrast, if mitochondrial 
fragmentation is the cause of dysfunction, the enhancement of mitochondrial fusion can help 
to normalize and enhance complementation of mitochondrial functionality by redistributing 
mutated and wild-type mtDNA as well as proteins [93].  
 
Drugs or molecules that affect mitochondrial function 
Several low molecular weight substances and macromolecules are known to directly act on 
mitochondria or to have an influence on their functionality. The therapies with some of these 
substances would benefit from a specific targeting strategy to exert their action directly on 
mitochondria, to improve their efficacy, to reduce dosages and side-effects or to apply new 
indications of approved drugs. Most of these molecules affect mitochondria as they exert 
ROS scavenging capacity that can be applied in degenerative diseases or they show 
proapoptotic activity that can be used as an anticancer strategy (Table 1.2). Drugs that have 
an influence on mitochondria are classified into non-peptide and peptide substances as well 
as drugs that affect mitochondrial dynamics. Examples from each class will be described in 
more detail. 
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drugs 
antiapoptotic effects  
(non-malignant cells) 
proapoptotic effects 
(malignant cells) 
antioxidants ROS-scavenging  
cyclosporin A prevents mPTPC formation  
SOD-mimicking peptides ROS-decomposition  
Szeto-Schiller-peptides 
ROS-scavenging,  
prevents mPTPC formation 
 
resveratrol stimulation of sirtuins induction of mPTPC formation 
potassium channel openers 
(diazoxide) 
prevents mPTPC formation 
inhibition of calcium channels, 
antiproliferative 
vitamine E ROS-scavenging 
triggers apoptosis, suppresses 
angiogenesis 
paclitaxel, 
 “mitocans”,  
PBR-agonists (diazepam 
analogs),  
3-bromopyruvate 
 induction of mPTPC formation 
imexon,  
menadione,  
motexafine gadolinium,  
β-lapachone,  
mangafodipir,  
parthenolide,  
photodynamic substances 
 
oxidative stress / 
overproduction of ROS 
anthracyclines,  
arsenic trioxide 
 
induction of mPTPC formation 
and oxidative stress 
betulinic acid, dichloroacetate,  
proapoptotic peptides 
(mastaparan, D(KLAKLAK)2) 
 
disruption of mitochondrial 
membrane potential 
4-quinolones (ciprofloxacin), 
nucleoside analogs 
 mtDNA damage 
benzothiazepines  Increasing of calcium influx 
cis-Pt  
induction of mPTPC formation, 
inhibition of glycolysis 
buthionine sulphoximine,  
estrogen derivatives 
 
inhibition of endogenous 
antioxidant system  
 
Table 1.2: Drugs that act on mitochondria; superoxide dismutase (SOD), reactive oxygen species (ROS), 
mitochondrial permeability transition pore complex (mPTPC), mitochondrial DNA (mtDNA), peripheral 
benzodiazepine receptor (PBR). 
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Non-peptide substances 
Antioxidants, compounds with free radical scavenging properties are a major group with 
numerous substances that can influence mitochondrial functionality. Lipoic acid, for example, 
a coenzyme of mitochondrial enzymes, can readily penetrate the blood brain barrier, and its 
effects on improving cognition and Alzheimer’s disease related pathology have been 
evaluated in disease models [83]. Lipoic acid can also recycle the endogenous antioxidants 
vitamin C, vitamin E and glutathione. Coenzyme Q10, also an endogenous coenzyme of 
electron transport chain proteins, and synthetic derivatives of Coenzyme Q10 such as 
idebenone can, orally supplemented, attenuate oxidative stress related dysfunctions and are 
used in the treatment of neurological and neuromuscular diseases [5,83]. The approval for 
idebenone in the therapy of an inherited mitochondrial optic neuropathy has been submitted 
recently [94]. Despite their clinical importance, antioxidants show limited therapeutic success 
when they are not selectively taken up by mitochondria [7]. Antioxidants that only have 
access to the cytosol have a limited impact on mitochondria. Therefore, it is necessary that 
antioxidants are delivered into mitochondria to scavenge mitochondrial reactive oxygen 
species effectively. Such mitochondrial targeted antioxidants have already been developed, 
and an improved clinical outcome has been shown [7,83]. Two general targeting strategies 
for antioxidants have been proven to be useful, the conjugation to lipophilic cations and the 
incorporation into mitochondria targeted peptides [7] which will be described in more detail 
later in this review. A well-characterized antioxidant, targeted to mitochondria by conjugation 
to the triphenylphosphonium (TPP) cation, is MitoQ that consists of an ubiquinone moiety 
linked to a TPP moiety by a ten-carbon alkyl chain. The TPP moiety on MitoQ leads to a 
rapid uptake across the plasma membrane, driven by the plasma membrane potential, 
followed by its accumulation in mitochondria. MitoQ is continually converted to the active 
ubiquinol antioxidant by respiratory complex II inside mitochondria, and it has been shown to 
have protective capacity in a large number of cell models of mitochondrial oxidative stress 
[7]. 
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Vitamins and coenzymes of respiratory chain proteins contribute to the function of these 
mitochondrial proteins. In diseases that are related to dysfunction of these proteins, the oral 
administration of coenzymes such as vitamin B1 or B2, succinic acid and coenzyme Q, and 
ATP itself can, to some extent, compensate mitochondrial dysfunction, resulting in positive 
therapeutic effects [41].  
Many clinically approved drugs directly act on mitochondria triggering apoptosis including 
paclitaxel [14,44]. Although it is largely believed that paclitaxel exerts its action by stabilizing 
microtubules of the cell, it has been shown that it induces the formation of the mPTPC and 
hence apoptosis [17]. Interestingly, in studies with intact cells that have been treated with 
paclitaxel, a 24 h delay of apoptosis was observed compared to studies with isolated 
mitochondria. This delay has been attributed to the interaction with several sites inside the 
cell, making only a fraction of the drug molecules available for mitochondria. Hence, 
paclitaxel appears to be a molecule whose action and efficiency may be significantly 
improved by specific subcellular delivery to the mitochondrion [17]. It has been shown that 
the encapsulation of paclitaxel in liposomes from dequalinium (DQAsomes) improved 
efficacy [17]. Similarly to paclitaxel, doxorubicin and cisplatin are also known for different 
mechanisms of action, but were shown to induce the formation of the mPTPC as well [87]. 
The anticancer activity of anthracyclines such as doxorubicin is mainly attributed to their DNA 
intercalation. However, the cytotoxic side effects of the widely used anthracyclines 
adriamycin and daunomycin have been associated with mitochondrial dysfunction. 
Interaction of these drugs with mitochondria appears to follow complex mechanisms, 
including major membrane disruption caused by the high affinity of anthracyclines to 
cardiolipin, and the redox activity of the quinone moiety which results in oxidative damage of 
proteins [5]. 
A group of anticancer agents called “mitocans”, an acronym for “mitochondrially targeted, 
apoptosis-inducing anticancer compounds”, usually cause mitochondrial destabilization of 
tumor cells through the activation of mitochondrial mediators of apoptosis including the 
proapoptotic proteins and the formation of the mPTPC [5,95]. These agents have been 
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classified and reviewed by Ralph and Neuzil [95]. Some of them are among the following 
agents that will be discussed below. 
Arsenic trioxide (Trisenox™) has been commercialized for the treatment of acute 
promyelocytic leukemia. As2O3 has undoubtedly multiple biological targets, but the most 
common mechanism of action seems to be its interaction with sulfhydryl groups, especially 
those of mPTPC members, leading to the production of ROS and subsequent apoptosis [5]. 
Other substances that target mitochondrial permeability transition by depleting inhibitors of 
mPTPC such as glucose, ATP, creatine phosphate, glutathione or by increasing calcium or 
by stimulating the production of ROS include lonidamine, bisphosphonate clodronate and 
retinoid-related compounds [6]. Lonidamine also inhibits oxygen consumption and blocks 
energy metabolism which results in the loss of the membrane potential and apoptosis [87].  
Imexon, an aziridine-containing iminopyrrolidone and isothiocyanates bind to thiols (GSH, 
cysteine), causing an accumulation of ROS and mitochondrial swelling, and that leads to 
apoptosis. Imexon is currently being evaluated for the treatment of pancreatic and lung 
cancers [5,6]. Other compounds that induce the overproduction of ROS offer potential 
strategies to cancer therapy such as menadione, motexafine gadolinium and β-lapachone or 
substances that inhibit the endogenous antioxidant systems such as buthionine sulphoximine 
which inhibits glutathione synthesis. Mangafodipir increases ROS in cancer cells and some 
estrogen derivatives inhibit ROS-scavenging enzymes [6]. 
Gamitrinibs, geldanamycin mitochondrial matrix inhibitors, that contain geldanamycin 
conjugated to a cyclic guanidium moiety which acts as a mitochondrial targeting signal, 
selectively target a heat shock protein in cancerous mitochondria inducing rapid tumor cell 
death [96]. 
As it was revealed that ceramides show an antiproliferative and proapoptotic activity in tumor 
cells, specific targeted liposomal carrier were formulated to deliver ceramides to 
mitochondria [97,98]. These specific carrier systems are another example of the 
improvement of drug efficacy by targeted drug delivery systems. 
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A variety of chemical agents cause depletion of mitochondrial DNA and could theoretically be 
used in cancer therapy. Examples are 4-quinolone drugs such as ciprofloxacin which cause 
loss of mtDNA and consequently loss of mitochondrial function and other substances such 
as the intercalating agent ditercalinium or antiviral nucleoside analogs [87]. 
The peripheral benzodiazepine receptor (PBR) as a component or a regulator of mPTPC in 
apoptosis can be addressed by PBR agonists such as diazepam analogs that act as 
proapoptotic antitumor agents and PBR antagonists such as isoquinoline derivatives that act 
as antiapoptotic agents, respectively [5,6]. 
Other approaches to cancer therapy are the targeting of the altered mitochondrial 
metabolism, such as the inhibition of glycolysis which increases the toxicity of cisplatin, the 
downregulation of the high membrane potential by dichloroacetate, the inhibition of the fatty 
acid synthesis by soraphen A resulting in reduced phospholipid content, growth inhibition and 
enhanced cell death, the promotion of mPTPC formation by 3-bromopyruvate or methyl 
jasmonate or the inhibition of lactate dehydrogenase A which converts pyruvate to lactate 
leading to acidification [6]. Targeting and inhibition of a cancer specific heat shock protein by 
shepherdin results in tumor growth inhibition. Betulinic acid triggers mitochondrial apoptosis 
in cancer cells by disrupting the membrane potential. Resveratrol improves mitochondrial 
function of non-malignant cells by the stimulation of sirtuins and contributes to cell death 
induction by inhibition of ATP synthesis and triggering of mPTPC in cancer cells as well. 
Vitamin E analogs trigger apoptosis in cancer cells and suppress angiogenesis. The 
sesquiterpene lactone parthenolide shows cytotoxic effects involving ROS-overproduction 
[6]. 
Mitochondrial potassium channels (mitoKATP) can be blocked by antidiabetic sulfonylureas 
such as glibenclamide or activated by potassium channel openers such as diazoxide. 
Potassium channel openers exert a cardioprotective action via the prevention of mPTPC 
formation and are therefore a potential therapeutic application in the treatment of myocardial 
infarction and stroke [5]. Diazoxide also affects the activity of uncoupling proteins and can 
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prevent cell death [99]. In another study, diazoxide was shown to inhibit calcium channels 
and to reduce calcium influx into tumor cells, suppressing tumor cell proliferation [14,90]. 
Benzothiazepines were shown to inhibit the mitochondrial Na+-Ca2+-exchange resulting in an 
increase in mitochondrial Ca2+-concentration and subsequent ATP production. These 
findings suggest that deficiencies in respiratory chain complexes are associated with altered 
cytosolic Ca2+-homeostasis [5]. The manipulation of mitochondrial associated calcium 
signaling provides an anticancer strategy as diazoxide was shown to inhibit calcium channels 
suppressing tumor cell proliferation [14,90]. 
Nucleoside analogs used as antiviral drugs, such as zidovudine, can cause mitochondrial 
damage through two mechanisms. The short-term mechanism directly affects the activity of 
mitochondrial enzymes, via the competitive inhibition of the ADP/ATP antiport and of the 
nucleoside diphosphate kinase. The long-term mechanism alters the mtDNA, via oxidative 
damage to mtDNA and inhibition of the polymerase responsible for mtDNA replication [5]. 
Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit the β-oxidation of fatty acids and 
cause the uncoupling of respiratory chain and ATP synthesis, partly due to induction of the 
formation of the mPTPC [5]. Local anesthetics also uncouple respiratory chain and ATP 
synthesis and also inhibit mitochondrial ATPase and respiratory chain enzymes [5]. Hence, 
besides possible new applications of approved drugs like nucleoside analogs, NSAIDs or 
local anesthetics, late-stage adverse drug toxicity events are related to mitochondrial toxicity 
[5]. 
In the growing group of photosensitizers for photodynamic therapy, there are substances 
known that accumulate in mitochondria causing ultrastructural and functional alterations that 
can be utilized in the therapy of cancer [100]. 
 
Peptide substances 
Besides non-peptide-based agents that act on mitochondria, there are also peptide- and 
amino acid-based molecules modulating mitochondrial functionality.  
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Proapoptotic peptides are capable of disrupting mitochondria and triggering apoptosis. They 
are typically derived from the sequences of membrane-disrupting antimicrobial peptides. 
Since they can be easily fused to tissue- or tumor-specific peptides or antibodies, they may 
be attractive as new targeted anticancer agents. However, they usually suffer from low 
potencies, thereby limiting their clinical utility. Mitochondrial localization and membrane-
disrupting activity of the widely used cationic amphipathic α-helical killer peptide D-
(KLAKLAK)2 could be improved by increasing its hydrophobicity via the exchange of amino 
acids. Thereby, a dramatic increase in potency could be achieved [5]. Mastoparan is a toxic 
peptide that targets the membrane potential promoting apoptosis [87]. 
Cyclosporin A (CsA), a cyclic peptide, was shown to inhibit the formation of the mPTPC and 
prevents or delays cell death caused by oxidative stress, protecting the heart and the brain 
from ischemia-reperfusion injury. Despite the potential of CsA as an anti-ischemic drug, there 
are other targets of CsA in the cell, this makes it difficult to predict concentrations of CsA in 
mitochondria. The therapy with CsA would benefit from a mitochondria-specific drug carrier 
system [56]. 
Manganese metalloporphyrin oligopeptide conjugates are a new class of mitochondria 
targeted superoxiddismutase (SOD)-mimics that consist of manganese metallopophyrin 
conjugated to a mitochondrial targeting sequence peptide. The natural SOD as well as the 
oligopeptide conjugates decompose highly reactive oxygen species and protect cells from 
oxidative stress [5]. 
Szeto-Schiller-peptides are not only a suitable targeting strategy for mitochondrial targeting 
(this will be reflected upon later), but some of them show an intrinsic antioxidant capacity as 
an additional feature [7,101]. The free radical scavenging abilities of these peptides are likely 
to originate from their tyrosine residues. They can reduce intracellular ROS production and 
apoptosis and prevent mitochondrial depolarization, formation of the mPTPC and Ca2+-
induced swelling [102]. Hence, such mitochondria-targeted antioxidants represent a 
promising approach in the therapy of neurodegenerative diseases [5]. 
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The tripeptide glutathione (GSH) plays an important role in protecting cells against oxidants 
and electrophiles. When donating an electron to unstable molecules such as ROS, two 
GSHs react to form glutathione disulfide (GSSG). Increasing mitochondrial glutathione and 
other thiol-based antioxidants can be an effective strategy to prevent mitochondrial oxidative 
stress. Using a similar approach as with the TPP conjugated antioxidants, choline esters of 
glutathione and of its analog N-acetyl-L-cysteine were shown to target mitochondria and to 
protect against oxidative damage [5]. 
The possibility of gramicidin as a potential targeting strategy has been proven by the 
tethering of a hemi-gramicidin S pentapeptide sequence to a stable free radical. Thereby, the 
gramicidine peptide acts as the targeting moiety, and the conjugated free radical acts as the 
ROS scavenging drug. The major advantage of sterically hindered free radicals is their 
electron acceptor/donor nature depending on the redox potential of the environment. By 
accepting one electron, they become reduced and can act as direct radical scavengers. 
Afterward, they are converted back into nitroxides. In other words, these compounds 
undergo redox recycling. Nitroxides also possess superoxide dismutase and catalase 
mimetic activities, thus offering additional protective benefits against oxidative cellular 
damage [5]. 
 
Substances that influence on mitochondrial dynamics 
In strategies toward influencing mitochondrial dynamics, genetic experiments have shown 
that inhibition of fusion shifts the equilibrium to fission and vice versa. A pharmacological 
agent that inhibits fission was shown to increase the proportion of fused mitochondria in cells 
that contain fragmented mitochondria. The quinazolinone derivative binds to fission-
mediating proteins, inhibiting their activity and thus, promoting fusion via the prevention of 
mitochondrial fragmentation. This compound could therefore be a therapeutic approach to a 
group of neurodegenerative diseases that result from aberrant mitochondrial fusion [93]. 
Pharmacological agents that induce the mitochondrial fusion by directly influencing the fusion 
machinery are currently unknown. 
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Although the list of compounds that can act on or interact with mitochondria is long, it 
certainly does not raise a claim to completeness. In addition, it remains unclear to what 
extent these molecules selectively accumulate at the desired target [9]. Targeting strategies 
that were shown to achieve a selective accumulation in mitochondria will be described in 
detail later in this review. They may help to find a suitable targeting approach for the 
mentioned drug molecules. Before mitochondrial targeting strategies are evaluated in detail, 
the next two chapters will reflect on structural characteristics that make targeting of 
mitochondria very challenging and will also give ideas about how barriers can be crossed by 
utilization of mitochondrial specificities. 
 
Challenges of targeting mitochondria and of working with isolated 
mitochondria 
Although mitochondria play a central role in various important pathologies, they have been a 
neglected target. This is in partly due to the difficulty of selectively targeting molecules to this 
organelle in vivo [7].  
General challenges of intracellular targeting, concerning drug molecules as well as drug 
carriers, are to cross the cellular membrane that prevents large molecules from 
spontaneously entering the cell and to escape the endosomes and reach the cytosol without 
degradation, in case of endocytosis of larger drug molecules, DNA or nanocarriers [14,48]. 
There is a need to develop strategies that bypass the endocytotic pathway and that achieve 
a sufficient intracellular transport [14]. 
To avoid the obstacles of drug delivery, namely the cell membrane as a transport barrier, 
endocytotic and lysosomal or cytosolic degradation processes before a drug reaches 
mitochondria, or to avoid invasive techniques that help to cross the cellular membrane such 
as microinjection or electroporation, it can be advantageous to work with isolated 
mitochondria. Isolation of mitochondria from tissues or cells is still a standard method to 
monitor mitochondrial bioenergetics and physiology. Experimental conditions can be 
precisely controlled and modified to accomplish the requirements of the scientific approach 
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by supplementation of substrates, inhibiting or uncoupling substances. Oxygen kinetics can 
only be analyzed on isolated mitochondria. Preparations of isolated mitochondria are also 
required to study and separate different mitochondrial subpopulations [103]. They are further 
required for investigations on the molecular level, such as enzyme activity, analytics of 
proteins, protein import and DNA or as a subsequent method after the application of 
molecules or carriers to intact cells, to determine site and extent of their subcellular 
accumulation [104,105]. Disadvantages that are associated with the isolation of mitochondria 
include separating mitochondria from their natural environment and signaling processes, the 
temporarily limited metabolic activity, the risk of damaging mitochondrial membranes due to 
shear forces during the isolation process and the risk that mitochondrial networks might be 
disrupted. Isolated mitochondria may not behave as they would do in their natural 
environment [106]. Working with isolated mitochondria is therefore controversially 
considered. Approaches with intact cells are preferred in many subjects, and it has to be 
emphasized that for purposes in which the cellular context contributes to the experimental 
outcome, it is essential to work with intact cells rather than with isolated mitochondria [106]. 
Studies that have investigated the influence of paclitaxel on mitochondria have shown a 
different outcome for intact cells compared to isolated mitochondria [17]. However, one can 
argue that even intact cells lack the true in vivo complexity of cell-cell interactions of tissues 
or organisms. Advantages and disadvantages of working with isolated mitochondria 
compared to intact cells have been recently summarized by Brand and Nicholls [107]. For the 
isolation of mitochondria, numerous protocols that are making use of fast methods, such as 
differential centrifugation [108,109], more time-consuming gradient-purification procedures 
[105,110], or antibody-based approaches [111] have been established over the years. The 
choice of the method depends on the source of mitochondria and the respective research 
goal. The isolation process itself can be challenging as large amounts of cells are required to 
obtain enough mitochondria for further studies. This means, in the case of mammalian cells 
that grow as monolayers, a large number of cell culture flasks have to be cultivated and 
processed for the isolation procedure. Purification steps after isolation can lead to the dilution 
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of the preparation and loss of mitochondria. Therefore, their application is not always 
practicable. Despite all challenges and disadvantages that are associated with isolated 
mitochondria, the first approaches in targeting mitochondria are widely investigated with 
isolated mitochondria to provide a basis of knowledge. However, to understand the relation 
of mitochondria to other aspects of cell physiology and to understand how other cell functions 
respond to changes in mitochondrial function, it is necessary to proceed with studies in intact 
cells [112]. 
The challenge of targeting mitochondria by itself is to transfer the drug or drug carrier across 
two membranes in the case of mitochondrial matrix targeting. In targeting of the 
intermembrane space, it is sufficient to pass the outer mitochondrial membrane, but almost 
all potential targets are located in the mitochondrial matrix. Therefore, it is necessary to 
overcome both mitochondrial membranes which have only small pores and a highly lipophilic 
inner membrane. Theoretically, membrane impermeable probes can enter mitochondria 
through protein import pores (TOM- and TIM-complex), the pore protein porin, also referred 
to as the voltage dependent anion channel (VDAC), the mitochondrial permeability transition 
pore complexes (mPTPCs), through mitochondrial apoptosis-related channels and through 
apoptosis-related ceramide pores. But only the VDAC and the protein import pores are 
relevant in normal mitochondrial function. The others are related to apoptosis and 
dysfunction and are localized in the outer but not the inner mitochondrial membrane [113]. 
Except a few membrane-permeable lipophilic compounds, such as molecular oxygen, 
acetaldehyde and short fatty acids, all metabolites that enter and leave mitochondria must 
cross the outer mitochondrial membrane through the VDAC [113] which is also the most 
abundant protein in the outer mitochondrial membrane [69]. The protein import pores in the 
outer mitochondrial membrane (TOM-complex) have a dimension of about 2–2.6 nm. The 
pores of the inner mitochondrial membrane (TIM-complex) are even smaller with a pore size 
of about 1.3 nm [114,115]. The size of the VDAC, only localized in the outer mitochondrial 
membrane, was determined to have a dimension of 3–6 nm with silver-enhanced gold 
nanoparticles in electron microscopy studies [113,116].  
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Therefore, targeting of mitochondria is limited to molecules and very small-sized 
nanocarriers. 
 
Utilization of mitochondrial properties for targeting 
Due to the fact that mitochondria exhibit some features that differ from other cellular 
compartments and in turn some of these features vary between normal and diseased 
mitochondria, these properties can be utilized for the targeting strategies that are reflected in 
the next section. 
The first property that can be utilized for targeting is the mitochondrial membrane potential. 
The electron transport chain and ATP synthesis via oxidative phosphorylation create a 
transmembrane electrochemical gradient that leads to a high membrane potential, negative 
inside and a pH difference, acidic outside. Therefore, positively charged molecules are 
attracted to mitochondria and selectively accumulate in the mitochondrial matrix in response 
to their membrane potential [2,14]. Carcinoma cell mitochondria show an even higher 
membrane potential due to metabolic changes. It is approximately 60mV higher than in 
normal mitochondria. This difference accounts for a tenfold greater accumulation of a 
positively charged compound in carcinoma mitochondria than in control mitochondria [54]. 
Therefore, cationic molecules are preferentially taken up by tumor cells leaving non-tumor 
cells unaffected [54]. 
The inner mitochondrial membrane that has to be crossed for the delivery of substances into 
the mitochondrial matrix exhibits a lipid composition that differs from other membranes. 
Cardiolipin is a major lipid component of the inner mitochondrial membrane and is very 
lipophilic. Therefore, lipophilic molecules or rather lipophilic and positively charged molecules 
that take advantage of the membrane potential accumulate in mitochondria [117]. 
In utilizing mitochondrial membrane pores, it is more appropriate to target the protein import 
pores than to target the VDAC because specific targeting sequences are known for the 
protein import pores, and they are present in both membranes, whereas the VDAC is only 
present in the outer mitochondrial membrane and cannot be targeted specifically.  
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An approach in mitochondrial targeting that has not been considered until now is the 
utilization of the mitochondrial fusion process. It might be a suitable approach to make use of 
mitochondrial fusion in order to deliver drug carriers to mitochondria that are too large to 
pass the mitochondrial protein import pores. Even though most pharmaceutical drug carriers 
have a size in the nano-range, they are too large for the 2.6 nm pores. It can be 
hypothesized that a pharmaceutical drug carrier which is decorated with moieties, peptidic or 
non-peptidic ones, that are attracted by mitochondria and accomplish a close binding of the 
carrier to the organelle, can be taken up by mitochondrial fusion subsequently to binding at 
the outer mitochondrial membrane. 
In the following, targeting strategies which make use of the described properties of 
mitochondria will be reflected in more detail. 
 
Targeting strategies for mitochondria 
It has been mostly presumed that molecules which exhibit a positive charge are attracted to 
mitochondria in response to the highly negative membrane potential. However, compounds 
that exhibit a positive charge cannot enter the mitochondrial matrix because the inner 
mitochondrial membrane is impermeable to polar molecules. Additional physicochemical 
properties are necessary to achieve a mitochondrial targeting [14]. Although it has been 
widely implied that mitochondrial targeting molecules should comprise the features positive 
charge and lipophilicity/amphiphilicity, there are still controversies regarding this idea [5]. A 
study that evaluated the characteristics of a large number of mitochondria targeting 
substances classified only one third as lipophilic cations. One third represented acids and 
anions, and another third were neutral compounds. Two thirds of the investigated substances 
were lipophilic and one third was hydrophilic. Therefore, a general correlation between 
physicochemical properties and extent of accumulation in mitochondria could not be verified 
[117]. However, several strategies toward mitochondrial targeting that were shown to 
selectively deliver drugs or molecules into mitochondria will be reflected in the following. The 
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targeting approaches comprise of non-peptide and peptide moieties as well as nanocarrieres 
and invasive or biological techniques. 
 
Non-peptide targeting strategies 
Delocalized lipophilic cations can easily pass the lipid bilayers of the plasma membrane and 
the mitochondrial membranes because the charge of the cation is effectively distributed over 
a large and hydrophobic surface area, thereby lowering the activation energy for their 
movement across the membrane [7]. The ability of these cations to move through 
membranes enables their accumulation in the mitochondrial matrix, in response to the large 
mitochondrial membrane potential that is negative inside [7]. Lipophilic cations do not require 
a specific import mechanism. The Nernst equation indicates that the uptake of lipophilic 
cations in the mitochondrial matrix that is only driven by the membrane potential increases 
10-fold for every 61.5 mV [7]. The mitochondrial membrane potential is about 180–200 mV 
which is the maximum a bilayer can sustain and simultaneously maintain integrity [14]. This 
leads to a 200–400 fold higher accumulation of lipophilic cations in the mitochondrial matrix. 
Uptake into cells is also driven by the membrane potential of the plasma membrane that is 
30–60 mV, negative inside [7]. Therefore, the accumulation of these compounds in 
mitochondria relative to the extracellular environment can be up to several thousand-fold 
higher according to the Nernst equation [7]. The best characterized and most widely used 
delocalized lipophilic cation for delivery to mitochondria is the triphenylphosphonium (TPP) 
cation, which was originally used to assess the mitochondrial membrane potential [5,7,118]. 
The TPP cation has been conjugated to a range of antioxidants in order to target them to 
mitochondria. There are a number of advantages of using the TPP cation approach as its 
uptake into mitochondria is well established and it is relatively straightforward to introduce 
this functionality into a compound late in the chemical synthesis scheme, typically by 
displacing a leaving group with triphenylphosphine [7]. A wide range of antioxidants have 
been targeted to mitochondria by conjugation to the TPP lipophilic cation, including vitamin 
E, ebselen, lipoic acid, plastoquinone, nitroxides, nitrones and Mito Q [7]. It is also possible 
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to conjugate DNA analogs like peptide nucleic acids to TPP for mitochondrial targeting in 
order to inhibit the replication of mutated mtDNA [18].  
 
Peptide-based targeting strategies 
Another approach in targeting substances to mitochondria is the use of small, positively 
charged peptides, called Szeto-Schiller (SS)-peptides that are composed of four alternating 
aromatic and basic amino acids [7,101,102]. Szeto-Schiller-peptides exhibit three positive 
charges at physiological pH, and studies with isolated cells showed their rapid uptake 
through the plasma membrane and accumulation in mitochondria, where they bind to the 
inner membrane [7,102]. Despite their positive charge, the uptake of Szeto-Schiller-peptides 
into mitochondria does not seem to occur in response to the membrane potential. The 
mechanism that underlies their selective uptake by mitochondria is currently not clear 
[7,101].  
More recently, it has been shown that peptides with a similar structure are taken up by 
mitochondria within cells due to the influence of the mitochondrial membrane potential on the 
positively charged peptides [7]. These so called mitochondria-penetrating peptides (MPPs) 
consist of four or eight alternating positively charged and hydrophobic, partly unnatural, 
amino acids. They are a very promising targeting approach as delivery vectors for selective 
and effective mitochondrial transport [119]. In a subsequent study, it has been shown that 
MPPs are able to deliver small molecules, biotin and trolox, a water soluble analog of vitamin 
E, into mitochondria [120]. The unanswered question is whether or not MPP are also able to 
deliver larger cargos such as DNA for gene delivery or nanocarriers into mitochondria. 
Approaches to target mitochondria with synthetic peptides are comparatively new. They 
followed up the targeting of cells with cell penetrating peptides and mitochondrial targeting 
with natural mitochondrial targeting peptides. Cell penetrating peptides are larger compared 
to SS-peptides or MPPs and consist of up to 30 only positively charged or alternating 
positively charged and hydrophobic amino acids. They can enter the cell membrane and are 
able to transport cargoes with a much higher molecular weight than their own ones [121]. It 
Chapter 1 – Introduction 
- 48 - 
 
has been shown that a wide range of molecules such as peptides, nucleic acids, proteins, 
and even nanoparticles and liposomes can be delivered in this way into cells [122].  
Natural mitochondrial leading sequences (MLSs), derived from mitochondrial proteins that 
are synthesized in the cytosol, are able to deliver molecules into mitochondria. All proteins 
synthesized in the cytosol must carry such an amino-terminal pre-protein to be translocated 
to their final mitochondrial destination. Mitochondrial targeting sequences have a typical size 
of about 10–80 amino acids with many positively charged, hydrophobic and hydroxylated 
amino acids. An important feature of these sequences is their ability to form an amphiphatic 
α-helix that presents one positively charged surface and one hydrophobic surface. These 
structural characteristics are important for the recognition by the mitochondrial protein import 
pores. When an MLS is attached to a non-mitochondrial protein, it can specifically direct the 
protein into mitochondria [69]. The utilization of the mitochondrial protein import pathway was 
used for the first demonstration of DNA delivery into mitochondria. A mitochondrial leading 
sequence peptide has been conjugated to oligonucleotides up to 322 bp and specifically 
introduced exogenous DNA into mitochondria [18]. These targeting sequences can also be 
coupled to drug molecules or drug carries to achieve a mitochondrial targeting. 
An alternative concept in mitochondrial targeting by peptides is based on the affinity of 
certain natural antibiotics to microbial cell membranes. Due to the close evolutionary 
relationship between bacterial membranes and the components of the inner mitochondrial 
membrane, in particular their lipid composition, the antibacterial membrane disruptor 
gramicidin S is hypothesized to serve as a template for mitochondrial targeting. It was shown 
that a hemi-gramicidin S pentapeptide sequence can target ROS scavengers to mitochondria 
[5]. 
 
Nanocarriers 
In the field of nanocarriers for mitochondrial drug targeting, approaches are mainly based on 
cationic liposomes prepared from trimethyl aminoethane carbamoyl cholesterol iodide 
(TMAEC-Chol) or dequalinium, as well as branched PEI to deliver peptide-DNA conjugates 
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[18] or micelles [17]. Liposomes are able to fuse with mitochondrial membranes delivering 
their cargo into mitochondria which is especially intriguing for the delivery of larger 
molecules. This approach takes advantage of the known fact that mitochondria are able to 
fuse with one another [123]. One of the first mitochondria targeted drug delivery systems that 
were able to deliver drugs and DNA has been self-assembling liposomes from dequalinium, 
called DQAsomes [18,124]. Dequalinium is an amphiphilic compound that is able to enter the 
mitochondrial membranes. DQAsomes are able to bind or to entrap drugs such as paclitaxel 
and DNA and transport them to mitochondria [14,17,56]. Other cationic liposomes composed 
of DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) and DOTAP (dioleoyl-1,2-diacyl-
3-trimethylammoniumpropane) were shown to deliver the propaoptotic peptide D-
(KLAKLAK)2 together with an antisense oligonucleotide into mitochondria in order to treat 
cancer [125]. A liposomal carrier system with octaarginine modifications at the surface that 
stimulate internalization into cells via macropinocytosis rather than clathrin-endocytosis, 
called MITO-Porter, promotes fusion with mitochondrial membranes and was shown to 
selectively deliver cargos into mitochondria [17,126]. Another gene delivery system that 
permits efficient and simple packaging of macromolecules is the multifunctional envelope-
type nano-device (MEND). It consists of a condensed core of plasmid DNA, proteins or other 
substances and a lipid envelope equipped with various functional devices to mimic envelope-
type viruses [104]. A further strategy to mitochondria specific drug carriers is the utilization of 
water soluble fullerene derivatives that accumulate in mitochondria as well [14,127]. 
Combinations of nanocarrier based strategies and targeting moieties, peptidic or non-peptidic 
ones are also useful approaches to mitochondrial drug targeting. A TPP modified fatty acid, 
stearyl triphenyl phosphonium (STPP), incorporated into liposomes that were composed of a 
phospholipid and cholesterol was shown to deliver molecules into mitochondria [17,128] and 
to improve the efficacy of ceramide as an antitumor agent [97,98]. Thereby, a proof of 
concept has been established which shows that targeted organelle specific drug delivery can 
reduce the dosage of a drug [17]. Conjugates of TPP to gold nanoparticles are under 
investigation, and it has to be shown, if they are also a suitable targeted delivery approach 
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[17]. By a study with quantum dots that are enfolded in micelles and conjugated to a 
mitochondrial targeting peptide, it could be demonstrated that these particles selectively 
accumulate in mitochondria when they are applied to intact cells [129].  
 
Invasive and biological approaches to mitochondrial targeting 
Completely different approaches to mitochondrial targeting comprise physical methods like 
electroporation or biolistic bombardment with DNA-coated heavy metal particles. These 
methods have been described to introduce DNA into mitochondria but are restricted to 
isolated organelles and are therefore hardly applicable in clinical treatments. It has also been 
reported that healthy isolated mitochondria can be endocytosed by cells, or they can be 
directly transferred into cells by physical methods such as microinjection or by biological 
methods like ovum transplantation and cytoplast fusion. In more recent methods, E. coli is 
used to transfer DNA into isolated mitochondria by conjugation of DNA-transformed E. coli 
and mitochondria [18]. 
 
Advances and techniques to probe the properties of mitochondria 
The methods to study mitochondrial function can be distinguished in two principle groups. 
One is the analysis of mitochondria in the cellular environment, and the other one is the 
analysis of isolated mitochondria [106]. 
The methods, described in the following, allow for the investigation of mitochondrial 
morphology, metabolism, calcium homeostasis, membrane potential, apoptosis, respiratory 
activity, mitochondrial dynamics, ROS production and accumulation of substances 
[56,105,106]. 
 
Methods to investigate mitochondria inside cells 
Approaches to study mitochondria in the cellular environment include confocal/fluorescence 
and electron microscopy, X-ray analysis, optical trapping, patch-clamp and flow cytometry 
[106]. Fluorescence based microscopy methods are applied to investigate the 
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permeabilization of the mitochondrial membranes induced by substances. For example, cells 
transfected with a mitochondrial targeted green fluorescent protein (GFP) show GFP 
fluorescence outside mitochondria after mitochondrial membrane permeabilization. With this 
method, it is also possible to detect alterations in mitochondrial membrane potential by using 
transmembrane potential sensitive dyes that accumulate in functional mitochondria. Agents 
that lead to the dissipation of the mitochondrial membrane potential alter the accumulation or 
the emission wavelength of the fluorescent dyes. Such studies allow detecting early stages 
of apoptosis that accompany with alterations in membrane potential [6,130]. Furthermore, 
confocal and fluorescence microscopy have been applied to investigate mitochondrial 
morphology, calcium uptake, ROS and mitochondrial connectivity using fluorescence 
recovery after photobleaching (FRAP) techniques [106]. Electron microscopy is applied to 
study mitochondrial morphology, membrane structure and for cytochemical determinations of 
mitochondrial enzymes to map metabolic activity [106]. X-ray microanalysis allows the 
determination of the elemental composition in mitochondria, such as calcium, iron, sodium, 
potassium and chloride, when a small diameter electron beam is focused on individual 
mitochondria [106]. Optical trapping is used to investigate the force of motion of mitochondria 
along microtubules, and the patch-clamping is applied to study mitochondrial membrane 
conductance [106]. Flow cytometry is a well-established technique to analyze mitochondria 
within whole cells [106]. It allows the examination of ROS production, mitochondrial 
cytochrome c release in apoptosis and mitochondrial transmembrane potentials [56,131–
133]. 
 
Methods to investigate isolated mitochondria 
Advances to study isolated mitochondria also include microscopy techniques as well as 
patch-clamping, optical trapping, capillary electrophoresis with laser induced fluorescence 
detection, functionality measurements and flow cytometry [106]. Electron microscopy allows 
for ultrastructural analysis, and fluorescence microscopy can be applied to determine 
membrane potential alterations [106]. Patch clamping monitors the electrophysiological 
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behavior of ion channels in membranes using a pipette electrode that is gently touched to the 
membrane surface. This method is suitable to study all events that are related to the opening 
of the mPTPC [106]. Optical trapping uses the force of laser beams and allows the analysis 
of only a few mitochondria. It has also been applied to measure the force with which a single 
mitochondrion moves along microtubules [106]. Capillary electrophoresis with laser-induced 
fluorescence detection has been shown to successfully separate and detect mitochondria 
[106]. Due to surface charges of the outer mitochondrial membrane, individual mitochondria 
can be separated electrophoretically. Post-column fluorescence detection then allows for the 
analysis of several mitochondrial features [106,134].  
To determine the functionality of isolated mitochondria, it is common practice to measure 
oxygen consumption and phosphorylating activities of isolated mitochondria with Clark 
electrodes [108,135].  
Flow cytometry was introduced to analyze isolated mitochondria in 1986 [136]. The 
advantages of flow cytometry are the capability for high throughput screening analysis [106], 
that it is applicable to analyze highly diluted samples and thus does not consume large 
amounts of isolated mitochondria. A disadvantage of this technique is that the size of 
mitochondria is at the lower limit of size related resolution [136]. Additionally, it is difficult to 
distinguish between different populations of mitochondria dependent on the size or to 
exclude double mitochondria from analysis. Therefore, most assays of isolated mitochondria 
analysis by flow cytometry are based on fluorescence measurements that allow for the 
analysis of individual mitochondria [137]. Alterations in membrane potential as a result of 
various treatments can be detected with transmembrane potential sensitive fluorescence 
dyes [106]. Flow cytometry further enables to measure reactive oxygen species with 
fluorescence dyes that react with ROS [135,138] and mitochondrial related changes during 
apoptosis can also be analyzed [139,140]. Fluorescently labeled antibodies can be used to 
determine the localization of proteins [106]. Further, the accumulation of substances or 
nanocarriers in mitochondria can be detected with this technique [9,47,141]. Flow cytometry 
has also been applied to separate individual mitochondria via a sorting device for 
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mitochondrial genome analysis after a following PCR amplification [106,142]. Until recently, a 
not described but possible application of flow cytometry is the analysis of mitochondrial 
dynamics, in particular mitochondrial fusion, a process that has been imitated and observed 
in vitro with GFP- and dsRed-transfected isolated mitochondria and analysis by microscopy 
techniques [143]. Flow cytometry also allows for the analysis of two and more fluorescent 
dyes simultaneously, i.e. multiparametric analysis, and therefore, it is thinkable that studies 
of mitochondrial fusion in vitro may also be carried out by flow cytometry.  An even higher 
number of mitochondria can be investigated compared to microscopy techniques that 
accompany with time consuming counting of a comparatively low sample number. 
 
Conclusions 
Due to the facts that mitochondria play a crucial role in various metabolic processes of the 
cell, that they exhibit a lot of structural and functional features which differ from other cellular 
compartments and that mitochondrial dysfunction is related to several diseases, these 
organelles went into the focus of drug and drug delivery research. But even though 
mitochondria exhibit a lot of potential targets and the knowledge about functional 
characteristics in relation to diseases and drug action increases continuously, the field of 
mitochondrial research, in particular regarding drug delivery, is still in its infancy. This is 
certainly due to the barriers that have to be crossed to achieve a selective targeting and 
accumulation in mitochondria. Even though several approaches to mitochondrial drug 
delivery have already been accomplished, there is still a demand for more selective targeting 
to improve drug efficiency and the therapeutic outcome in various diseases. Thereby, 
applicable analytics to assure drug accumulation and their physiological effects on 
mitochondria are required as well.  
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1.2 Goals of the thesis 
This thesis was focused on mitochondria as an intracellular target for drug delivery. The main 
idea was to accomplish targeting of mitochondria with nanomaterials by utilization of the 
mitochondrial fusion process instead of the mitochondrial protein import pores. To achieve 
recognition by mitochondria, the nanomaterials were conjugated to mitochondrial targeting 
peptides that are known to be recognized by mitochondria and in particular, by the 
mitochondrial protein import pores. This means, the goal was to combine targeting strategies 
by using specific targeting peptides and utilization of mitochondrial fusion to accomplish an 
uptake of nanomaterials into mitochondria. The challenge was to establish methods that are 
able to follow the individual steps of this process.  
First, a protocol for the isolation of mitochondria was developed (Chapter 2). Furthermore, 
methods to characterize these preparations in order to demonstrate integrity and functionality 
of mitochondria by making use of a membrane integrity assay, staining with a potential 
dependent dye und analysis of mitochondrial ultrastructure by transmission electron 
microscopy are described.  
A method, established to monitor long time functionality of isolated mitochondria in terms of 
their oxygen consumption, is described in Chapter 3. Analytical techniques to image isolated 
mitochondria and making them accessible to fluorescence microscopy and flow cytometry 
are described in Chapter 4.  
Chapter 5 summarizes protocols to accomplish and detect mitochondrial fusion in vitro. 
Mitochondrial fusion in vitro was detected qualitatively by confocal laser scanning microscopy 
that detects merged colors of fluorescent labels and transmission electron microscopy that 
reveals fusion intermediates of mitochondria with distinct inner membranes and fused outer 
membranes. Finally, mitochondrial fusion in vitro was determined quantitatively by 
establishing a protocol based on flow cytometry. 
The targeting of mitochondria with nanoparticles by utilization of mitochondrial fusion and 
several approaches to affect mitochondrial fusion itself are summarized in Chapter 6. Based 
on the successful in the presence of PEG, the idea evolved to affect mitochondrial fusion in 
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vitro specifically by other PEG derivatives and nanomaterials that carry targeting peptides 
which are known to be recognized by mitochondria. For this set of experiments, two different 
targeting peptides, a natural mitochondrial targeting sequence (MLS) and a mitochondria 
penetrating peptide (MPP) were conjugated to 8arm PEGs, dendrimers, a polyetheramine 
and quantum dots. The efficiency of these additives on mitochondrial fusion in vitro was 
evaluated using flow cytometry. 
As a consequence of the results of affecting mitochondrial fusion efficiency in vitro, the 
binding behavior of the mitochondrial targeting peptides, MLS and MPP, to isolated 
mitochondria was investigated, described in Chapter 7. Therefore, the MLS was labeled with 
quantum dots and fluorescent dyes to determine binding by flow cytometry. MLS capped 
gold nanoparticles were synthesized for a transmission electron microscopy study. The 
binding behavior of the MPP was determined by a photoconversion method in transmission 
electron microscopy using an 8armPEG modified with MPP and a fluorescent dye. 
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Abstract 
A protocol for the isolation of mitochondria from CHO-K1 cells based on differential 
centrifugation in an isotonic isolation buffer was established. Several purification procedures 
were evaluated regarding to their applicability for the preparative separation of isolated 
mitochondria from cell fragments. The protein concentration of the crude isolated 
mitochondrial fraction was determined using a Bradford-Assay. Integrity of the outer 
mitochondrial membranes was evaluated by Cytochrome c Oxidase Assay, revealing that 
more than 90 % of mitochondria were intact immediately after isolation. Furthermore, the 
accumulation of the membrane potential sensitive fluorescent dye JC-1 in isolated 
mitochondria indicated intactness of mitochondrial membranes and hence, functionality of 
mitochondria. The characterization of isolated mitochondria by transmission electron 
microscopy (TEM) revealed typical features of mitochondria such as the double membrane 
that is folded into cristae. The size of isolated mitochondria was also determined by TEM and 
photon correlation spectroscopy.  
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2.1 Introduction 
The isolation of mitochondria can be a necessary procedure for many purposes [1]. It can be 
the step prior to the purification of mitochondrial subcomponents such as proteins or nucleic 
acids, the performance of metabolic measurements such as respiratory activity 
measurements or enzymatic assays and the performance of metabolic analyses on 
biogenetic activity [1,2]. Isolation of mitochondria can also be utilized as a subsequent step 
following the application of molecules or nanocarriers to intact cells, to determine site and 
extent of their subcellular accumulation [3,4]. It can also be used as the primary step in such 
targeting approaches to bypass the cellular membrane and to prevent endocytosis and 
lysosomal or cytosolic degradation of the molecules or carriers that are intended to target 
mitochondria. Although working with isolated mitochondria is controversially discussed and 
exhibits disadvantages such as the lack of signaling processes and the risk of damaging 
mitochondria [5,6] it can be helpful in first approaches toward targeting mitochondria in which 
the organelle  and not overcoming the cellular membrane is primary goal of the 
investigations. 
Over the years, numerous isolation procedures with several modifications depending on the 
differences in tissues or cells have evolved. Most of them comprise the basic steps of 
rupturing cells or homogenizing tissues and differential centrifugation with a first 
centrifugation step at low speed to pelletize nuclei und unbroken cells and a second 
centrifugation step at higher speed to pelletize mitochondria [1]. These steps are usually 
carried out in a special isolation buffer. The composition of such buffers varies between 
different protocols but they usually contain sugars or sugar alcohols to adjust the osmolarity, 
buffering agents such as Tris or HEPES to adjust the pH and EDTA to chelate divalent 
cations which can act as uncouplers by inhibition of the coupling between respiratory chain 
and oxidative phosphorylation followed by impaired mitochondrial metabolic activity. 
Additionally, other salts can be added to isolation buffers for special requirements of further 
investigations. Some protocols make use of hypotonic buffers that cause swelling of the cells 
and ease rupturing. But such buffers may also cause swelling and damage of mitochondria 
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that is why isotonic buffers should be preferred. Usually all steps of the isolation procedures 
are carried out on ice to reduce enzymatic activity and to prevent degradation processes. 
There are different methods to break cells or to rupture tissues such as Dounce-type glass 
homogenizers with loose- or tight-fitting glass pestles or Elvehjem-type glass potters with 
motor-driven Teflon pestles that break cells due to liquid shear forces [1,7]. Nitrogen 
cavitation, sonication and mechanical homogenization by the Ultra-Turrax® are other 
methods to rupture cells [7]. Beside differential centrifugation following the rupture of cells, 
other methods to separate mitochondria are antibody-based immunoisolation approaches 
[7,8] and separation by electrophoresis [7]. Especially the differential centrifugation 
procedures result in crude mitochondrial preparations with several contaminants such as 
fragments of the cell membrane and other organelles. Working with these crude 
mitochondrial fractions can be sufficient but in case of isolation of mitochondrial components 
such as proteins or nucleic acid further purification steps might be required [1]. 
Purification methods make use of density gradients and ultracentrifugation. Gradient media 
vary from polyhydric alcohols such as sucrose, glycerol or sorbitol, to polysaccharides such 
as dextran and Ficoll®, and Percoll® that consists of colloidal silica [7,9]. Different gradient 
types can be distinguished: discontinuous gradients formed by layering techniques, 
continuous gradients and self-generating gradients. Percoll® is easy to handle as it consists 
of polydispers silica particles that are able to form a continuous density gradient by 
themselves via ultracentrifugation without time-consuming layering techniques. It is usable to 
separate populations of cell organelles based in their density [4]. All gradient media and 
gradient types have advantages and disadvantages and hence limitations [7,10]. For 
example, a limit of sucrose, glycerol and sorbitol gradients is the high osmolarity that can 
cause damage of the osmotically active mitochondria [7,10]. Therefore, the purification 
method has to be carefully selected with respect to the source of mitochondria and 
requirements of further investigations. Another method to purify isolated mitochondria is the 
utilization of size exclusion chromatography [11]. General disadvantageous of all purification 
methods are that they are time consuming and lower the already limited metabolic activity of 
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isolated mitochondria. They also lead to dilution of the mitochondrial fraction and loss of 
material. Therefore, purification steps should only be applied when they are reasonable. 
To characterize and standardize or rather determine the yield of the mitochondrial 
preparation, it is common practice to determine the protein content of the mitochondrial 
fraction or to assess mitochondrial enzyme activity [1,12]. A standard method to determine 
protein concentrations is the Bradford assay, a colorimetric assay that is based on the 
absorbance shift of coomassie blue from 495 nm to 595 nm after binding to proteins [13]. It 
has to be considered that contaminants in the mitochondrial preparation can adulterate the 
results when using unpurified mitochondrial fractions. 
The determination of mitochondrial functionality and integrity includes the measurement of 
the activity of various mitochondrial enzymes, the determination of the mitochondrial 
membrane potential, the evaluation of mitochondrial respiratory activity and the analysis of 
the mitochondrial ultrastructure [1,7,14,15].  
The assessment of the outer mitochondrial membrane integrity is necessary due to risk of 
outer membrane damage during isolation [7] leading to loss of functionality. The loss of outer 
mitochondrial membrane integrity inside the cell and the release of cytochrome c into the 
cytosol lead to apoptosis [16]. Therefore, the determination of cytochrome c oxidase activity 
is a useful tool to determine the extent of mitochondrial outer membrane damage of isolated 
mitochondria [17]. It is a rapid and convenient method assaying the rate of oxidation of 
exogenous, reduced cytochrome c. Exogenous cytochrome c cannot penetrate the outer 
mitochondria membrane and is only oxidized when it has access to the cytochrome c 
oxidase in the inner mitochondrial membrane due to damage of the outer mitochondrial 
membrane. The more exogenous cytochrome c is oxidized, the more damaged mitochondria 
are present in the preparation. Disruption of mitochondria with a suitable detergent unmasks 
complete cytochrome c activity and is set as a reference value in comparison to intact 
mitochondria [7]. 
JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide) is a 
fluorescent dye that accumulates in a membrane potential dependent manner in 
Chapter 2 – Isolation of mitochondria and characterization of isolated mitochondria preparations 
 
- 76 - 
 
mitochondria followed by a fluorescence shift from green (529 nm) in the cytosol to red (590 
nm) in mitochondria by the formation of so called J-aggregates. It can be used as an 
indicator of the mitochondrial membrane potential in intact cells as well as isolated 
mitochondria and as an indicator for early stages of apoptosis [17]. 
The determination of mitochondrial ultrastructure and extent of possible damages can be 
directly assessed by using electron microscopy although this technique allows only 
qualitative investigations, is time consuming and particularly not convenient [7]. 
In this study, the establishment of a differential centrifugation method for the isolation of 
mitochondria will be described as well as approaches toward purification by Percoll® 
gradients, ultrafiltration and size exclusion chromatography. 
The characterization methods for isolated mitochondria focus on the determination of the 
protein concentration, mitochondrial outer membrane integrity, mitochondrial membrane 
potential, mitochondrial ultrastructure, mitochondrial fusion competence and respiratory 
activity.  
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2.2 Materials and methods 
2.2.1 Materials 
HAM F-12 nutrient mixture and fetal calf serum (FCS) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trypsin-EDTA 0.25 % was obtained from Gibco-Invitrogen 
(Karlsruhe, Germany). Purified water was obtained by using a Milli-Q water purification 
system from Millipore (Schwalbach, Germany). All cell culture materials were purchased from 
Corning (Bodenheim, Germany). 
Isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % bovine serum albumin (BSA) (Sigma-
Aldrich, Steinheim, Germany). Percoll® was obtained from Sigma-Aldrich (Steinheim, 
Germany). Ultrafree-MC centrifugal filter units with microporous Durapore membrane (PVDF) 
and a pore size of 0.45 µm were purchased from Millipore (Schwalbach, Germany). PD-10 
columns filled with Sephadex G-25 medium and Sephacryl™ S-1000 were obtained from GE 
Healthcare (Freiburg, Germany). Bradford-reagent was prepared by dissolving 100 mg 
Coomassie Brilliant Blue G250 (Sigma-Aldrich, Steinheim, Germany) in 50 ml ethanol  
95 %, 100 ml ortho-phosphoric acid 85 % (Merck, Darmstadt, Germany) and subsequent 
addition of purified water to 1000 ml. The mixture was filtrated through a folded filter 
afterwards and stored in the dark. The Cytochrome c Oxidase Assay Kit was purchased from 
Sigma-Aldrich (Steinheim, Germany). JC-1 was obtained from Invitrogen (Karlsruhe, 
Germany). Antimycin A was purchased from Sigma-Aldrich (Steinheim, Germany). DPBS 
without calcium and magnesium was obtained from Gibco-Invitrogen (Karlsruhe, Germany). 
0.1 M cacodylate fixation buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany), 40 mM sodium chloride (Merck, 
Darmstadt, Germany) and 2 % glutaraldehyde (Serva, Heidelberg, Germany). 0.1 M 
cacodylate washing buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
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calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, 
Darmstadt, Germany). Osmium tetroxide (ScienceServices, Munich, Germany) was 
dissolved to 1 % in 0.1 M cacodylate buffer that consisted of 100 mM sodium cacodylate 
(Roth, Karlsruhe, Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, 
Germany), 1 mM calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM 
sodium chloride (Merck, Darmstadt, Germany). Agarose was purchased from Biozym 
(Hessisch Oldendorf, Germany). Embedding in Epon was carried out with an Epoxy 
Embedding Medium Kit (Fluka by Sigma-Aldrich, Steinheim, Germany). Propylen oxide was 
purchased from Sigma-Aldrich (Steinheim, Germany). Uranyl acetate was obtained from 
Roth (Karlsruhe, Germany). Lead citrate by Reynolds consisted of lead nitrate (Merck, 
Darmstadt, Germany) and tri-sodium citrate dihydrate (Merck, Darmstadt, Germany). 
 
2.2.2 Establishment of a protocol for the isolation of mitochondria 
CHO-K1 cells were cultured in HAM-F12 nutrient mixture containing 10 % FCS in 150 cm2 
culture flasks until confluency, harvested by Trypsin-EDTA 0.25 % and washed with isolation 
buffer. The centrifugation steps for the washing steps of the cells were carried out in a GS-
15R centrifuge (Beckman, Krefeld, Germany). Afterwards, cells from one culture flask were 
suspended in 250 µl isolation buffer. Then, cells from four flasks were pooled and the 
resulting one milliliter of cell suspension was transferred into a cooled 2-ml Dounce glass 
homogenizer (Sigma-Aldrich, Steinheim, Germany) where the cells were disrupted by 25 
strokes. The suspension was transferred into a 2-ml safe-lock tube (Eppendorf, Hamburg, 
Germany) and centrifuged at 1500 g at 4 °C for 10 min a type 5415 R centrifuge (Eppendorf, 
Hamburg, Germany) to pelletize nuclei as well as remaining intact cells. The first supernatant 
was kept on ice, while the pellet was resuspended in isolation buffer and homogenized by 25 
Dounce strokes for a second time to break remaining intact cells. A second centrifugation 
step at 1500 g at 4 °C for 10 min yielded a pellet that was the nuclei enriched fraction. The 
first and the second supernatant were mixed and centrifuged at 16000 g at 4 °C for 15 min to 
obtain a pellet that was the mitochondria enriched fraction. The supernatant of this last 
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centrifugation step was considered an organelle-free soluble fraction. The isolation process 
is depicted in Figure 2.1. The amount of cells used for the isolation of mitochondria 
depended on the required amount for the different experiments. 
 
Figure 2.1: Isolation of mitochondria from CHO-cells by differential centrifugation. 
 
2.2.3 Purification of isolated mitochondria 
Cells were cultured and mitochondria were isolated as described previously. For purification 
of isolated mitochondria by a Percoll® gradient, the Percoll® solution was diluted to different 
initial densities according to the provider´s instruction [18]. The pH of the initial solution was 
adjusted to 7.4 with 0.1 N HCl and the osmolarity was adjusted to 280 mosmol/l by a 2.5 M 
sucrose solution. The volume of the initial solution for each gradient was 10 ml. Various 
gradients were formed via ultracentrifugation in a TFT70.13 rotor. After ultracentrifugation, 
each gradient was separated into 12 fractions with 800 µl each. The density range of the 
gradients was determined by refractive index and calculated according to Pertoft [19]. Three 
different initial densities were tested: an initial density of 1.04 g/ml, ultracentrifuged at  
27100 rpm = 50000 g that resulted in a gradient of 1.15 g/ml – 1.1 g/ml, an initial density of 
1.09 g/ml, ultracentrifuged at 27200 rpm = 50132 g that formed a gradient of 1.19 g/ml –  
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1.08 g/ml and an initial density of 1.1 g/ml, ultracentrifuged at 20000 rpm = 27104 g that 
resulted in a gradient of 1.19 g/ml – 1.11 g/ml. The fractions of the gradients were stained 
with JC-1 2.5 µg/ml and fluorescence was determined with a fluorescence spectrometer 
LS55 (Perkin-Elmer, Rodgau, Germany). 
Purification of isolated mitochondria by ultrafiltration was carried out in centrifugal filter units 
with a pore size of 0.45 µm at 4°C and 12000 g for 5 min in a type 5415 R centrifuge 
(Eppendorf, Hamburg, Germany) to separate cell fragments with a size lower than 0.45 µm 
and to obtain purified isolated mitochondria as the filtration residue. The size of separated 
mitochondria and particles was determined by photon correlation spectroscopy (PCS). 
Purification of isolated mitochondria by size exclusion chromatography was carried out in 
PD-10 columns filled with Sephadex G-25 medium. 20 fractions with 1 ml each were 
collected and the size of separated mitochondria and particles was determined by PCS. As a 
second gel filtration medium, Sephacryl™ S-1000 was filled into a 10 ml syringe to obtain a 
gel filtration column. Isolated mitochondria were layered on top and 20 fractions with each  
1 ml were collected. The size of separated mitochondria and particles was determined by 
photon correlation spectroscopy (PCS).  
 
2.2.4 Characterization of mitochondrial protein concentration (Bradford-Assay) 
Cells were cultured and mitochondria were isolated as described previously. For the 
determination of mitochondrial protein concentration, a calibration curve with 1, 2, 4, 6, 8 and 
10 µg/µl BSA was recorded to calculate the protein concentration of the mitochondrial 
fraction. Each sample of the calibration curve and the mitochondrial fraction was diluted to 
100 µl with purified water in micro-cuvettes. Then, 1 ml of Bradford-reagent was added, 
mixed and incubated at room temperature in the dark for 10 min. Afterwards, absorption of 
the coomassie-protein-complexes at 595 nm was determined by a Kontron Instruments 
Uvikon 900 spectrophotometer (Goebel Instrumentelle Analytik, Hallertau, Germany). 
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2.2.5 Characterization of mitochondrial outer membrane integrity  
 (Cytochrome c Oxidase Assay) 
Cells were cultured and mitochondria were isolated as described previously. The principle of 
the Cytochrome c Oxidase Assay is based on the impermeability of the outer mitochondrial 
membrane to exogenous cytochrome c. The cytochrome c oxidase is located at the inner 
mitochondrial membrane. If the outer mitochondrial membrane is intact, added 
ferrocytochrome c cannot be oxidized to ferricytochrome c by the cytochrome c oxidase. In 
case of outer mitochondrial membrane damage, the exogenous substrate has access to the 
enzyme and can be oxidized, resulting in a decrease of absorbance of ferrocytochrome c at 
550 nm. For the determination of mitochondrial membrane integrity, ferrocytochrome c was 
added to a sample of isolated mitochondria and absorption of ferrocytochome c at 550 nm 
was measured to determine the cytochrome c oxidase activity of intact mitochondria. To 
calculate the amount of undamaged mitochondria according to the provider´s instruction [20], 
it was also necessary to determine the total cytochrome c oxidase activity. Therefore, the 
outer mitochondrial membrane of an isolated mitochondria sample was lysed by the 
detergent n-dodecyl-β-D-maltoside and absorption of added ferrocytochrome c was also 
measured at 550 nm. The concentration of mitochondrial protein was determined by 
Bradford-assay [13]. Isolated mitochondria were diluted to a concentration of 0.2 mg/ml and 
2 µg of mitochondrial protein were used for each sample. All absorption measurements were 
carried out at a Kontron Instruments Uvikon 900 spectrophotometer (Goebel Instrumentelle 
Analytik, Hallertau, Germany) immediately after isolation and 1 h, 2 h, 4 h and 5 h after 
isolation. 
 
2.2.6 Determination of mitochondrial membrane potential (JC-1) 
Cells were cultured and mitochondria were isolated as described previously. The 
carbocyanine dye JC-1 forms red fluorescent J-aggregates with an emission wave length 
maximum of 590 nm when it is taken up into the mitochondrial matrix compared to green 
fluorescent monomers with an emission wave length maximum of 529 nm. Isolated 
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mitochondria were stained with 2.5 µg/ml JC-1. Additionally, isolated mitochondria were 
treated with 10 µM antimycin A for 30 min. Fluorescence was determined by the 
fluorescence spectrometer LS55 (Perkin-Elmer, Rodgau, Germany). 
 
2.2.7 Characterization of mitochondrial ultrastructure  
 (transmission electron microscopy – TEM) 
Cells were cultured and mitochondria were isolated as described previously. Isolated 
mitochondria were fixed in cacodylate fixation buffer at room temperature for 5 min and on 
ice overnight. Afterwards, mitochondria were washed by five washing steps, each of them in 
cacodylate washing buffer for 2 min. Then, isolated mitochondria were pelletized in a 1 % 
agarose solution that was heated up to 40 °C. All centrifugation steps were carried out in a 
himac CT15RE (VWR Leuven, Belgium by Hitachi Koki Co. Ltd.). After gelation of the 
agarose, the gel block was cut and fixed with osmium tetroxide solution overnight. Then, the 
samples were washed in DPBS four times for 15 min. Afterwards, the samples were 
dehydrated in a graded series of ethanol: 50 %, 70 %, 80 %, 90 % and 100 %. Each 
dehydration step was carried out two times for 15 min. Then, the samples were treated in an 
equal mixture of acetone or propylene oxide and ethanol for 20 min and two times in acetone 
or propylene oxide for 20 min. Afterwards, the samples were treated with a mixture of 
acetone or propylene oxide and Epon (2:1) for 2 h, then, in a mixture of acetone or propylene 
oxide and Epon (1:1) for 2 h and subsequently in a mixture of acetone or propylene oxide 
and Epon (1:2) in an open vial overnight. Then, the samples were embedded and hardened 
in Epon at room temperature for 1 h, at 30 °C for 2 h and at 60 °C for 2 days.   
Epon blocks were cut into sections of 50 nm with a microtome Leica EM UC6 (Leica, Vienna, 
Austria) and transferred to copper slot grids with a 1.5 % hyaloform foil. They were examined 
either unstained or stained with uranyl acetate and lead citrate in a transmission electron 
microscope Zeiss EM 902 (Carl Zeiss, Oberkochen, Germany), operating at 80kV. Digital 
images were recorded by a slow scan CCD camera (TRS Typ 7888, Serial No. 321/08). 
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2.2.8 Characterization of mitochondrial size  
Cells were cultured and mitochondria were isolated as described previously. Measurements 
of the hydrodynamic diameter of isolated mitochondria by photon correlation spectroscopy 
(PCS) were carried out with a Zetasizer nano ZS (Malvern, Herrenberg, Germany). All size 
measurements were carried out in isolation buffer at 25 °C.  
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2.3 Results and discussion 
An isolation procedure comprising homogenization by a Dounce-type homogenizer and 
differential centrifugation was established. It was essential to start with an appropriate 
amount of cultured cells to obtain a visible and experimentally manageable pellet of the 
mitochondrial fraction. Thereby, the amount of cells that were cultured prior to the isolation 
procedure varied from 12 to 24 150 cm2 culture flasks, or sometimes more, depending on the 
sample size of the study. The final protocol for the isolation of mitochondria that was used for 
all studies with isolated mitochondria is described in the materials and methods section. 
The mitochondrial fraction was purified by Percoll®-gradients, by ultrafiltration and by size 
exclusion chromatography. The Percoll®-gradients were separated into 12 fractions and the 
presence of isolated mitochondria was determined by measuring the fluorescence intensity 
of JC-1, with which isolated mitochondria were stained prior to the purification procedure. 
Various initial densities of the Percoll® suspension and different centrifugation conditions 
were investigated. All of them led to a high dilution of the mitochondrial fraction with almost 
no more detectable fluorescence of JC-1 in the Percoll®-fractions (Figure 2.2). 
 
Figure 2.2: Fluorescence intensity of isolated mitochondria and isolated mitochondria after separation into 12 
Percoll
®
 fractions. Isolated mitochondria and Percoll
®
 fractions were stained with 2.5 µl/ml JC-1. JC-1 was excited 
at 490 nm and emission of J-aggregates was detected at 590 nm. 
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It was also not possible to separate isolated mitochondria from the Percoll®-fractions 
preparatively. For the purification of isolated mitochondria by ultrafiltration, ultrafiltration units 
with a cut-off of 0.45 µm were used to separate cell fragments that were smaller than 0.45 
µm from isolated mitochondria. The size of the cell fragments and isolated mitochondria in 
the filtrate and filter residue was determined by photon correlation spectroscopy. Before 
ultrafiltration, the mitochondrial fraction contained one population of particles with a size of 
500-600 nm which approximately corresponds to the size of isolated mitochondria [21]. After 
ultrafiltration, one population of particles with a size of 190 nm was detected in the filtrate and 
two populations of particles with a size of 100 nm (90 %) and 500-600 nm (10 %) were 
detected in the filter residue. Hence, it was possible to separate fragments with a size lower 
than isolated mitochondria but the mitochondrial fraction was divided into two populations 
with a high amount of small fragments compared to a low amount of particles that were in the 
size-range of isolated mitochondria. Maybe, isolated mitochondria were disrupted during the 
ultrafiltration process leading to this high amount of small fragments in the filter residue. 
Therefore, ultrafiltration was not a suitable method for the purification of isolated 
mitochondria. For the purification of isolated mitochondria by size exclusion chromatography, 
two gel filtration media were investigated. 20 fractions 1 ml each were collected and the size 
of the fragments and isolated mitochondria was determined by photon correlation 
spectroscopy. Before gel filtration, the mitochondrial fraction contained one population of 
particles with a size of 500-600 nm. After gel filtration through a Sephadex G 25 column, two 
populations of particles, 100 nm (90 %) and 500-600 nm (6-10 %) were detected in the 
fractions 8-12. After gel filtration through the Sephacyrl medium, particles of 200-300 nm 
were detected in all fractions. Hence, it seemed that isolated mitochondria were disrupted by 
both gel filtration media. Beside this, the preparation became highly diluted and it was not 
possible to separate isolated mitochondria from the fractions preparatively. Therefore, size 
exclusion chromatography was also not a suitable method for the purification of isolated 
mitochondria and all studies were carried out with the crude isolated mitochondrial fraction. 
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For standardization and to determine the yield of the mitochondrial preparation, the protein 
concentration of each isolated mitochondrial preparation was determined. Therefore, a 
Bradford-assay [13] was applied after isolation and prior to entering into further experiments. 
The protein concentration was calculated by a calibration curve that was recorded at the 
beginning of each assay. One example is shown in Figure 2.3. 
 
Figure 2.3: Calibration curve of a Bradford Assay determined by UV-Vis absorption at 595 nm. 
 
One 150 cm2 culture flask with approximately 25 million cells yielded 61 ± 16 µg 
mitochondrial protein (mean of 20 measurements ± standard deviation). 
Beside the yield of the mitochondrial preparation, the integrity of the isolated mitochondria 
preparation was determined as only intact mitochondria are functional. Therefore, the 
integrity of the outer mitochondrial membrane was examined by the Cytochrome c Oxidase 
assay [20]. The established differential centrifugation protocol for the isolation of 
mitochondria yielded in an amount of 91.9 ± 0.6 % undamaged mitochondria (mean of three 
individual isolated mitochondria preparations ± standard deviation). This value gave evidence 
that the used isolation procedure did not disrupt the majority of isolated mitochondria and 
was comparable to data from literature that report on 8-44 % damaged mitochondria that 
were isolated from various tissues [22]. Additionally, the integrity of the outer membrane and 
the amount of intact mitochondria was determined over a period of 5 h as most of the studies 
with isolated mitochondria described in this thesis took over a period of several hours.  
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Figure 2.4 shows that the amount of intact mitochondria decreased over time but even after 4 
h, over 80 % of mitochondria were intact. After 5 h, the standard deviation increased 
indicating the loss of integrity after this period of time. 
 
Figure 2.4: Determination of the amount of intact mitochondria immediately after isolation and 1 h, 2 h, 4 h, and 5 
h after isolation by Cytochrome c Oxidase Assay [20]. Data are expressed as means of three measurements ± 
standard deviations (SD). 
 
The membrane potential was also an indicator for the intactness and functionality of isolated 
mitochondria. If isolated mitochondria were intact and functional, the membrane potential 
could be determined by the accumulation of JC-1 in mitochondria and the formation of J-
aggregates that showed fluorescence at 590 nm. Figure 2.5 shows the fluorescence intensity 
of JC-1 stained isolated mitochondria at 590 nm compared to isolated mitochondria that were 
treated with antimycin A, an inhibitor of the respiratory chain. Isolated mitochondria treated 
with antimycin A showed almost no more fluorescence intensity because the membrane 
potential was disrupted. 
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Figure 2.5: Determination of the fluorescence intensity of isolated mitochondria and isolated mitochondria treated 
with antimycin A after staining with 2.5 µg/ml JC-1. JC-1 was excited at 490 nm and emission of J-aggregates 
was detected at 590 nm. 
 
The investigation of the ultrastructure of isolated mitochondria was another method to study 
the integrity of isolated mitochondrial membranes. Figure 2.6, 2.7 and 2.8 show transmission 
electron microscopy (TEM) images of an isolated mitochondrial preparation. The figures 
gave evidence that the applied isolation procedure led to a crude mitochondrial fraction 
containing intact isolated mitochondria but also a lot of cell fragments. The images also show 
that isolated mitochondria had a size of approximately 500-1000 nm. 
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Figure 2.6: TEM image of an isolated mitochondria preparation, 7000x magnification, red arrows indicate intact 
isolated mitochondria. 
 
 
Figure 2.7: TEM image of an isolated mitochondria preparation, 12000x magnification, red arrows indicate intact 
isolated mitochondria. 
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Figure 2.8: TEM image of an isolated mitochondria preparation, 20000x magnification, red arrows indicate intact 
isolated mitochondria. 
 
Beside the determination of the size of isolated mitochondria by TEM images, the size was 
also determined by photon correlation spectroscopy. This method was also applied for the 
characterization of purified isolated mitochondrial samples, described previously. 
Furthermore, the size was determined over a period of several hours. Immediately after 
isolation, one population with a size of 500-600 nm was found. After 2.5 h, the size of the 
population increased up to 600-700 nm indicating a swelling of mitochondria. Beside the 600-
700 nm population, a population of 100 nm fragments was detectable after 5 h, indicating 
disrupture of mitochondria. These results corresponded to the results of the Cytochrome c 
Oxidase assay. 
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2.4 Conclusions 
The goals of this study were to establish a suitable protocol for the isolation of mitochondria 
from cultured cells and to characterize these isolated mitochondria. An isolation procedure 
can be either quick or time consuming especially when purification steps follow the isolation 
process. All investigated purification methods were time consuming, led to dilution of the 
samples and therefore, were not applicable for preparative purposes. Additionally, 
ultrafiltration and gel filtration led to disrupture of isolated mitochondria. As it depends on the 
requirements of the subsequent studies, it should be decided as the case arises whether 
purification steps are reasonable or not. In case of the studies presented in this thesis, it was 
essential to obtain intact and functional mitochondria that showed functionality over several 
hours. Therefore, a quick isolation protocol without further purification steps was established. 
It led to a crude mitochondrial fraction containing intact isolated mitochondria and cell 
fragments as the TEM studies showed. Staining with the potential sensitive dye JC-1 showed 
intactness of isolated mitochondria by the presence of the mitochondrial membrane potential. 
The Cytochrome c Oxidase assay showed that a high amount of isolated mitochondria was 
intact after isolation with the established protocol, indicating that the isolation procedure was 
very gentle. It was also shown that mitochondria were intact for up to 4 h after isolation which 
means that all studies with isolated mitochondria should be accomplished within 4 h.  
.  
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Abstract 
We have investigated the ability of optical oxygen sensors incorporated in a microplate to 
determine the respiratory activity of cell fractions. Different cell fractions were monitored, in 
particular to evaluate the long term functionality of isolated mitochondria. It is possible to 
continuously sense respiratory activity of isolated mitochondria over time. We found that they 
are functional for three hours but stop respiring at a critical limit of 20 % air saturation in the 
system. Furthermore, inhibition and enhancement of respiratory activity were detected. In 
conclusion, oxygen sensors are a powerful tool to evaluate the functionality of isolated 
mitochondria. 
 
Keywords 
Isolated mitochondria, respiratory activity, optical oxygen sensor, high throughput screening 
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3.1 Introduction 
Due to the emergence of evidence that mitochondria are involved in diseases [1] such as 
cancer [2,3], neurodegenerative diseases [4–6] and diabetes [7,8] mitochondria have 
become an increasingly important target of contemporary cellular research [9–12].  
Studies with isolated mitochondria are thereby common practice and have been applied to 
several aspects of mitochondrial research, such as mitochondrial physiology [13], altered 
mitochondrial function in diseases [14], biogenetical activities like mtDNA expression, tRNA 
aminoacylation, protein synthesis and protein import [15]. In addition, the influence of 
substances on mitochondrial respiratory competence [16], the accumulation of drugs [17] 
and drug carriers [18] have also been reported.  
Isolated mitochondria are advantageous in that experimental conditions can be precisely 
controlled and adapted to the requirements of the scientific approach by supplementation of 
substrates, inhibiting and uncoupling substances. Hence, isolation of mitochondria is a widely 
used procedure in mitochondrial research. Numerous protocols have evolved over the years, 
making use of fast methods, such as differential centrifugation [19], more time-consuming 
gradient-purification procedures [17,20] and antibody-based approaches [21]. The choice of 
the method depends on the source of mitochondria and the respective research goal.  
The ultimate goal of a preparation of isolated mitochondria is to obtain the organelles as 
functional as possible. Therefore, it is common practice to measure the functionality of 
isolated mitochondria in terms of their oxygen consumption [19]. Amperometry is the 
standard method for the determination of oxygen partial pressure in aqueous solutions by 
using Clark electrodes. Even though they are sensitive, Clark electrodes suffer from a 
number of drawbacks in that they are difficult to miniaturize, consume oxygen, are limited to 
discrete measurements and difficult to use in high throughput applications [22]. 
Measurements with such oxygen electrodes are carried out over a short period of time and 
can, therefore, only be used on respiring mitochondria that have been obtained prior to 
entering into further experiments. Optical sensors and microplate based systems can 
overcome these limitations [22] allowing the possibility to work with moderate sample 
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volumes, hence limiting the wastage of the majority of the preparation and making it possible 
to measure over long periods of time [23]. The quantification of dissolved oxygen with such 
systems was first described for cytotoxicity and proliferation assays of living cells [23–26] and 
more recently for isolated mitochondria. The influence of cisplatin on the respiratory activity 
of isolated mitochondria [27] and a high throughput method [28] have been reported. 
The advantages of optical oxygen sensors compared to standard amperometry methods led 
us to the establishment of a method that monitors the oxygen consumption of cell fractions 
(in particular isolated mitochondria) over a long period of time, consumes only a small part of 
the preparation, is easy to handle and allows for automation in high throughput assays. 
Applications of this method in various biological, medical and pharmacological experiments 
should be conceivable.  
A 96 well microplate with optical oxygen sensors was integrated in a polymer film in the 
bottom of each well (OxoPlate®) and served to determine oxygen depletion by monitoring the 
oxygen concentration in the surrounding medium continuously over a period of four hours. 
Different cell fractions obtained from CHO-K1 cells were monitored and particular attention 
was paid to the respiratory competence of the mitochondria-enriched fraction. The sensitivity 
of isolated mitochondria to respiration inhibiting and uncoupling substances was also studied. 
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3.2 Materials and methods 
3.2.1 Materials  
The isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % BSA (Sigma-Aldrich, Steinheim, 
Germany). The respiration buffer consisted of 250 mM sucrose (Merck, Darmstadt, 
Germany), 10 mM Tris (USB Corporation, Cleveland, OH USA), 2 mM K2HPO4 (Merck, 
Darmstadt, Germany), 5 mM succinic acid (Sigma-Aldrich, Steinheim, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.4 mM ADP (Sigma-Aldrich, Steinheim, 
Germany). Antimycin A and carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) 
were purchased from Sigma-Aldrich (Steinheim, Germany). The microtiter plate with 
integrated optical sensos for oxygen (OxoPlate®) was obtained from PreSens (Regensburg, 
Germany) and paraffin oil was purchased from Caelo (Hilden, Germany). 
 
3.2.2 Preparation of cell fractions  
Three cell fractions: the mitochondria enriched fraction, the nuclei enriched fraction and the 
organelle-free soluble fraction were obtained using a modified differential centrifugation 
procedure based on methods that were reviewed by Fernández-Vizarra [15]. In brief, CHO-
K1 cells were cultured until confluency in culture flasks of 150 cm2, then harvested and 
washed with isolation buffer. Cells from one culture flask were suspended in 250 µl isolation 
buffer. Then, cells were pooled from four flasks and the resulting one milliliter cell suspension 
was transferred into a 2-ml Dounce glass homogenizer (Sigma-Aldrich, Steinheim, 
Germany), where the cells were disrupted by 25 strokes. The suspension was transferred 
into a 2-ml safe-lock tube (Eppendorf, Hamburg, Germany) and centrifuged at 1500 g and 4 
°C for 10 min in a type 5415 R centrifuge (Eppendorf, Hamburg, Germany) to pelletize nuclei 
as well as remaining intact cells. The first supernatant was kept on ice, while the pellet was 
resuspended in isolation buffer and homogenized by 25 Dounce strokes for a second time to 
break the cells. A second centrifugation step at 1500 g and 4 °C for 10 min yielded a pellet 
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containing the nuclei enriched fraction. It was resuspended in respiration buffer for the 
oxygen consumption measurements. The pellet that contained nuclei from four cell culture 
flasks was resuspended in one milliliter of respiration buffer and an amount of 25 µl was used 
for the measurement of oxygen consumption.  
The first and the second supernatant were mixed and centrifuged at 16000 g and 4 °C for 15 
min to obtain a pellet. This gave the mitochondria enriched fraction and was also 
resuspended in respiration buffer for the measurements of oxygen consumption. The 
supernatant of this last centrifugation step is considered an organelle-free soluble fraction. 
We used about 40 µg of isolated mitochondria resuspended in 25 µl respiration buffer per 
individual sample which approximately corresponds to mitochondria from confluently grown 
cells in one 150 cm2 cell culture flask. A Bradford-assay was applied to determine the 
amount of isolated mitochondria. 
 
3.2.3 Determination of oxygen consumption  
The measurement of the oxygen concentration was based on an optical sensing scheme. 
The fluorescent probe Pt(II)-pentafluorophenylporphyrin was incorporated into polystyrene 
microparticles which in turn were contained in a thin film of a polymer that was deposited on 
the bottom of the well of a conventional microtiter plate. The red fluorescence of the probe 
(indicator dye) in the sensor film was photoexcited at 544 nm and its intensity was 
dynamically quenched by molecular oxygen [29]. An inert reference dye (sulforhodamine) 
was also contained in the sensor film and could be excited at the same wavelength as the 
indicator dye, yielding a yellow reference signal that was independent of the partial pressure 
of oxygen (pO2) [30]. The oxygen partial pressure (pO2) was then calculated by the plate 
reader via the Stern–Volmer equation after a two-point calibration [31]. The determined 
oxygen concentration was indicated as the percentage of air saturation (% air saturation), a 
relative measure for the amount of dissolved oxygen in a medium related to the oxygen 
concentration in ambient air. Completely air saturated medium was defined as 100 %. 
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Resuspended cell fractions (25 µl of each) and buffer as a control were pipetted into the 
microplate wells, and each sample was then covered with approximately 100 µl of paraffin oil 
to prevent oxygen in the air from diffusing into the samples. The functionality of the 
mitochondria enriched fraction was evaluated by monitoring the oxygen depletion of the 
surrounding buffer and by investigating the effect of substances that inhibit or enhance 
respiration. Antimycin A and FCCP (each in 10 µM concentration) were applied to inhibit 
respiration, while a 1 µM concentration of FCCP was used to enhance respiration. Standards 
with oxygen-free and oxygen-saturated water were also measured and used for the 
calculation of oxygen concentrations. The measurements started 1 h after the preparation of 
cell fractions. Oxygen concentrations in each well were determined over 4 h in 5 min 
intervals. The optical sensors were read out through the optically transparent bottom of the 
plate by a commercially available fluorescence intensity microplate reader (Thermo Fisher 
Scientific Fluoroskan Ascent Microplate Reader, Waltham, MA USA). Fluorescence of each 
well was measured in a dual kinetic mode to detect the fluorescence of the indicator (at 
544/650 nm) and the reference dye (at 544/590 nm). Analysis of the raw data and calculation 
of the oxygen concentration was carried out as described [24]. 
 
3.2.4 Statistical analysis 
Data are expressed as means of five measurements ± standard deviations (SD). 
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3.3 Results and discussion 
3.3.1 Differences of oxygen consumption in cell fractions  
We first measured the oxygen concentration of all cell fractions obtained by differential 
centrifugation over a period of 4 h (Figure 1). The mitochondria enriched fraction (Figure 1A) 
showed a high depletion of oxygen with a minimum of about 20 % air saturation after 
approximately 100 min. In contrast the organelle-free soluble fraction (Figure 1C) showed no 
oxygen consumption because these fractions contained no oxygen consuming cell 
components.  
 
Figure 3.1: Oxygen consumption of (A) mitochondria enriched fraction (black rhombs) compared to buffer (gray 
squares), (B) nuclei enriched fraction (black rhombs) compared to buffer (gray squares) and (C) soluble fraction 
(black rhombs) compared to buffer (gray squares). The mitochondria enriched fraction shows a high depletion of 
oxygen whereas the nuclei enriched fraction and the soluble fraction show only marginal or no oxygen 
consumption compared to buffer. 
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The mitochondria enriched fraction showed a maximum oxygen consumption of about 60 % 
air saturation. After approximately 100 min at a concentration of about 20 % air saturation in 
the surrounding medium, the mitochondria stopped respiring. Considering that there was a 1 
h delay between isolation and starting of the measurements, mitochondria respired for 
approximately 3 h. The continuous increase of oxygen concentration in the mitochondria-
enriched fraction after approximately 100 min occurred due to the diffusion of oxygen from 
the environment. This occurred permanently but is only detectable after the mitochondria 
stopped respiring. The paraffin cover could not completely prevent diffusion of oxygen from 
ambient air and hence partly compensated oxygen consumption [32]. The same effect was 
observed for bacteria under treatment of bactericidal compounds: once the bacteria stopped 
respiring after they were killed by antibiotics, the oxygen concentration caused by oxygen 
diffusion from the environment increased [24]. 
The nuclei enriched fraction (Figure 1B) shows an oxygen consumption of about 10 % air 
saturation during the first 20 min of the measurements. Among others, this effect can be 
explained by the contamination of the nuclei enriched fraction with mitochondria. The 
organelle containing cell fractions are defined as enriched fractions, nuclei and mitochondria 
enriched fraction, but it has to be considered that they were obtained by a quick isolation 
procedure without purification. Therefore, it is likely that all cell fractions contained 
contaminants. Beside contamination of the nuclei enriched fraction with mitochondria, 
intranuclear mitochondria that can be functional have also been reported [33–36]. Both 
phenomena, contamination of the nuclei enriched fraction and intranuclear mitochondria, are 
responsible for the marginal oxygen consumption in the nuclei enriched fraction. 
 
3.3.2 Effect of respiration inhibiting substances on the consumption of oxygen by the  
 mitochondria enriched fraction  
After having established a measurement protocol, we evaluated, if the effect of substances 
that inhibit mitochondrial function can be detected. We, therefore, blocked the respiratory 
chain using antimycin A (an inhibitor of complex III) or stopped the oxidative phosphorylation 
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using FCCP at high concentration (10 µM). Both substances interrupted the respiratory chain 
and consequently decreased oxygen consumption. Figure 2 shows that it is possible to 
detect the inhibition of mitochondrial respiration under the applied experimental conditions. 
Antimycin A seems to have inhibited respiration more efficiently than FCCP since both 
substances were added to the same molar concentration half an hour prior to the 
measurement started. Antimycin A led to almost no oxygen depletion, while mitochondria 
under a 10 µM FCCP treatment still consumed oxygen of about 20 % air saturation over 45 
min. Hence, it is possible to detect time-dependent differences in the toxicity of substances. 
FCCP required more than 1 h of incubation time to show a toxic effect whereas mitochondria 
had already stopped respiring after half an hour at the antimycin A treatment. After 
mitochondria had stopped respiring under a 10 µM FCCP treatment, the effect of increasing 
oxygen concentration due to oxygen diffusion from the environment was also detectable. 
 
Figure 3.2: Inhibition of mitochondrial respiration with antimycin A (black triangles) and FCCP (black circles) at 
concentrations of 10 µM compared to respiration of mitochondria under normal conditions (gray rhombs) and 
buffer (gray squares). Mitochondria completely stopped respiring under antimycin A treatment while half an hour 
preincubation with 10 µM FCCP was not enough to inhibit respiration entirely. They stop respiring after 
additionally 45 min incubation time. 
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3.3.3 Effect of a respiration enhancing substance on the consumption of oxygen by  
 the mitochondria enriched fraction  
We also tested if an increase of oxygen consumption that is known to follow the 
supplementation with low concentrations of FCCP that thereby acts as an uncoupling agent 
is detectable [37]. To this end, we added FCCP to a 1 µM concentration which uncouples the 
respiratory chain and oxidative phosphorylation and hence leads to increased oxygen 
consumption. Figure 3 shows that an increase in the consumption of oxygen under a 1 µM 
FCCP treatment was indeed detectable. The starting point of the FCCP curve at 60 % air 
saturation is related to the time delay between adding FCCP to the sample, pipetting into the 
well-plate, covering with paraffin and starting the experiment. During this time mitochondria 
had already consumed oxygen of about 20 % air saturation compared to the sample without 
FCCP 1 µM. Uncoupled mitochondria stopped respiring at concentrations of about 20 % air 
saturation. This occurred approximately after 50 min. This means that uncoupled 
mitochondria respired of half the time compared to untreated mitochondria. Again, after 
mitochondria had stopped respiring, oxygen concentration increased due to the diffusion of 
oxygen from the environment. 
 
Figure 3.3: Enhancement of mitochondrial respiration with low concentration (1µM) of FCCP (black circles) 
compared to respiration of mitochondria under normal conditions (gray rhombs) and buffer (gray squares). The 
respiration rate under 1 µM FCCP treatment is higher than under normal conditions. In both cases mitochondria 
stop respiring at about 20 % air saturation but under FCCP treatment they reach this value in half the time. 
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It is likely that an oxygen concentration of about 20 % air saturation in the surrounding 
medium is a critical limit below which mitochondrial death is induced. It is also possible that a 
change in respiratory states which depends on the availability of substrates occurred. Five 
respiratory states of isolated mitochondria can be distinguished according to Chance and 
Williams [38]. State 1 is indicated by high oxygen levels, low ADP and low substrate levels. 
State 2 shows high oxygen and high ADP levels but almost no substrate. In state 3, all 
components are available in excess. State 4 indicates high oxygen and high substrate levels 
but low ADP levels and state 5 shows high substrate and ADP levels but no oxygen.  
It is likely that an oxygen concentration of about 20 % air saturation in the surrounding 
medium is a critical limit below which mitochondrial death is induced. It is also possible that a 
change in respiratory states which depends on the availability of substrates occurred. Five 
respiratory states of isolated mitochondria can be distinguished according to Chance and 
Williams [38]. State 1 is indicated by high oxygen levels, low ADP and low substrate levels. 
State 2 shows high oxygen and high ADP levels but almost no substrate. In state 3, all 
components are available in excess. State 4 indicates high oxygen and high substrate levels 
but low ADP levels and state 5 shows high substrate and ADP levels but no oxygen.  
The applied experimental conditions are related to state 3 when the measurement started. 
This means that all components were available in excess and enzymes of the respiratory 
chain worked at the highest level when ADP, substrates such as succinate and oxygen were 
available in excess. In this case, the respiration rate was high. While mitochondria were 
respiring, oxygen was consumed and became a respiration rate limiting component moving 
the system into respiratory state 5 with no respiration activity. Succinate and ADP were also 
metabolized but they were added in excess. If the concentration of succinate or ADP 
reduced to a critical limit, the respiration rate would slow down but not reach zero like in state 
5.  
Respiration came to an end at an oxygen concentration of approximately 20 % air saturation 
which gives evidence that this concentration is a critical limit for mitochondrial respiration and 
oxygen is the respiration rate limiting substance.  
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3.4 Conclusions  
We are presenting a tool to monitor the functionality of mitochondrial preparations over 
several hours. Typical features include the need of only a few microliters of isolated 
mitochondria, the possibility of using microplate sensor technology which allows for the high 
throughput screening of large sample numbers. The duration of the measurements can be 
extended easily without any additional experimental effort. With the data from the oxygen 
consumption measurements a user of this setup can subsequently control the functionality of 
a mitochondrial preparation at each step of an experiment under different experimental 
conditions, for example varying buffers or additives. The system is finally able to detect 
whether substances act directly on mitochondrial respiratory competence.  
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Abstract 
Isolated mitochondria were labeled with fluorescent dyes and fluorescent proteins to make 
them accessible for fluorescence based analytical methods. The study revealed that staining 
with fluorescent dyes (JC-1 and MitoTracker® Deep Red) was only temporary as the dyes 
washed out. In contrast to that, mitochondria were labeled permanently with fluorescent 
proteins. Therefore, cells were transfected using plasmid vectors that encode fluorescent 
proteins. After transfection, fluorescing cells were separated from cells that did not carry 
fluorescent proteins by antibiotic selection and flow cytometry sorting. Thereby, stable cells 
lines containing different mitochondrial fluorescent proteins were obtained. The cell lines 
either carried a mitochondria targeted green fluorescent protein (mtGFP) or a mitochondria 
targeted red fluorescent protein (mtRFP). Additionally, cells that already contained a 
mitochondria targeted aequorin were transfected with mtGFP to detect green fluorescence of 
the mtGFP without excitation by a laser but by excitation due to Förster resonance energy 
transfer (FRET) from aequorin to GFP.  
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4.1 Introduction 
A permanent fluorescent labeling of isolated mitochondria is essential to make them 
accessible to fluorescence based analytical methods such as fluorescence microscopy and 
flow cytometry to study, for example, mitochondrial fusion. Thereby, it is possible to tag 
unlabeled isolated mitochondria or to label mitochondria inside cells and to isolate them 
afterwards. There are various possibilities to label mitochondria. Among these, there are 
numerous organic dyes that are lipophilic, positively charged and that accumulate potential 
dependent in mitochondria or that are sensitive to oxidation in mitochondria [1,2]. They are 
mainly used to stain mitochondria in cells but some of them can also be used to stain 
isolated mitochondria. Other methods to label mitochondria make use of fluorescent proteins 
that contain a mitochondrial targeting sequence and label mitochondria independently of their 
function as well as antibodies that bind to mitochondrial proteins and that can be detected by 
a secondary fluorescently labeled antibody [1]. 
In the following, imaging of mitochondria by fluorescent dyes, fluorescent proteins and the 
natural Förster resonance energy transfer (FRET) pair of the photoprotein aequorin and the 
green fluorescent protein (GFP) are compared. The two fluorescent dyes that have been 
chosen are JC-1 and the MitoTracker® Deep Red FM. MitoTracker® probes are mitochondria 
selective dyes with a mildly thiol reactive chloromethyl moiety that appears to be responsible 
for keeping the dye associated with mitochondria even after fixation [3,4]. The MitoTracker® 
Deep Red FM is a far red fluorescent dye that exhibits an absorption maximum at 644 nm 
and an emission maximum at 665 nm [5,6]. The green-fluorescent JC-1 dye (5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide) exists as a monomer at low 
concentrations or at low membrane potential and emits light of approximately 529 nm. At 
higher concentrations or higher potentials it accumulates potential dependent in mitochondria 
and forms red-fluorescent J-aggregates with an emission maximum at approximately 590 
nm. Thus, the emission of this cyanine dye and the ratio red/green can be used as an 
indicator of mitochondrial membrane potential and mitochondrial depolarization at early 
stages of apoptosis [3,7–9]. Various types of ratio measurements are possible by combining 
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signals from the green-fluorescent JC-1 monomer and the J-aggregate. Thereby, the ratio of 
red-to-green JC-1 fluorescence is only dependent on the membrane potential and not on 
other factors that may influence single-component fluorescence signals, such as 
mitochondrial size, shape and density. Both forms of the dye can be effectively excited at 
488 nm [3].  
Another method to label mitochondria fluorescently is the transfection with fluorescent 
proteins. Thereby, expression vectors that encode fluorescent proteins fused to a 
mitochondrial targeting sequence [10] are delivered into cells by baculoviruses [11,12] or 
transfection reagents such as Lipofectamine® [13,14]. The genes of the plasmid are 
transcribed in the nucleus and the proteins are expressed in the cytosol. After their 
expression, they are translocated into mitochondria due to the mitochondrial targeting 
sequence and there, they can exhibit their fluorescence. In this study, cells were transfected 
with a mitochondria targeted green fluorescent protein (mtGFP) or a mitochondria targeted 
red fluorescent protein (mtRFP). 
Imaging of mitochondria by the natural FRET pair aequorin and GFP is an additional method 
that was applied, in particular as a possibility to detect mitochondrial fusion in a further study. 
Aequorin is a luminescent photoprotein of the jellyfish Aequorea victoria that emits light of 
approximately 470 nm when it binds to its prosthetic group coelenterazine and calcium. The 
jellyfish shows green luminescence due to the energy transfer to GFP [15]. Recombinant 
aequorin is mainly used in sensing intracellular calcium signals [16]. The idea was to detect 
mitochondrial fusion of isolated mitochondria in vitro by mixing isolated mitochondria that 
contain mitochondria targeted aequorin and isolated mitochondria that contain mitochondria 
targeted GFP [17]. After mitochondrial fusion, the green fluorescence of GFP should be 
detectable only by excitation of aequorin after supplementation of calcium and 
coelenterazine. 
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4.2 Materials and methods 
4.2.1 Materials 
HAM F-12 nutrient mixture and fetal calf serum (FCS) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trypsin-EDTA 0.25 % was obtained from Gibco-Invitrogen 
(Karlsruhe, Germany). Purified water was obtained by using a Milli-Q water purification 
system from Millipore (Schwalbach, Germany). All cell culture materials were purchased from 
Corning (Bodenheim, Germany). Imaging plates 24 CG, sample cover glass, were obtained 
from Zell-Kontakt (Nörten-Hardenberg, Germany). 
Isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % bovine serum albumin (BSA) (Sigma-
Aldrich, Steinheim, Germany). JC-1 and MitoTracker® Deep Red FM were obtained from 
Invitrogen (Karlsruhe, Germany) and dissolved in DMSO (Sigma-Aldrich, Steinheim, 
Germany). pShooter™ pCMV/myc/mito and pCMV/myc/mito/GFP were purchased from 
Invitrogen (Karlsruhe, Germany) and pTurboRFP-mito was obtained from BioCat 
(Heidelberg, Germany). The pDsRed2-N1 plasmid was purchased from Takara Bio 
Europe/Clontech (Saint-Germain-en-Laye, France). Opti-MEM® I Reduced Serum Medium, 
Lipofectamine® 2000 and Zeocin Selection Reagent were purchased from Invitrogen 
(Karlsruhe, Germany). G418 was obtained from Sigma-Aldrich (Steinheim, Germany) and 
dissolved in DPBS without calcium and magnesium from Gibco-Invitrogen (Karlsruhe, 
Germany). Hygromycin B and coelenterazine h were purchased from Sigma-Aldrich 
(Steinheim, Germany) and calcium chloride dihydrate was obtained from Merck (Darmstadt, 
Germany). Digitonin was purchased from Calbiochem/Merck (Darmstadt, Germany) and NPY 
was kindly provided by Prof. Buschauer (Department of Pharmaceutical/Medicinal Chemistry 
II, University of Regensburg, Germany). 
Restriction enzymes Not I and Xho I, antarctic phosphatase, BSA, NEBuffers, T4 DNA ligase 
and T4 DNA ligase buffer with 10mM ATP were purchased from New England Biolabs 
(Frankfurt, Germany). Sodium acetate trihydrate was obtained from Merck (Darmstadt, 
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Germany). The QIAquick Gel Extraction Kit and the QIAGEN Plasmid Purification Maxi Kit 
were purchased from Qiagen (Hilden, Germany). Agarose was obtained from Bio-Rad 
(Munich, Germany). Tris acetate EDTA (TAE)-buffer was purchased from Sigma-Aldrich 
(Steinheim, Germany). The DNA ladder TrackIt 100 bp was obtained from Invitrogen 
(Karlsruhe, Germany). Competent E. coli JM 109 were purchased from Promega (Mannheim, 
Germany). Ampicillin was obtained from Sigma-Aldrich (Steinheim, Germany). LB-medium 
consisted of 10 g Bacto Yeast Extract (BD Bioscience, Heidelberg, Germany), 5 g Bacto 
Tryptone (BD Bioscience, Heidelberg, Germany), 5 g sodium chloride (Merck, Darmstadt, 
Germany) in 1000 ml purified water, pH-value was adjusted by 10 N NaOH to 7.5 and 
sterilized by autoclave. Standard nutrient agar was obtained from Merck (Darmstadt, 
Germany). SOC-medium consisted of 2 g Bacto Yeast Extract (BD Bioscience, Heidelberg, 
Germany), 0.5 g Bacto Tryptone (BD Bioscience, Heidelberg, Germany), 10 mM sodium 
chloride (Merck, Darmstadt, Germany), 2.5 mM potassium chloride (Merck, Darmstadt, 
Germany), 20 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany) and 
magnesium sulfate heptahydrate (Merck, Darmstadt, Germany) and 20 mM glucose (Sigma-
Aldrich, Steinheim, Germany) in 100 ml purified water and sterilized by autoclave. CHO-K1 
cells transfected with mitochondrial aequorin (CHO-hY2-k9-qi5-k9-mtAEQ-A7) were a kind 
gift from Prof. Bernhardt (Department of Pharmaceutical/Medicinal Chemistry II, University of 
Regensburg, Germany). 
  
4.2.2 Staining mitochondria with fluorescent dyes 
CHO-K1 cells were cultured in HAM-F12 nutrient mixture containing 10 % FCS in 150 cm2 
culture flasks until confluency, harvested by Trypsin-EDTA 0.25 % and washed with isolation 
buffer. The centrifugation steps for the washing steps of the cells were carried out in a GS-
15R centrifuge (Beckman, Krefeld, Germany). Afterwards, cells from one culture flask were 
suspended in 250 µl isolation buffer. Then, cells from four flasks were pooled and the 
resulting one milliliter of cell suspension was transferred into a cooled 2-ml Dounce glass 
homogenizer (Sigma-Aldrich, Steinheim, Germany) where the cells were disrupted by 25 
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strokes. The suspension was transferred into a 2-ml safe-lock tube (Eppendorf, Hamburg, 
Germany) and centrifuged at 1500 g at 4 °C for 10 min a type 5415 R centrifuge (Eppendorf, 
Hamburg, Germany) to pelletize nuclei as well as remaining intact cells. The first supernatant 
was kept on ice, while the pellet was resuspended in isolation buffer and homogenized by 25 
Dounce strokes for a second time to break remaining intact cells. A second centrifugation 
step at 1500 g at 4 °C for 10 min yielded a pellet that was the nuclei enriched fraction. The 
first and the second supernatant were mixed and centrifuged at 16000 g at 4 °C for 15 min to 
obtain a pellet enriched with isolated mitochondria.  
Isolated mitochondria were stained with either 2.5 µg/ml (~3.8 nmol/ml) JC-1 or 2 µg/ml (~3.8 
nmol/ml) MitoTracker® Deep Red FM, incubated for 15 min on ice and washed with isolation 
buffer three times. Afterwards, isolated mitochondria were analyzed by confocal laser 
scanning microscopy (CLSM) with a Zeiss Axiovert LSM 510 (Carl Zeiss, Oberkochen, 
Germany) and an AxioCam HRc (Carl Zeiss, Oberkochen, Germany). Thereby, JC-1 was 
excited at 488 nm and detected at 560–615 nm whereas the MitoTracker® Deep Red FM was 
excited at 633 nm and detected with a 650 nm long pass filter. In samples containing both 
dyes, a multitrack scan mode was applied. Flow cytometry of JC-1- and MitoTracker®-stained 
samples was carried out with a FACSCaliburTM (BD Bioscience, Heidelberg, Germany). 
Thereby, JC-1 was excited at 488 nm and detected at 564–606 nm whereas the 
MitoTracker® Deep Red FM was excited at 633 nm and detected with a 670 nm long pass 
filter. 
 
4.2.3 Cloning of DsRed into pCMV/myc/mito 
The plasmid vector pShooter™ pCMV/myc/mito encoded a mitochondrial targeting sequence 
to translocate proteins to mitochondria. It expressed proteins fused to the mitochondrial 
targeting sequence [18]. The multiple cloning site (MCS) of the pShooter was cleaved by the 
restriction enzymes Xho I and Not I. The sequence that encoded DsRed in the pDsRed2-N1 
plasmid was also separated by Xho I and Not I. Therefore, both plasmids were incubated 
with Xho I and Not I in NEB3 and BSA at 37 °C for 1 h. Afterwards, DNA was precipitated by 
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sodium acetate and ethanol at -20 °C for 15 min and at 4 °C centrifugation at 16000 g for 15 
min. The pellet was washed with ethanol 70 % and dried at 37 °C for 10 min. Then, the pellet 
was dissolved in purified water at room temperature for 10 min and on ice for 30-60 min. To 
prevent self-ligation, the pShooter was additionally treated with antarctic phosphatase for 
dephosphorylation at 37 °C for 1 h and at 65 °C for 10 min. Afterwards, electrophoresis was 
applied for both plasmids at 120 V for 30 min to separate the fragments that were obtained 
by restriction. Electrophoresis of the agarose gel was carried out in TAE-buffer with ethidium 
bromide. A loading buffer containing bromphenol blue and xylene cyanole was added to both 
plasmids. A DNA ladder was also separated to evaluate the size of the fragments. The large 
fragment of the pShooter and the small fragment of the pDsRed2-N1 were detected by UV 
excitation, cut from the gel and extracted by the QIAquick Gel Extraction Kit. Afterwards, 
ligation of the pShooter and DsRed insert was conducted by T4 ligase in ligase buffer 
containing ATP at 16 °C overnight. Then, the clonal plasmid was transformed into E. coli. 
Therefore, the clonal plasmid DNA was added to E. coli, incubated on ice for 20 min, treated 
at 42 °C for 45-50 s and incubated on ice for 2 min again. Afterwards, SOC-medium was 
added and incubated at 37 °C on a shaker for 1 h. Then, E. coli were plated on LB-agar 
plates with 100 µg/ml ampicillin to select transformants containing the plasmid as the 
pShooter vector contains a resistance gene for ampicillin. The plates were incubated at  
37 °C overnight with a maximum of 12-16 h. Afterwards, transformants were picked, 
transferred into LB-medium containing 100 µg/ml ampicillin and incubated at 37 °C on a 
shaker overnight. On the next day, glycerol stocks of E. coli were prepared for long-term 
storage. Afterwards, plasmid DNA was extracted from E. coli by a QIAGEN Plasmid 
Purification Maxi Kit. DNA was resuspended in water and the concentration was determined 
photometrically. 
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4.2.4 Transfection of fluorescent proteins into CHO-cells 
For transfection of CHO-K1 cells, 38.000 cells per well were seeded into 24 well plates on 
the day before transfection and cells were cultured in HAM-F12 nutrient mixture containing 
10 % FCS. Cells were transfected with 0.5 µg, 1 µg or 2 µg plasmid DNA (pDNA) of 
pShooter™ pCMV/myc/mito/GFP and pTurboRFP-mito. A pDNA to Lipofectamin™ 2000 
transfection reagent ratio of 1:2 or 1:3 was applied. Therefore, both pDNA and 
Lipofectamin™ 2000 were diluted in Opti-MEM® I Reduced Serum Medium separately. 
Afterwards, the Lipofectamine solution was added to the pDNA solution, gently mixed and 
incubated at room temperature for 20 min. During the incubation and formation of the 
polyplexes, the medium of the cells was exchanged to serum-free HAM-F12 medium after 
washing the cells with DPBS. Then, the pDNA-Lipofectamine solution was added to the cells 
and incubated for 4 h. Afterwards, the medium of the cells was exchanged to HAM-F12 
containing 10 % FCS. After 24-48 h, mitochondrial fluorescence of the cells was detected by 
CLSM with a Zeiss Axiovert LSM 510 (Carl Zeiss, Oberkochen, Germany) and pictures were 
recorded with an AxioCam HRc (Carl Zeiss, Oberkochen, Germany). Thereby, GFP was 
excited at 488 nm and detected at 505–530 nm whereas RFP was excited at 488 nm and 
detected at 530–600 nm. For stable transfection, transfected cells were split 1:10 into fresh 
medium and after 24 h the medium was changed to selection medium, HAM-F12 containing 
10 % FCS and 400 µg/ml G418, an aminoglycoside antibiotic. As the used plasmids contain 
a resistance factor to G418, only transfected cells should survive the selection antibiotic. 
After 3–4 h incubation in the selection medium transfected cells were sorted by flow 
cytometry with a FACSCalibur™ (BD Bioscience, Heidelberg, Germany) to separate 
fluorescent cells from non-fluorescent cells and to obtain stably transfected, fluorescent cell 
lines with either mitochondrial GFP or mitochondrial RFP. Thereby, GFP was excited a 488 
nm and detected at 515–545 nm whereas RFP was excited at 488 nm and detected at 564–
606 nm. Stably transfected CHO-mtGFP and CHO-mtRFP cell lines were cultured in HAM-
F12 containing 10 % FCS and 400 µg/ml G418. 
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4.2.5 Imaging with natural FRET-pair aequorin-GFP 
As a positive control for an approach to detect mitochondrial fusion in vitro with aequorin 
containing and GFP containing mitochondria, CHO-cells that contained mitochondrial 
aequorin were co-transfected with GFP as described previously. CHO-AEQ-GPF cells were 
cultured in selection medium HAM-F12 containing 10 % FCS and 400 µg/ml G418, 400µg/ml 
hygromycin B and 250 µg/ml zeocin. Aequorin emits light of 470 nm after binding to 
coelenterazine and calcium. The energy transfer of aequorin to GFP and the following 
fluorescence of GFP in intact cells was induced by the addition of 2 or 5 µM coelenterazine h 
and incubation for 2 h to reconstitute the holoenzyme. Afterwards, 150 µM or 1.5 mM of Ca2+ 
was added as a co-factor of aequorin leading to conformational changes and luminescence 
of aequorin (Figure 4.1).  
 
 
Figure 4.1: Conformational changes of aequorin after binding of coelenterazine and calcium [19]. Coelenterazine 
is bound to aequorin via a peroxide linkage and aequorin has three binding sites for calcium. After binding of 
calcium, the conformation of aequorin changes and the intramolecular reaction of coelenterazine starts. Thereby, 
an instable dioxetanone reacts to coeleteramide after decarboxylation. After relaxation into the ground state, a 
photon of 470 nm is emitted. 
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Fluorescence of GFP after fluorescence resonance energy transfer (FRET) and excitation by 
aequorin in adherent cells was observed by a CLSM Zeiss Axiovert LSM 510 (Carl Zeiss, 
Oberkochen, Germany) with an AxioCam HRc (Carl Zeiss, Oberkochen, Germany). 
Luminescence of aequorin in intact cells and isolated mitochondria was determined with a 
GENios Pro plate reader (Tecan, Salzburg, Austria). Therefore, adherent cells were 
detached by trypsin to obtain suspended cells and mitochondria were isolated as described 
previously. Coelenterazine h was added to suspended cells and isolated mitochondria and 
incubated for 2 h. Luminescence of aequorin in cells was stimulated by addition of 1.5 mM 
Ca2+ after cell membrane permeabilization with 50 µM digitonin or by intracellular calcium 
release after binding of an agonist (NPY) to a G-protein coupled receptor (GPCR). The 
measurement started 2 h after addition of digitonin or rather immediately after addition of the 
agonist. Luminesence of aequorin in isolated mitochondria was stimulated by the addition of 
150 µM or 1.5 mM Ca2+. The measurement started 2 h after the addition of calcium.  
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4.3 Results and discussion 
The principle of mitochondrial fusion experiments in vitro, described in a further study [20], 
was based on differently labeled isolated mitochondria. The hypothesis was to mix differently 
labeled isolated mitochondria and to detect both labels in one mitochondrion after two 
differently labeled mitochondria had fused. For labeling with fluorescent dyes, isolated 
mitochondria were stained either with the fluorescent dyes JC-1 or MitoTracker® Deep Red. 
Staining intact cells, JC-1 exists as a green monomer in the cytosol and forms orange J-
aggregated as it accumulates potential dependent in mitochondria (Figure 4.2) [21]. 
 
Figure 4.2: CLSM image of JC-1 stained cells showing green fluorescent dye monomers in the cytosol and 
orange fluorescent J-aggregates in mitochondria. 
 
Staining isolated mitochondria with JC-1, only orange J-aggregates were detected (Figure 
4.3) indicating that isolated mitochondria were intact and the membrane potential was still 
existent [8]. Isolated mitochondria stained with Mito Tracker® Deep Red are shown in Figure 
4.4. 
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Figure 4.3: CLSM image of JC-1 stained isolated mitochondria. 
 
 
Figure 4.4: CLSM image of MitoTracker® Deep Red stained isolated mitochondria. 
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Figure 4.5: CLSM image of a mixture of JC-1 and MitoTracker® Deep Red stained isolated mitochondria, the left 
image shows fluorescence of JC-1, the image in the middle shows fluorescence of MitoTracker
®
 Deep Red and 
the right image shows both fluorescence channels. 
 
It was hypothesized that JC-1 and MitoTracker® Deep Red could only be detected in one 
isolated mitochondrion after two differently labeled isolated mitochondria, one stained with 
JC-1 and the other one stained with MitoTracker® Deep Red, had fused. Isolated 
mitochondria did not undergo mitochondrial fusion in vitro. Additional conditions had to be 
applied to induce mitochondrial fusion of isolated mitochondria in vitro [22]. Therefore, it was 
expected that isolated mitochondria containing JC-1 or MitoTracker® Deep Red could be 
detected individually labeled side by side when samples of isolated mitochondria stained with 
JC-1 and samples of isolated mitochondria stained with Mito Tracker® Deep Red were simply 
mixed without the application of conditions that induce mitochondrial fusion in vitro. But the 
merged image of the CLSM study showed that most of the isolated mitochondria carried both 
fluorescent dyes (Figure 4.5). Therefore, the hypothesis that two different labels can only be 
detected in one mitochondrion after two differently labeled mitochondria had fused was not 
appropriate. This can be explained by distribution effects. The dyes were not only inside 
mitochondria, but there were still free dye molecules in the surrounding medium that 
accumulated in the oppositely stained mitochondria when the samples were mixed. This 
problem could not be solved by extensive washing of the single-stained samples. As a 
consequence, fluorescent dyes were not applicable for the imaging of mitochondrial fusion in 
vitro. 
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As an alternative, mitochondria were labeled with fluorescent proteins by transfection of 
CHO-cells with different mitochondria targeted fluorescent proteins. At first, CHO-cells were 
transfected with a commercially available plasmid that expressed a mitochondria targeted 
green fluorescent protein (mtGFP). Only a few cells showed green fluorescence 24 h after 
transfection (Figure 4.6). Then, cells were selected with a G418 containing medium as the 
plasmid also carried a resistance gene against the antibiotic G418. After selection with G418, 
more but yet not all cells showed green fluorescence (Figure 4.7).   
 
Figure 4.6: CLSM images showing cells transfected with mitochondria targeted GFP 24 h after transfection, the 
left image shows fluorescence of GFP, the image in the middle shows the bright field image and the right panel 
shows the merged image. Only some cells show GFP fluorescence. 
 
 
Figure 4.7: CLSM images showing cells transfected with mitochondria targeted GFP after G418 selection, the left 
image shows fluorescence of GFP, the image in the middle shows the bright field image and the right panel 
shows the merged image. Not all cells show GFP fluorescence. 
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Because selection with G418 was not sufficient, cells were sorted by flow cytometry. Only 
strong fluorescing cells were selected, resulting in a stable transfected cell line in which all 
cells showed green fluorescence (Figure 4.8). Figure 4.9 shows in more detail that the GFP 
resided in mitochondria. 
 
Figure 4.8: CLSM images showing cells transfected with mitochondria targeted GFP after sorting by flow 
cytometry, the left images show fluorescence of GFP, the images in the middle show the bright field images and 
the right panels show the merged images. All cells show GFP fluorescence. 
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Figure 4.9: CLSM images showing cells transfected with mitochondria targeted GFP. 
 
DsRed was chosen as second label for isolated mitochondria. Therefore, the sequence that 
encoded DsRed was cloned into the plasmid vector that expressed the mitochondria targeted 
GFP, resulting in the expression of a mitochondria targeted DsRed. After successful cloning 
and isolation of the plasmid from E. coli, CHO cells were transfected with the mitochondria 
targeted DsRed. Some of the cells showed orange fluorescence 24 h after transfection 
(Figure 4.10). Unfortunately, the fluorescence of the DsRed was weak and the cells lost the 
plasmid after more than 24 h and after selection with G418. It was not possible to produce a 
stable transfected cell line with mitochondria targeted DsRed. 
 
Figure 4.10: CLSM images showing cells transfected with mitochondria targeted DsRed 24 h after transfection, 
the left image shows fluorescence of DsRed, the image in the middle shows the bright field image and the right 
panel shows the merged image. 
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As an alternative to the fluorescent protein pair GFP – DsRed, the natural FRET-pair GFP – 
aequorin was chosen. The idea was to use isolated mitochondria that carry aequorin and 
isolated mitochondria that carry GFP for the detection of mitochondrial fusion in vitro. The 
hypothesis was that the FRET of aequorin to GFP could be detected after two mitochondria, 
one carrying aequorin and one carrying GFP, had mixed their contents after fusion. To proof 
that the FRET of aequorin to GFP is effective in mitochondria, cells that carried a 
mitochondria targeted aequorin were co-transfected with the mitochondria targeted GFP. 
Transfection with GFP was detected by laser excitation of GFP. After antibiotic and flow 
cytometry selection, a stable transfected cell line with mitochondria targeted aequorin and 
mitochondria targeted GFP was obtained (Figure 4.11). 
 
Figure 4.11: CLSM images showing cells transfected with mitochondria targeted aequorin and mitochondria 
targeted GFP, the left image shows the laser excited fluorescence of GFP, the image in the middle shows the 
bright field image and the right panel shows the merged image. 
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After stimulation of aequorin by coelenterazine h and calcium, the excitation of GFP by FRET 
from aequorin to GFP was not detectable and no green fluorescence of GFP was visible by 
microscopy. Therefore, the luminescence of aequorin was assessed. Intact cells and isolated 
were incubated with coelenterazine h. In intact cells, luminescence was stimulated by 
calcium after cell permeabilization with digitonin or by intracellular release of calcium after 
binding of NPY to a G-protein coupled receptor. In isolated mitochondria, luminescence was 
stimulated by the addition of calcium (Figure 4.12). 
 
Figure 4.12: Luminescence intensity of aequorin of CHO cells (CHO) and CHO cells transfected with 
mitochondria targeted aequorin (CHO-AEQ). Luminescence was stimulated by NPY or calcium after 
permeabilization with digitonin in intact cells and with calcium in isolated mitochondria. 
  
In intact cells carrying aequorin, no luminescence was detectable as well as in cells that did 
not carry aequorin, neither immediately after stimulation nor 2 h after stimulation. It seemed 
that luminescence decayed too fast. In contrast to that, luminescence of aequorin in isolated 
mitochondria was detectable even 2 h after stimulation by calcium. This indicated that 
aequorin was functional. Therefore, the failure of the FRET from aequorin to GFP could not 
be attributed to the functionality of aequorin as aequorin showed as strong and long lasting 
luminescence but the failure may be attributed to the concentrations of GFP and aequorin in 
mitochondria. The concentrations of both proteins were eventually too low for allowing a 
FRET effect.     
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Because DsRed and aequorin were not usable as counterparts to GFP, mitochondria were 
labeled with a red fluorescent protein (RFP). Therefore, cells were transfected with a 
commercially available plasmid that expressed a mitochondria targeted RFP (mtRFP). Only a 
few cells showed red fluorescence 24 h after transfection (Figure 4.13). Then, cells were 
selected with a G418 containing medium as the plasmid also carried a resistance gene 
against the antibiotic G418. After selection with G418, more but yet not all cells showed red 
fluorescence (Figure 4.14).   
 
Figure 4.13: CLSM images showing cells transfected with mitochondria targeted RFP 24 h after transfection, the 
left image shows fluorescence of RFP, the image in the middle shows the bright field image and the right panel 
shows the merged image. Only some cells show RFP fluorescence. 
 
 
Figure 4.14: CLSM images showing cells transfected with mitochondria targeted RFP after G418 selection, the 
left image shows fluorescence of RFP, the image in the middle shows the bright field image and the right panel 
shows the merged image. Not all cells show RFP fluorescence. 
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Because selection with G418 was not sufficient, cells were again sorted by flow cytometry. 
Only strong fluorescing cells were selected, resulting in a stable transfected cell line in which 
all cells showed red fluorescence (Figure 4.15).  
 
Figure 4.15: CLSM images showing cells transfected with mitochondria targeted RFP after sorting by flow 
cytometry, the left image shows fluorescence of RFP, the image in the middle shows the bright field image and 
the right panel shows the merged image. All cells show RFP fluorescence. 
 
When isolated mitochondria containing GFP were mixed with isolated mitochondria 
containing RFP, only single-labeled mitochondria were detected (Figure 4.16) as fluorescent 
proteins did not wash out and labeled isolated mitochondria permanently. 
   
Figure 4.16: CLSM image of isolated mitochondria containing GFP on the left image, isolated mitochondria 
containing RFP in the middle and a mixture of GFP and RFP containing mitochondria on the right image. 
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4.4 Conclusions 
The goal was to tag isolated mitochondria with two different labels to detect mitochondrial 
fusion in vitro in further studies. It was possible to label isolated mitochondria with 
mitochondria specific fluorescent dyes which was a quick and comfortable method. 
Additionally, intactness of isolated mitochondria was shown by the potential sensitive dye  
JC-1. But when samples of differently stained isolated mitochondria were mixed, the samples 
stained each other due to washing out of the fluorescent dyes. Therefore, it emerged that 
fluorescent dyes were not applicable for mitochondrial fusion studies in vitro. Alternatively, 
mitochondria targeted fluorescent proteins were chosen. Transfection of cells with 
commercially available plasmids was successful even though several selection cycles with 
an antibiotic were not sufficient to obtain a stable cell line. After sorting cells by flow 
cytometry, stable cell lines were obtained. In contrast to the commercially available plasmids, 
cloning of DsRed into a plasmid that carried a mitochondrial targeting sequence was a time 
consuming process. It was successful at last but the transfection efficiency of the cloned 
plasmid was low, the fluorescence of the DsRed was low and the cells lost the plasmid within 
a short period of time. It was not possible to create a stable cell line with DsRed containing 
mitochondria. It was also not possible to use the natural FRET pair aequorin – GFP for the 
detection of mitochondrial fusion in vitro as the positive control, a co-transfection of aequorin 
and GFP, failed. The aequorin was active after stimulation but it was likely that the 
concentrations of both proteins were too low and hence, the distance between both proteins 
was too far. Because transfection with mitochondria targeted GFP and RFP was successful 
and stable, GFP- and RFP-labeled mitochondria were used in further studies of 
mitochondrial fusion in vitro.      
Chapter 4 – Permanent labeling of isolated mitochondria 
 
- 135 - 
 
4.5 References 
[1] Invitrogen, Fluorescent detection reagents for imaging mitochondria and lysosomes, 
http://de-de.invitrogen.com/site/de/de/home/References/Molecular-Probes-The-
Handbook/tables/Fluorescent-detection-reagents-for-imaging-mitochondria-and-
lysosomes.html. 
[2] Invitrogen, Molecular Probes fluorescent organelle stains,  
http://de-de.invitrogen.com/site/de/de/home/References/Molecular-Probes-The-
Handbook/tables/Molecular-Probes-organelle-selective-probes.html. 
[3] Invitrogen, Probes for Mitochondria—Section 12.2,  
http://de-de.invitrogen.com/site/de/de/home/References/Molecular-Probes-The-
Handbook/Probes-for-Organelles/Probes-for-Mitochondria.html. 
[4] Invitrogen, Spectral characteristics of the MitoTracker probes—Table 12.2,  
http://de-de.invitrogen.com/site/de/de/home/References/Molecular-Probes-The-
Handbook/tables/Spectral-characteristics-of-the-MitoTracker-probes.html. 
[5] Invitrogen, MitoTracker® Deep Red 633,  
 http://products.invitrogen.com/ivgn/product/M22426. 
[6] E.R. Dabkowski, C.L. Williamson, V.C. Bukowski, R.S. Chapman, S.S. Leonard, C.J. 
Peer, P.S. Callery, J.M. Hollander, Diabetic cardiomyopathy-associated dysfunction in 
spatially distinct mitochondrial subpopulations, Am. J. Physiol. Heart Circ. Physiol 296 
(2009) H359-69. 
[7] Invitrogen, JC-1, http://products.invitrogen.com/ivgn/product/T3168. 
[8] S.-H. Yang, S.N. Sarkar, R. Liu, E.J. Perez, X. Wang, Y. Wen, L.-J. Yan, J.W. Simpkins, 
Estrogen Receptor as a Mitochondrial Vulnerability Factor, Journal of Biological 
Chemistry 284 (2009) 9540–9548. 
[9] S.S. Winter, D.M. Lovato, H.M. Khawaja, B.S. Edwards, I.D. Steele, S.M. Young, T.I. 
Oprea, L.A. Sklar, R.S. Larson, High-throughput screening for daunorubicin-mediated 
drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent, J 
Biomol Screen 13 (2008) 185–193. 
Chapter 4 – Permanent labeling of isolated mitochondria 
 
- 136 - 
 
[10] F. Fuchs, H. Prokisch, W. Neupert, B. Westermann, Interaction of mitochondria with 
microtubules in the filamentous fungus Neurospora crassa, J. Cell. Sci 115 (2002) 1931–
1937. 
[11] Invitrogen, Baculovirus-Mediated Transduction of Mammalian Cells,  
http://de-de.invitrogen.com/site/de/de/home/References/Molecular-Probes-The-
Handbook/Technical-Notes-and-Product-Highlights/BacMam-Gene-Delivery-
Technology.html. 
[12] F. Distelmaier, W.J.H. Koopman, E.R. Testa, A.S. de Jong, H.G. Swarts, E. Mayatepek, 
J.A.M. Smeitink, P.H.G.M. Willems, Life cell quantification of mitochondrial membrane 
potential at the single organelle level, Cytometry A 73 (2008) 129–138. 
[13] Invitrogen, Lipofectamine™,  
http://de-de.invitrogen.com/site/de/de/home/brands/Product-Brand/lipofectamine.html. 
[14] N. Hirota, D. Yasuda, T. Hashidate, T. Yamamoto, S. Yamaguchi, T. Nagamune, T. 
Nagase, T. Shimizu, M. Nakamura, Amino acid residues critical for endoplasmic reticulum 
export and trafficking of platelet-activating factor receptor, J. Biol. Chem 285 (2010) 
5931–5940. 
[15] A. Chiesa, E. Rapizzi, V. Tosello, P. Pinton, M. de Virgilio, K.E. Fogarty, R. Rizzuto, 
Recombinant aequorin and green fluorescent protein as valuable tools in the study of cell 
signalling, Biochem. J 355 (2001) 1–12. 
[16] M. Brini, Calcium-sensitive photoproteins, Methods 46 (2008) 160–166. 
[17] F. de Giorgi, M. Brini, C. Bastianutto, R. Marsault, M. Montero, P. Pizzo, R. Rossi, R. 
Rizzuto, Targeting aequorin and green fluorescent protein to intracellular organelles, 
Gene 173 (1996) 113–117. 
[18] Invitrogen, pShooter,  
http://tools.invitrogen.com/content/sfs/manuals/pshooter_pcmv_man.pdf. 
[19] Wikipedia, Luciferin, http://de.wikipedia.org/wiki/Luciferin. 
Chapter 4 – Permanent labeling of isolated mitochondria 
 
- 137 - 
 
[20] A. Heller, Chapter 5: Mitochondrial fusion in vitro, in: A. Heller (Ed.), Targeting 
mitochondria by mitochondrial fusion, mitochondria-specific peptides and 
nanotechnology: Dissertation. 
[21] N.M. Mhaidat, Y. Wang, K.A. Kiejda, X.D. Zhang, P. Hersey, Docetaxel-induced 
apoptosis in melanoma cells is dependent on activation of caspase-2, Molecular Cancer 
Therapeutics 6 (2007) 752–761. 
[22] S. Meeusen, J.M. McCaffery, J. Nunnari, Mitochondrial Fusion Intermediates Revealed 
in Vitro, Science 305 (2004) 1747–1752. 
  
 
 
 
 
 
 
- 139 - 
 
 
 
Chapter 5 
 
Mitochondrial fusion in vitro 
Chapter 5 – Mitochondrial fusion in vitro 
 
- 140 - 
 
Abstract 
Mitochondrial fusion is an important process in cellular physiology. A protocol for fusion of 
isolated mitochondria from mammalian CHO-K1 cells was established. Mitochondrial fusion 
efficiency was evaluated qualitatively by microscopic methods and quantitatively by flow 
cytometry. Transmission electron microscopy revealed fusion intermediates, mitochondria 
with fused outer membranes but separated inner membranes detected by the ultrastructure 
whereas confocal light scanning microscopy revealed completely fused mitochondria with 
mixed matrices detected by the mixed yellow color of the mitochondrial green and red 
fluorescent proteins. A flow cytometry protocol for the quantitative analysis of mitochondrial 
fusion in vitro was established. It involved control samples to exclude mitochondria that stick 
together from fused mitochondria. A fusion efficiency of about 25 % was determined with this 
method.  
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5.1 Introduction 
Mitochondria are dynamic organelles that move along the cytoskeleton inside cells [1] and 
that form dynamic networks via continuous elapsing fusion and fission processes [2]. Fusion 
and fission regulate mitochondrial morphology, distribution, activity and result in exchange of 
mitochondrial content [2,3]. They are a protective mechanism as the exchange of 
mitochondrial DNA (mtDNA) and proteins facilitates the redistribution of dysfunctional 
proteins and mutated mtDNA to maintain mitochondrial functionality and stability of the 
mitochondrial genome [4]. Mitochondrial fusion is mediated by GTPases in the mitochondrial 
membranes. Mitofusin (Mfn) 1 and 2 are located in the outer membrane of mammalian 
mitochondria and OPA 1 is the fusion GTPase of the inner membrane [2,5]. The N- and C-
terminal regions of the mitofusins protrude into the cytosol forming a U-shaped 
transmembrane domain. The N-terminal domain contains a GTPase and a heptad repeat 
region, HR1 whereas the C-terminus contains a second heptad repeat region, HR2. The 
interaction of mitofusions on adjacent mitochondria is mediated by these HR2 regions 
forming an antiparallel coiled coil that results in tethering of mitochondria [2,6]. OPA1 is 
located within the intermembrane space and is associated with the inner membrane. Fusion 
of the inner membrane is also an energy dependent process mediated by the GTPase 
domain of OPA1 [2]. 
Components of the mitochondrial fission machinery are the dynamin related protein (Drp) 1 
and Fis1. Drp1 contains a GTPase domain and is one key component of the fission 
machinery. It is mainly localized in the cytosol. Fis1, the other key component of the fission 
machinery is localized in the outer mitochondria membrane and does not contain a GTPase 
domain [2].  
Defects in mitochondrial fusion are related to several diseases. Dysfunction of mitochondrial 
fusion due to absence or defective fusion proteins results in fragmentation of mitochondria 
and affects cell growth and development, membrane potential, cellular respiration and plays 
a proapoptotic role [2,7]. Although it is known that mitochondrial fusion plays an important 
role in cellular development, the mechanisms that occur during this event have not been 
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revealed in detail yet. A step towards the understanding of mitochondrial fusion has been the 
establishment of a protocol that captured this process in vitro by Meeusen et al. [8]. It relies 
on studies with yeast mitochondria and has been the initial point for the fusion experiments of 
mitochondria isolated from mammalian cells, described in this study as well as in further 
studies. 
This study focusses on the establishment of a fusion protocol for mammalian mitochondria 
and the methods to detect mitochondrial fusion in vitro. The protocols described in this study 
are based on the imaging methods for isolated mitochondria. To detect mitochondrial fusion 
in vitro, it is necessary to start with two differently labeled populations of isolated 
mitochondria. The behavior of populations, individually labeled with fluorescent proteins, has 
been investigated. Applied detection methods have been confocal laser scanning microscopy 
(CLSM), flow cytometry and transmission electron microscopy (TEM). Both microscopic 
methods allow for the qualitative analysis of mitochondrial fusion in vitro whereas flow 
cytometry has been used for the quantitative determination of mitochondrial fusion efficiency 
in vitro. 
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5.2 Materials and methods 
5.2.1 Materials 
HAM F-12 nutrient mixture and fetal calf serum (FCS) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trypsin-EDTA 0.25 % was obtained from Gibco-Invitrogen 
(Karlsruhe, Germany). G418 was purchased from Sigma-Aldrich (Steinheim, Germany). 
Purified water was obtained by using a Milli-Q water purification system from Millipore 
(Schwalbach, Germany). All cell culture materials were purchased from Corning (Bodenheim, 
Germany). 
Isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % bovine serum albumin (BSA) (Sigma-
Aldrich, Steinheim, Germany). Antimycin A was purchased from Sigma-Aldrich (Steinheim, 
Germany). Fusion buffer consisted of 600 mM sorbitol (Sigma-Aldrich, Steinheim, Germany), 
20 mM Tris (USB Corporation, Cleveland, OH USA), 150 mM potassium acetate (Merck, 
Darmstadt, Germany), 5 mM magnesium acetate tetrahydrate (Merck, Darmstadt, Germany), 
0.1 % BSA (Sigma-Aldrich, Steinheim, Germany), 0.5 mM GTP (Sigma-Aldrich, Steinheim, 
Germany), 1mM ATP (Sigma-Aldrich, Steinheim, Germany), 40mM creatine phosphate 
(Sigma-Aldrich, Steinheim, Germany) and 30 units/ml creatine phosphokinase (Sigma-
Aldrich, Steinheim, Germany). DPBS without calcium and magnesium was obtained from 
Gibco-Invitrogen (Karlsruhe, Germany).  
0.1 M cacodylate fixation buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany), 40 mM sodium chloride (Merck, 
Darmstadt, Germany) and 2 % glutaraldehyde (Serva, Heidelberg, Germany). 0.1 M 
cacodylate washing buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, 
Darmstadt, Germany). Osmium tetroxide (ScienceServices, Munich, Germany) was 
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dissolved to 1 % in 0.1 M cacodylate buffer that consisted of 100 mM sodium cacodylate 
(Roth, Karlsruhe, Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, 
Germany), 1 mM calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM 
sodium chloride (Merck, Darmstadt, Germany). Agarose was purchased from Biozym 
(Hessisch Oldendorf, Germany). Embedding in Epon was carried out with an Epoxy 
Embedding Medium Kit (Fluka by Sigma-Aldrich, Steinheim, Germany). Propylen oxide was 
purchased from Sigma-Aldrich (Steinheim, Germany). Uranyl acetate was obtained from 
Roth (Karlsruhe, Germany). Lead citrate by Reynolds consisted of lead nitrate (Merck, 
Darmstadt, Germany) and tri-sodium citrate dihydrate (Merck, Darmstadt, Germany). 
 
5.2.2 Mitochondrial fusion in vitro 
Long-time cultivation of CHO-cell lines that were stably transfected with mitochondria 
targeted green fluorescent protein (mtGFP) and mitochondria targeted red fluorescent 
protein (mtRFP) was carried out in selection medium HAM-F12 containing 10 % FCS and 
400 µg/ml G418. The last cultivation step of CHO-mtGFP and CHO-mtRFP cells prior to 
fusion experiments was carried out in G418-free medium because the cells did not lose the 
plasmid within one week. Cells were cultured in HAM-F12 nutrient mixture containing 10 % 
FCS in 150 cm2 culture flasks until confluency, harvested by Trypsin-EDTA 0.25 % and 
washed with isolation buffer. The centrifugation steps for the washing steps of the cells were 
carried out in a GS-15R centrifuge (Beckman, Krefeld, Germany). Afterwards, mtGFP- or 
mtRFP-containing cells from one culture flask were suspended in 250 µl isolation buffer. 
Then, cells from four flasks were pooled and the resulting one milliliter of cell suspension was 
transferred into a cooled 2-ml Dounce glass homogenizer (Sigma-Aldrich, Steinheim, 
Germany) where the cells were disrupted by 25 strokes. The suspension was transferred into 
a 2-ml safe-lock tube (Eppendorf, Hamburg, Germany) and centrifuged at 1500 g at 4 °C for 
10 min a type 5415 R centrifuge (Eppendorf, Hamburg, Germany) to pelletize nuclei as well 
as remaining intact cells. The first supernatant was kept on ice, while the pellet was 
resuspended in isolation buffer and homogenized by 25 Dounce strokes for a second time to 
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break remaining intact cells. A second centrifugation step at 1500 g at 4 °C for 10 min 
yielded a pellet that was the nuclei enriched fraction. The first and the second supernatant 
were mixed and centrifuged at 16000 g at 4 °C for 15 min to obtain a pellet enriched with 
GFP- or RFP-containing isolated mitochondria. The amount of cells used for the isolation of 
mitochondria depended on the required amount for the different experiments. Mitochondrial 
protein concentration was determined by Bradford-Assay [9]. 
Mitochondrial fusion was carried out according to Meeusen et al. [8]. Thereby, equal 
amounts of GFP- and RFP-containing isolated mitochondria regarding to the mitochondrial 
protein concentration were mixed and centrifuged at 16000 g, 4 °C for 10 min. The pellet was 
incubated on ice for 10 min and was resuspended in fusion buffer, 40 µl for 500 µg total 
mitochondrial protein. After incubation at room temperature for 1 h, the fusion samples were 
analyzed by CLSM, TEM or flow cytometry. Isolated mitochondria of the control samples 
(G+R) were treated in the same manner like isolated mitochondria for mitochondrial fusion in 
vitro (F), except the fusion buffer that was exchanged by isolation buffer. 
 
5.2.3 Qualitative characterization of mitochondrial fusion in vitro by CLSM 
Fluorescence of the fusion samples was analyzed by CLSM with a Zeiss Axiovert LSM 510 
(Carl Zeiss, Oberkochen, Germany) and an AxioCam HRc (Carl Zeiss, Oberkochen, 
Germany). Thereby, GFP was excited a 488 nm and detected at 505–530 nm and RFP was 
excited at 488 nm and detected at 530–600 nm. In samples containing both fluorescent 
proteins, a multitrack scan mode was applied. 
 
5.2.4 Qualitative characterization of mitochondrial fusion in vitro by TEM  
For qualitative analysis by TEM, unlabeled isolated mitochondria were used instead of GFP- 
and RFP-containing isolated mitochondria. Isolation and mitochondrial fusion in vitro were 
accomplished as described previously. Fusion samples were fixed in cacodylate fixation 
buffer at room temperature for 5 min and on ice overnight. Afterwards, mitochondria were 
washed by five washing steps, each of them in cacodylate washing buffer for 2 min. Then, 
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isolated mitochondria were pelletized in a 1 % agarose solution that was heated up to 40 °C. 
All centrifugation steps were carried out in a himac CT15RE centrifuge (VWR Leuven, 
Belgium by Hitachi Koki Co. Ltd.). After gelation of the agarose, the gel block was cut and 
fixed with osmium tetroxide solution overnight. The samples were washed in DPBS four 
times for 15 min. Afterwards, the samples were dehydrated in a graded series of ethanol:  
50 %, 70 %, 80 %, 90 % and 100 %. Each dehydration step was carried out two times for  
15 min. Then, the samples were treated in an equal mixture of acetone or propylene oxide 
and ethanol for 20 min and two times in acetone or propylene oxide for 20 min. Afterwards, 
the samples were treated with a mixture of acetone or propylene oxide and Epon (2:1) for 2 
h, followed by in a mixture of acetone or propylene oxide and Epon (1:1) for 2 h and 
subsequently in a mixture of acetone or propylene oxide and Epon (1:2) in an open vial 
overnight. Then, the samples were embedded and hardened in Epon at room temperature 
for 1 h, at 30 °C for 2 h and at 60 °C for 2 days. Epon blocks were cut into sections of 50 nm 
with a Leica EM UC6 microtome (Leica, Vienna, Austria) and transferred to copper slot grids 
with a 1.5 % hyaloform foil. They were examined either unstained or stained with uranyl 
acetate and lead citrate in an EM 902 transmission electron microscope from Zeiss (Carl 
Zeiss, Oberkochen, Germany), operated at 80kV. Digital images were recorded by a slow 
scan CCD camera (TRS Typ 7888, Serial No. 321/08). 
 
5.2.5 Quantitative characterization of mitochondrial fusion efficiency in vitro by  
 flow cytometry 
For the quantitative evaluation of mitochondrial fusion efficiency in vitro by flow cytometry, 
control samples, treated similar to the fusion samples, were analyzed. Therefore, GFP- and 
RFP-containing isolated mitochondria were mixed and centrifuged at 16000 g, 4 °C for 10 
min. The pellet was incubated on ice for 10 min and resuspended in isolation buffer, 40 µl for 
500 µg total mitochondrial protein. After incubation at room temperature for 1 h, the control 
samples (G+R) were analyzed in the same way like the fusion samples (F). That means 
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treatment of fusion and control sample was similar, only the influence of fusion buffer was 
evaluated as it was exchanged by isolation buffer in the control sample (G+R). 
Quantitative analysis of mitochondrial fusion in vitro of GFP- and RFP-containing samples 
was carried out by flow cytometry with a FACSCanto™ (BD Bioscience, Heidelberg, 
Germany). Therefore, the samples were diluted to not exceed the critical count rate of the 
flow cytometer. GFP and RFP were excited by a 488 nm blue laser. GFP was detected at 
515–545 nm and RFP was detected at 564–606 nm. Single labeled isolated mitochondria 
with either GFP or RFP were used to define GFP- and RFP-positive quadrants and to 
separate fluorescent mitochondria from non-fluorescent cell fragments. For the analysis of 
mitochondrial fusion in vitro, plots that indicated fluorescence of GFP on the x-axis and 
fluorescence of RFP on the y-axis were created. Quadrants of the plots were defined as 
follows: the lower left quadrant (LL) indicated non fluorescent cell fragments, the upper left 
quadrant (UL) was determined by single-labeled RFP-mitochondria, the lower right quadrant 
(LR) was determined by single-labeled GFP-mitochondria and the upper right quadrant (UR) 
was positive for GFP and RFP showing mitochondria that contain both fluorescent proteins, 
either by fusing or by sticking together (Figure 5.1). 
 
Figure 5.1: Flow cytometry plot for the analysis of mitochondrial fusion. 
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Because mitochondria (UL, UR and LR quadrant) could be easily distinguished from cell 
fragments (LL quadrant) by this method, the amount of double positive, GFP- and RFP-
containing mitochondria of all mitochondria (single GFP, single RFP and double GFP-RFP) 
was calculated for the fusion sample, defined as (F raw) and for the control sample, defined 
as (G+R), as follows: 
(     )   (   )   
  
        
 . 
The flow cytometer could not distinguish between fused mitochondria and mitochondria that 
simply stick together. Therefore, the calculated amount of double positive results for RFP 
and GFP in the control sample (G+R) that did not contain fused mitochondria but that could 
contain mitochondria which stick together, was subtracted from the amount of double positive 
results for RFP and GFP in the fusion sample (F raw) resulting in a value that indicated only 
fused mitochondria, defined as F:  
( )  (     )  (   ). 
These calculations are illustrated in Figure 5.2. Thereby, it was assumed that the amounts of 
mitochondria that stick together without fusing were similar in the fusion sample (F raw) and 
in the control sample (G+R) because both samples were treated in the same way. It has to 
be considered that the fusion sample (F) can contain mitochondria in which both membranes 
were fused and mitochondria in which only the outer membrane was fused. 
 
Figure 5.2: Flow cytometry plots of the quantitative analysis of mitochondrial fusion. 
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G+R samples were evaluated in every flow cytometry experiment and this value was 
subtracted from all fusion samples that were analyzed in the same experiment. 
 
5.2.6 Statistical analysis 
Results were expressed as means ± standard deviation (SD).  
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5.3 Results and discussion 
A protocol for mitochondrial fusion in vitro of isolated mitochondria from mammalian cells 
was established according to a protocol for yeast mitochondria that was published by 
Meeusen et al. [8]. For detection of mitochondrial fusion in vitro with fluorescence based 
methods such as confocal light scanning microscopy or flow cytometry, it was essential to 
work with permanently labeled isolated mitochondria. As it emerged that fluorescence dyes 
were not applicable for studying mitochondrial fusion in vitro due to washing out of the dyes 
[10], the studies were accomplished with fluorescence proteins expressed in mitochondria 
that labeled isolated mitochondria permanently. Equal amounts of red and green fluorescent 
isolated mitochondria were mixed. The mixture was centrifuged to bring isolated 
mitochondria in close contact and then, they were resuspended in a fusion buffer that 
provided the required energy for mitochondrial fusion. In the control samples, only 
individually labeled green or red mitochondria were detected (Figure 5.3). 
 
Figure 5.3: CLSM image of the control sample (G+R) containing a mixture of GFP and RFP mitochondria that 
was treated in the same way like the fusion sample (F). Only single labeled mitochondria were detected. No 
mitochondrion contained both fluorescent proteins. 
 
In the fusion samples (F), yellow mitochondria containing a mixture of green and red 
fluorescent proteins were detected (Figure 5.4). The yellow color indicated that the matrices 
Chapter 5 – Mitochondrial fusion in vitro 
 
- 151 - 
 
of differently labeled mitochondria had mixed due to fusion of outer and inner mitochondrial 
membranes. Beside the mixed-colored mitochondria, also individually labeled green and red 
mitochondria were detected. Individually labeled mitochondria could either be non-fused 
mitochondria or mitochondria that had fused with a mitochondrion of the same color (green-
green or red-red) which could not be detected by this method. 
 
 
 
Figure 5.4: CLSM images of fusion samples (F). Single labeled mitochondria and mitochondria containing a 
mixture of GFP and RFP are visible as yellow dots. These fused mitochondria are indicated by red arrows.  
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For the quantitative analysis of mitochondrial fusion efficiency in vitro, a flow cytometry 
protocol was established. Flow cytometry has been used for the analysis of isolated 
mitochondria since 1986 [11]. It allowed for the simultaneous analysis of two and more 
fluorescent dyes, was capable for high throughput analysis [12] and was applicable for the 
analysis of highly diluted samples that did not consume large amounts of isolated 
mitochondria. Therefore, it was the method of choice for the evaluation of mitochondrial 
fusion efficiency in vitro. Thereby, mitochondria containing both fluorescent proteins due to 
fusion of outer or of both membranes were detected and the amount of fused isolated 
mitochondria among all analyzed isolated mitochondria was calculated and expressed as 
fusion efficiency. Mitochondria that were treated with antimycin A, an inhibitor of the 
respiratory chain that interrupted mitochondrial functionality and integrity, were not fusion 
competent anymore (Figure 5.5)   
 
Figure 5.5: Quantitative evaluation of fusion efficiency in vitro by flow cytometry in comparison to fusion efficiency 
after pre-treatment of isolated mitochondria with antimycin A. Data are expressed as means of three 
measurements ± standard deviations (SD). 
 
A disadvantage of the method was the limitation to size related resolution as the size of 
mitochondria was at the lower size resolution limit. Therefore, only fluorescence based 
analysis was applied. 
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The analysis of the fusion samples by TEM revealed fusion intermediates with fused outer 
and separated adjacent inner membranes (Figure 5.6, 5.7 and 5.8). Completely fused 
mitochondria with fused outer and inner membrane could not be detected with this 
transmission electron microscopy method. It was rather rare to detect such fusion 
intermediates as the change of mitochondrial morphology and mitochondrial fusion were very 
rapid elapsing processes [8]. It is known that mitochondria can form 15-20 different shapes in 
10 min [13]. No fusion intermediates were detected in samples with isolated mitochondria 
that were not treated according to the fusion protocol. 
 
Figure 5.6: TEM image of the fusion sample (F), 7000x magnification. Fusion intermediates of mitochondria with 
separated inner membranes and fused outer membrane are indicated by red arrows. 
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Figure 5.7: TEM image of the fusion sample (F), 12000x magnification. The fusion intermediate with separated 
inner membranes and fused outer membrane is indicated by a red arrow. 
 
 
Figure 5.8: TEM image of the fusion sample (F), 12000x magnification. The fusion intermediate with separated 
inner membranes and fused outer membrane is indicated by a red arrow. 
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5.4 Conclusions 
According to mitochondrial fusion in vitro of yeast mitochondria [8], successful mitochondrial 
fusion in vitro of mitochondria from mammalian cells was shown. The occurrence of 
mitochondrial fusion in vitro was detected qualitatively with microscopic methods. Thereby, 
the analysis by CLSM revealed fused mitochondria with fused outer and inner mitochondrial 
membranes due to mixed-colored fluorescent mitochondrial matrices whereas the analysis 
by TEM revealed fusion intermediates with fused outer, but separated inner membrane. Flow 
cytometry was the method of choice for quantification and evaluation of mitochondrial fusion 
efficiency due to several advantages such as the capability for high throughput analysis, the 
possibility to analyze highly diluted samples that did not consume large amounts of isolated 
mitochondria and an even higher number of mitochondria that could be investigated 
compared to microscopy techniques that would accompany with time consuming counting of 
a comparatively low number of mitochondria. Thereby, a protocol for the determination and 
calculation of mitochondrial fusion efficiency was established. 
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Abstract 
The influence of several polymers such as PEGs and 8arm PEGs, nanocarriers such as 
dendrimers or quantum dots, and targeting peptides on mitochondrial fusion in vitro was 
evaluated. Mitochondrial fusion was affected unspecifically by highly concentrated polymer 
solutions and specifically by polymers and nanocarriers that were modified with mitochondria 
specific targeting peptides. Thereby, a natural mitochondrial targeting sequence (MLS) and a 
synthetic mitochondria penetrating peptide (MPP) were investigated. Highly concentrated 
PEG solutions increased mitochondrial fusion efficacy unspecifically due to physical effects. 
MPP-modified polymers and dendrimers increased fusion efficiency specifically whereas 
MLS-modified polymers and nanocarriers did not increase mitochondrial fusion efficiency in 
vitro.  
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6.1 Introduction 
Due to the fact that mitochondrial fusion deficiencies are involved in diseases [1,2] and the 
imbalance towards mitochondrial fragmentation contributes to programmed cell death [3], 
manipulation of mitochondrial fusion can be a promising strategy to improve mitochondrial 
functionality [4]. Beside the approach of affecting mitochondrial fusion, specific targeting of 
mitochondria is another goal. But targeting of mitochondria is challenging due to the 
enclosure by two membranes and only small pores in these membranes [5,6]. To achieve a 
mitochondria specific targeting, it is not possible to utilize all different pore complexes that 
can be found in the mitochondrial membranes. It is only feasible to utilize the mitochondrial 
protein import pores that recognize specific targeting sequences [7,8].   
Therefore, this study focuses on strategies that combine the utilization of the mitochondrial 
fusion machinery and the utilization of mitochondrial protein import machinery with the goals 
to enhance mitochondrial fusion and to achieve a specific targeting of mitochondria. All 
investigations described in this study are based on protocols for mitochondrial fusion of 
isolated mammalian mitochondria in vitro and established protocols for the detection of 
mitochondrial fusion in vitro as well as the quantitative determination of mitochondrial fusion 
efficiency in vitro, described in a previous study [9]. 
It is known that polyethylene glycol (PEG) with molecular weights from 400-6000 Da at 
concentrations of 50-55 % can induce cell fusion [10] in which the detail mechanisms that 
underlie PEG-mediated, artificial cell fusion are not known [11]. Dehydration due to the water 
binding properties of PEG in solutions of 35 % or higher may play a role in PEG-mediated 
fusion [12]. Therefore, the initial step towards the specific manipulation of mitochondrial 
fusion in vitro by using targeting strategies was the unspecific enhancement of mitochondrial 
fusion in vitro by using PEG 1500 at a concentration of 50 %. 
Specific targeting strategies that have been applied were a natural mitochondrial leading 
sequence (MLS) derived from a mitochondrial protein [7] and a mitochondria penetrating 
peptide (MPP) [13,14] that has been shown to deliver cargos selectively into mitochondria. 
The used MLS consists of 17 amino acids derived from the targeting sequence of the 
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saccharomyces cerevisiae protein cytochrome c oxidase subunit IV (CoxIV) plus an 
additional cysteine at the C-terminus to make use of the thiol group for the covalent 
attachment to other molecules. This targeting sequence has been shown to have a high 
binding affinity to the translocator complexes in the mitochondrial membranes [15–17]. An 
important feature, that applies to all mitochondrial targeting sequences, is the high content of 
basic and hydrophobic amino acids with the ability to form an amphiphatic α-helix that 
presents one positively charged surface and one hydrophobic surface that are necessary for 
the recognition by the mitochondrial protein import pores [7]. Natural mitochondrial targeting 
sequences are also known to deliver non-protein cargos into mitochondria [18]. The used 
MPP consists of 6 amino acids according to MPPs described by Horton et al. [13]. As a sixth 
amino acid, cysteine has been attached to the C-terminus for reasons of chemical reactivity. 
The amino acid sequence and properties of the MLS and the MPP are shown in the 
Appendix of this thesis. 
The nanomaterials that have been used for specific enhancement of mitochondrial fusion in 
vitro were dendritic polymers: 8arm PEGs of 20 and 40 kDa molecular weight and PAMAM-
dendrimers G4-G7, as well as a polyetheramine (Jeffamine®) of 2 kDa and quantum dots. All 
these materials have been modified with either the MLS or the MPP and their influence on 
mitochondrial fusion at different concentrations has been investigated in comparison to the 
same nanomaterials modified in a non-targeting manner by conjugating them to β-
mercaptoethanol and cysteine. According to the unspecific PEG-mediated cell fusion, the 
influence of all unconjugated nanomaterials and both targeting moieties on mitochondrial 
fusion in vitro has also been investigated. The dendritic polymers (8arm PEGs and 
dendrimers) have been chosen as they contain several arms that can be modified with 
multiple targeting moieties. In particular, the 8arm PEGs have been chosen to eventually 
utilize the effects of PEG-mediated cell fusion transferring these effects to mitochondrial 
fusion and specifying the mechanisms by conjugation of targeting moieties. Dendrimers have 
been chosen because they are known as effective carriers for anticancer agents [19] and the 
specific delivery of anticancer agents to mitochondria may be desirable goal to improve 
Chapter 6 – Affecting mitochondrial fusion efficiency in vitro 
 
- 163 - 
 
therapy [20]. Polyamidoamine (PAMAM) dendrimers, in particular, are known to affect 
mitochondria [21]. Jeffamine® was chosen because of the lower molecular weight compared 
to the 8arm PEGs to investigate the effects of a polymer with a molecular weight in the range 
of PEG for PEG-mediated cell fusion. Quantum dots (Qdots) have been chosen because of 
their fluorescent properties to establish a detectable system with respect to achieve and 
detect a specific targeting and uptake into mitochondria mediated by mitochondrial fusion. 
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6.2 Materials and methods 
6.2.1 Materials 
HAM F-12 nutrient mixture and fetal calf serum (FCS) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trypsin-EDTA 0.25 % was obtained from Gibco-Invitrogen 
(Karlsruhe, Germany). G418 was purchased from Sigma-Aldrich (Steinheim, Germany). 
Purified water was obtained by using a Milli-Q water purification system from Millipore 
(Schwalbach, Germany). All cell culture materials were purchased from Corning (Bodenheim, 
Germany). 
Isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % bovine serum albumin (BSA) (Sigma-
Aldrich, Steinheim, Germany). Fusion buffer consisted of 600 mM sorbitol (Sigma-Aldrich, 
Steinheim, Germany), 20 mM Tris (USB Corporation, Cleveland, OH USA), 150 mM 
potassium acetate (Merck, Darmstadt, Germany), 5 mM magnesium acetate tetrahydrate 
(Merck, Darmstadt, Germany), 0.1 % BSA (Sigma-Aldrich, Steinheim, Germany), 0.5 mM 
GTP (Sigma-Aldrich, Steinheim, Germany), 1mM ATP (Sigma-Aldrich, Steinheim, Germany), 
40mM creatine phosphate (Sigma-Aldrich, Steinheim, Germany) and 30 units/ml creatine 
phosphokinase (Sigma-Aldrich, Steinheim, Germany).   
PEG 1500, 4000 and 10000 were obtained from Hoechst (Frankfurt, Germany). 8arm PEG-
maleimide 20 kDa and 40 kDa were purchased from Nanocs Inc. (New York, NY, USA). The 
Polyetheramine (Jeffamine® ED-2003) with a molecular weight of 2000 Da was obtained from 
Huntsman (Everberg, Belgium). The PAMAM Dendrimer Kit generation 4-7 was purchased 
from Sigma-Aldrich (Steinheim, Germany). Qdot 655 ITK amino (PEG) quantum dots were 
obtained from Invitrogen (Karlsruhe, Germany). Sulfo-SMCC was purchased from Thermo 
Fisher Scientific (Bonn, Germany). β-mercaptoethanol and L-cysteine hydrochloride 
monohydrate were obtained from Sigma-Aldrich (Steinheim, Germany). 
Sodium phosphate/sodium chloride buffer consisted of 0.1 M disodium hydrogenphosphate 
dihydrate (Merck, Darmstadt, Germany) and 0.15 M sodium chloride (Merck, Darmstadt, 
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Germany). The pH-value was adjusted to 7.2 by TitriPUR® 1 N hydrochloric acid (Merck, 
Darmstadt, Germany). 
MLS and MPP peptides were synthesized by GeneCust (Dudelange, Luxembourg) and were 
reduced prior to use by TCEP Reducing Gel (Thermo Fisher Scientific, Bonn, Germany) or 
TCEP (Sigma-Aldrich, Steinheim, Germany) in sodium phosphate/sodium chloride buffer. 
Amicon® Ultra-4 centrifugal filter unit 10 kDa and 100 kDa (Millipore, Schwalbach, Germany) 
were used for purification by ultrafiltration. The dialysis tube was obtained from Sigma-
Aldrich (Steinheim, Germany). DPBS without calcium and magnesium was obtained from 
Gibco-Invitrogen (Karlsruhe, Germany). 
0.1 M cacodylate fixation buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany), 40 mM sodium chloride (Merck, 
Darmstadt, Germany) and 2 % glutaraldehyde (Serva, Heidelberg, Germany). 0.1 M 
cacodylate washing buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, 
Darmstadt, Germany). BODIPY® FL L-cystine was obtained from Invitrogen (Karlsruhe, 
Germany). Diaminobenzidine was purchased from Sigma-Aldrich (Steinheim, Germany) and 
agarose was obtained from Biozym (Hessisch Oldendorf, Germany). Osmium tetroxide 
(ScienceServices, Munich, Germany) was dissolved to 1 % in 0.1 M cacodylate buffer that 
consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, Germany), 2 mM magnesium 
chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM calcium chloride dihydrate 
(Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, Darmstadt, Germany). 
The freeze substitution medium for the fixation by high pressure freezing/freeze substitution 
(HPF/FS) consisted of 2 % osmium tetroxide (ScienceServices, Munich, Germany), 5 % 
hydrogen peroxide (Merck, Darmstadt, Germany) and 0.25 % uranyl acetate (Roth, 
Karlsruhe, Germany). Agarose was purchased from Biozym (Hessisch Oldendorf, Germany). 
Embedding in Epon was carried out with an Epoxy Embedding Medium Kit (Fluka by Sigma-
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Aldrich, Steinheim, Germany). Propylen oxide was purchased from Sigma-Aldrich 
(Steinheim, Germany).  
 
6.2.2 Unspecific manipulation of mitochondrial fusion in vitro  
Cell culture 
Long-time cultivation of CHO-cell lines that were stably transfected with mitochondria 
targeted green fluorescent protein (mtGFP) and mitochondria targeted red fluorescent 
protein (mtRFP) was carried out in selection medium HAM-F12 containing 10 % FCS and 
400 µg/ml G418, an antibiotic for the selection of plasmid containing cells. The last cultivation 
step of CHO-mtGFP and CHO-mtRFP cells before fusion experiments was carried out in 
G418-free medium because the cells did not lose the plasmid within one week. Cells were 
cultured in HAM-F12 nutrient mixture containing 10 % FCS in 150 cm2 culture flasks until 
confluency, harvested by Trypsin-EDTA 0.25 % and washed with isolation buffer. The 
centrifugation steps during washing of cells were carried out in a GS-15R centrifuge 
(Beckman, Krefeld, Germany). 
 
Isolation of mitochondria 
MtGFP- or mtRFP-containing cells from one culture flask were suspended in 250 µl isolation 
buffer. Cells from four flasks were pooled and the resulting one milliliter cell suspension was 
transferred into a cooled 2-ml Dounce glass homogenizer (Sigma-Aldrich, Steinheim, 
Germany) where the cells were disrupted by 25 strokes. The suspension was transferred into 
a 2-ml safe-lock tube (Eppendorf, Hamburg, Germany) and centrifuged at 1500 g at 4 °C for 
10 min a type 5415 R centrifuge (Eppendorf, Hamburg, Germany) to pelletize nuclei as well 
as remaining intact cells. The first supernatant was kept on ice, while the pellet was 
resuspended in isolation buffer and homogenized by 25 Dounce strokes for a second time to 
break remaining intact cells. A second centrifugation step at 1500 g at 4 °C for 10 min 
yielded a pellet that was the nuclei enriched fraction. The first and the second supernatant 
were mixed and centrifuged at 16000 g at 4 °C for 15 min to obtain a pellet enriched with 
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mtGFP- or mtRFP-containing isolated mitochondria. The amount of cells used for the 
isolation of mitochondria depended on the required amount for the different experiments. 
Mitochondrial protein concentration was determined by a Bradford-Assay [22]. 
 
Mitochondrial fusion in vitro and unspecific manipulation of mitochondrial fusion in vitro 
Mitochondrial fusion was carried out according to Meeusen et al. [23]. Thereby, equal 
amounts of mtGFP- and mtRFP-containing mitochondria regarding to the mitochondrial 
protein concentration were mixed and centrifuged at 16000 g, 4 °C for 10 min. The pellet was 
incubated on ice for 10 min and was resuspended in 40 µl fusion buffer for 500 µg total 
mitochondrial protein. After incubation at room temperature for 1 h, the fusion samples were 
centrifuged at 16000 g, 4°C for 5min. Then, the pellet was covered with a 50 % PEG 1500 
solution in isolation buffer and incubated at room temperature for 60 s. Afterwards, the pellet 
was washed three times with isolation buffer and resuspended in isolation buffer.  
Fusion efficiency of mitochondria in vitro was also evaluated for treatment with 50% PEG 
4000, 50% PEG 10000, 100µM and 1mM PEG 1500, 25% 8arm PEGs 20k Da and 8arm 
PEG 40 kDa, 5% PAMAM dendrimers G4-G7 and 50% Jeffamine®. These studies were 
carried out as described previously for 50% PEG 1500.  
 
Qualitative analysis of mitochondrial fusion by CLSM 
Qualitative analysis of mitochondrial fusion in vitro was carried out by confocal laser 
scanning microscopy (CLSM). Fluorescence of the fusion samples was analyzed with a 
Zeiss Axiovert LSM 510 (Carl Zeiss, Oberkochen, Germany) and an AxioCam HRc (Carl 
Zeiss, Oberkochen, Germany). Thereby, GFP was excited a 488 nm and detected at 505–
530 nm whereas RFP was excited at 488 nm and detected at 530–600 nm. In samples 
containing both fluorescent proteins, a multitrack scan mode was applied. 
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Qualitative analysis mitochondrial fusion in vitro by TEM 
Qualitative analysis of mitochondrial fusion in vitro was also carried out by transmission 
electron microscopy (TEM) in which fixation was accomplished by high pressure freezing 
(HPF) and freeze substitution (FS). The high pressure freezing was carried out in a Leica EM 
PACT2 high pressure freezer (Leica, Vienna, Austria) and freeze substitution was 
accomplished in a freeze substitution processor Leica EM AFS2 (Leica, Vienna, Austria). 
The samples were treated with an osmium tetroxide containing medium at -90 °C for 8 h, 
heated from -90 °C – -60 °C for 2 h, left at -60 °C for 6 h, heated from -60 °C – -30 °C for 2 h, 
left at -30 °C for 8 h, heated from -30 °C – 0 °C for 2 h and left at 0 °C for 8 h. Then, the 
mixture was treated three times with acetone at 0 °C for 1 h. Afterwards, the samples were 
treated with a mixture of acetone and Epon (2:1) for 30 min and heated from 0 °C to room 
temperature. Then, the samples were transferred to a mixture of acetone and Epon (2:1) at 
room temperature for 30 min. Subsequently, they were treated in a mixture of acetone and 
Epon (1:1) at room temperature for 2 h. Afterwards, the samples were left in a mixture of 
acetone and Epon (1:2) in an open vial overnight. Then, the samples were embedded and 
hardened in Epon at 30 °C for 2 h and at 60 °C for 2 days. Epon blocks were cut into 
sections of 50 nm with a microtome Leica EM UC6 (Leica, Vienna, Austria) and transferred 
to copper slot grids with a 1.5 % hyaloform foil. They were examined either unstained or 
stained with uranyl acetate and lead citrate in a transmission electron microscope Zeiss EM 
902 (Carl Zeiss, Oberkochen, Germany), operating at 80kV. Digital images were recorded by 
a slow scan CCD camera (TRS Typ 7888, Serial No. 321/08). 
 
Quantitative analysis of mitochondrial fusion efficiency by flow cytometry 
Quantitative analysis of mitochondrial fusion efficiency in vitro was accomplished by flow 
cytometry with a FACSCanto™ (BD Bioscience, Heidelberg, Germany) as described 
previously [9]. Data in the graphs of quantitative fusion efficiency were normalized to the data 
of untreated fusion samples (F = 1) for reasons of relative comparison of the fusion efficiency 
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of untreated fusion samples (F = 1) and fusion efficiency after unspecific manipulation (F = 1 
± xy).   
 
6.2.3 Specific manipulation of mitochondrial fusion in vitro  
Modification of 8arm PEGs 
8arm PEG-maleimides 20 kDa and two batches of 40 kDa were modified with a twentyfold 
molar excess of MLS, MPP, cysteine and β-mercaptoethanol. Therefore, 8arm PEGs were 
dissolved in sodium phosphate/sodium chloride buffer to concentrations of 100 µM or 1 mM. 
Prior to use, MLS, MPP and cysteine were dissolved in purified water and reduced by a 
thirtyfold molar excess of TCEP in the dark for 30 min. Reduced MLS, MPP or cysteine 
solutions as well as β-mercaptoethanol diluted in sodium phosphate/sodium chloride buffer 
were added to the 8arm PEG solutions in a twentyfold molar excess. Reactions were carried 
out at 4 °C overnight. Afterwards, β-mercaptoethanol was added in excess to react with 
unmodified maleimides. The modified 8arm PEGs were purified by three ultrafiltration steps 
in ultrafiltration units with a cut-off of 10 kDa and sodium phosphate/sodium chloride buffer. 
Unmodified 8arm PEGs in concentrations of 100 µM and 1 mM were also purified by 
ultrafiltration to obtain equal concentrations for the comparison of unmodified and modified 
8arm PEGs. 
 
Modification of quantum dots 
Quantum dots were modified with a twentyfold molar excess of MLS, MPP, cysteine and β-
mercaptoethanol. Therefore, the buffer of the quantum dots was exchanged to sodium 
phosphate/sodium chloride buffer by ultrafiltration in ultrafiltration units with a cut-off of  
10 kDa. Afterwards, 10 nM and 100 nM quantum dots that carried an amino-PEG shell were 
activated by a 1000-fold molar excess of sulfo-SMCC. The reaction was carried out at room 
temperature in the dark on a shaker for 30 min. Activated quantum dots were purified by 
three ultrafiltration steps in ultrafiltration units with a cut-off of 10 kDa and sodium 
phosphate/sodium chloride buffer. Before use, MLS, MPP and cysteine were dissolved in 
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purified water and reduced by a thirtyfold molar excess of TCEP in the dark for 30 min. 
Reduced MLS, MPP or cysteine solutions as well as β-mercaptoethanol diluted in sodium 
phosphate/sodium chloride buffer were added to the quantum dots in a twentyfold molar 
excess. Reactions were carried out at 4 °C overnight. Afterwards, β-mercaptoethanol was 
added in excess to react with unmodified maleimides. The modified quantum dots were 
purified by three ultrafiltration steps in ultrafiltration units with a cut-off of 10 kDa and sodium 
phosphate/sodium chloride buffer. Unmodified quantum dots in concentrations of 10 nM and 
100 nM were also purified by ultrafiltration to obtain equal concentrations for the comparison 
of unmodified and modified quantum dots. Quantum dots were stored in low-bind cups, 
likewise all reactions were carried out in low-bind cups (Eppendorf, Hamburg, Germany). 
 
Modification of dendrimers 
Dendrimers were activated and modified similar to the quantum dots. The amount of amine 
groups on the surface depended on the generation of the dendrimer. G4 dendrimers 
contained 64 amine groups, G5 dendrimers contained 128 amine groups, G6 dendrimers 
contained 256 amine groups and G7 dendrimers contained 512 amine groups. G4 – G7 
dendrimers were modified at a concentration of 1 µM with a twentyfold molar excess of MLS, 
MPP, cysteine or β-mercaptoethanol as well as with equal and double molar concentrations 
of MLS or MPP according to the amine groups on the surface. That means for equal 
concentrations of MLS or MPP according to the amine groups (1:1), a 64-fold molar excess 
of peptide was added to G4 dendrimers, a 128-fold molar excess of peptide was added to G5 
dendrimers, a 256-fold molar excess of peptide was added to G6 dendrimers and a 512-fold 
molar excess of peptide was added to G7 dendrimers. For double concentrations of MLS or 
MPP according to the amine groups (1:2), a 128-fold molar excess of peptide was added to 
G4 dendrimers, a 256-fold molar excess of peptide was added to G5 dendrimers, a 512-fold 
molar excess of peptide was added to G6 dendrimers and a 1024-fold molar excess of 
peptide was added to G7 dendrimers. G4 and G5 dendrimers were modified at a 
concentration of 100 µM with a twentyfold molar excess of MLS, MPP, cysteine or β-
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mercaptoethanol as well as with an equal molar concentration of MLS or MPP according to 
the amine groups on the surface. That means for equal concentrations of MLS or MPP 
according to the amine groups (1:1), a 64-fold molar excess of peptide was added to G4 
dendrimers and a 128-fold molar excess of peptide was added to G5 dendrimers. 
Unmodified dendrimers in concentrations of 1 µM and 100 µM were also purified by 
ultrafiltration to obtain equal concentrations for the comparison of unmodified and modified 
dendrimers. 
 
Modification of Jeffamine® 
The polyetheramine Jeffamine® was activated and modified similar to the quantum dots and 
dendrimers. Jeffamine® in concentrations of 100 µM and 1 mM was modified with a 
twentyfold molar excess of MLS, MPP, cysteine and β-mercaptoethanol. Purification steps 
were carried out by dialysis instead of ultrafiltration. Unmodified Jeffamine® in concentrations 
of 100 µM and 1 mM was also purified by dialysis to obtain equal concentrations for the 
comparison of unmodified and modified Jeffamine®. 
 
Targeting peptides 
For studying the efficacy of the targeting peptides MLS and MPP without carrier, 
concentrations of 10 nM, 100 nM, 100 µM and 1 mM, reduced on a TCEP-gel or not reduced, 
were investigated.  
 
Cell culture 
Long-time cultivation of stably transfected CHO-mtGFP and CHO-mtRFP cell lines was 
carried out as described previously. 
 
Isolation of mitochondria 
Isolation of mitochondria was carried out as described previously. 
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Mitochondrial fusion in vitro and specific manipulation of mitochondrial fusion in vitro 
Mitochondrial fusion was carried out according to Meeusen et al. [23]. Thereby, equal 
amounts of mtGFP- and mtRFP-containing mitochondria regarding to the mitochondrial 
protein concentration were mixed and defined amounts of MLS, reduced or not reduced; 
MLS-modified 8arm PEGs, quantum dots, dendrimers or Jeffamine®; MPP, reduced or not 
reduced or MPP-modified 8arm PEGs, quantum dots, dendrimers or Jeffamine® as well as 
cysteine- and β-mercaptoethanol-modified 8arm PEGs, quantum dots, dendrimers and 
Jeffamine® were added. Each mixture was centrifuged at 16000 g, 4 °C for 10 min. Then, the 
pellet was incubated on ice for 10 min and was resuspended in fusion buffer, 40 µl for 500 µg 
total mitochondrial protein. The mixture was incubated at room temperature for 1 h.  
 
Quantitative analysis of mitochondrial fusion in vitro by flow cytometry 
Mitochondrial fusion efficiency was evaluated by flow cytometry with a FACSCanto™ (BD 
Bioscience, Heidelberg, Germany) as described in a previous study [9]. Data in the graphs of 
quantitative fusion efficiency were normalized to the data of untreated fusion samples (F = 1) 
for reasons of relative comparison of the fusion efficiency of untreated fusion samples (F = 1) 
and fusion efficiency after specific manipulation (F = 1 ± xy).   
 
Qualitative analysis of mitochondrial fusion in vitro by TEM after photooxidation 
It is possible to visualize a fluorescence dye for TEM by photooxidation of diaminobenzidine. 
Thereby, the fluorescent dye is excited and bleaches, in which diaminobenzidine is oxidized 
to an insoluble polymer that can be stained by osmium tetroxide and appears in black.  
Therefore, the 8arm PEG 40 kDa 1mM was labeled with BODIPY® FL L-cystine and modified 
with MPP or β-mercaptoethanol. Therefore, the BODIPY® FL L-cystine was reduced by 
TCEP and was added in an equal molar concentration to the 8arm PEG. Before use, the 
MPP was reduced by a thirtyfold molar excess of TCEP in the dark for 30 min. The reduced 
MPP was added to the 8arm PEG solution in a tenfold molar excess. The reaction was 
carried out at 4 °C overnight. Afterwards, β-mercaptoethanol was added in excess to react 
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with unmodified maleimids. The modified 8arm PEGs were purified by six ultrafiltration steps 
in ultrafiltration units with a cut-off of 10 kDa and sodium phosphate/sodium chloride buffer.  
Mitochondrial fusion in vitro was carried out as described previously and was evaluated by 
photooxidation and TEM. Therefore, isolated mitochondria were fixed in cacodylate fixation 
buffer with glutaraldehyde at room temperature for 5 min and on ice overnight. Afterwards, 
mitochondria were washed by five washing steps, each of them in cacodylate washing buffer 
for 2 min. Then, the buffer solution was exchanged by diaminobenzide in cacodylate buffer 
0.1 M and photooxidation was carried out at an Axiovert 200 (Carl Zeiss, Göttingen, 
Germany) with an excitation wave length of 488 nm and an emission wave length of 515 nm. 
Afterwards, the diaminobenzidine solution was exchange by cacodylate buffer 0.1 M. Then, 
isolated mitochondria were pelletized in a 1 % agarose solution that was heated up to 40 °C. 
All centrifugation steps were carried out in a himac CT15RE (VWR Leuven, Belgium by 
Hitachi Koki Co. Ltd.). After gelation of the agarose, the gel block was cut and fixed with 
osmium tetroxide solution overnight. The samples were washed in DPBS four times for 15 
min. Afterwards, the samples were dehydrated in a graded series of ethanol: 50 %, 70 %,  
80 %, 90 % and 100 %. Each dehydration step was carried out two times for 15 min. 
Then, the samples were treated in an equal mixture of acetone or propylene oxide and 
ethanol for 20 min and two times in acetone or propylene oxide for 20 min. Afterwards, the 
samples were treated with a mixture of acetone or propylene oxide and Epon (2:1) for 2 h, 
then, in a mixture of acetone or propylene oxide and Epon (1:1) for 2 h and subsequently in a 
mixture of acetone or propylene oxide and Epon (1:2) in an open vial overnight. The samples 
were subsequently embedded and hardened in Epon at room temperature for 1 h, at 30 °C 
for 2 h and at 60 °C for 2 days. Epon blocks were cut into sections of 50 nm with a Leica EM 
UC6 microtome (Leica, Vienna, Austria) and transferred to copper slot grids with a 1.5 % 
hyaloform foil. They were examined either unstained or stained with uranyl acetate and lead 
citrate in a transmission electron microscope Zeiss EM 902 (Carl Zeiss, Oberkochen, 
Germany), operating at 80kV. Digital images were recorded by a slow scan CCD camera 
(TRS Typ 7888, Serial No. 321/08). 
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6.2.4 Statistical analysis 
Results were expressed as means ± standard deviations. Statistical analysis was performed 
using SigmaPlot 12.0 one-way analysis of variance (ANOVA) with subsequent Holm-Sidak 
test to assess the significance of differences between groups. The acceptance level of 
significance was p < 0.05, denoted by (°) or p < 0.01, denoted by (*). Before analysis, a 
normality test was conducted. In case of failure of the normality test, analysis of variance on 
ranks was conducted (Kruskal Wallis analysis of variance on ranks with subsequent Dunnett 
test). 
 
6.2.5 Characterization of MLS-conjugates 
For characterization of the unmodified and modified 8arm PEGs, UV measurements and 1H-
NMR measurements were conducted. UV-spectra of the samples were recorded by a 
Kontron Instruments Uvikon 900 spectrophotometer (Goebel Instrumentelle Analytik, 
Hallertau, Germany). For 1H-NMR measurements, 20 mg of the samples were dissolved in 1 
ml deuterated chloroform or deuterated DMSO. 1H-NMR spectra were recorded at 300 MHz 
with an Avance 300 NMR spectrometer (Bruker BioSpin, Ettlingen, Germany).  
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6.3 Results and discussion 
Characterization of MLS-conjugates 
For verification that conjugation of the MLS, cysteine and β-mercaptoethanol to the 8arm 
PEGs was successful, UV-spectra and 1H-NMR measurements were conducted. A first hint 
that conjugation was successful was the non-toxicity of the conjugated 8arm PEGs 
compared to the toxicity of the unconjugated 8arm PEGs (see Figure 6.14). 
The maleimide of the 8arm PEGs showed an absorption band at 215-240 nm (Figure 6.1). 
A B 
 
Figure 6.1: UV-spectra of 20 kDa 8arm PEG (A) and 40 kDa 8arm PEG (B). 
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After conjugation of MLS and cysteine, the absorption band of the maleimide disappeared 
which indicated that conjugation was successful and that cysteine could be used as a model 
molecule for conjugation studies (Figure 6.2).  
A B 
 
C D 
 
Figure 6.2: UV-spectra of 20 kDa 8arm PEG conjugated with MLS (A) and cysteine (B) and UV-spectra of  
40 kDa 8arm PEG conjugated with MLS (C) and cysteine (D). 
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It emerged that β-mercaptoethanol was not suitable for UV-related characterization of 
conjugation to maleimides as the UV-spectrum of β-mercaptoethanol also showed a strong 
absorption at 215-240 nm (Figure 6.3). 
A B 
 
C 
 
Figure 6.3: UV-spectra of 20 kDa 8arm PEG conjugated with β-mecaptoethanol (A) and 40 kDa 8arm PEG 
conjugated with β-mecaptoethanol (B) and UV-spectrum of β-mecaptoethanol (C). 
 
The 1H-NMR spectra of the native 8arm PEGs showed a peak for PEG at 3.3-3.9 ppm and a 
peak for the maleimide at 6.7 ppm (Figure 6.4 and Figure 6.5). In the 1H-NMR spectra of the 
β-mecaptoethanol conjugated 8arm PEGs, the peak for PEG was detectable at 3.3-3.9 ppm 
whereas the peak for the maleimid disappeared (Figure 6.4 and Figure 6.5). This indicated 
that conjugation of β-mecaptoethanol to the 8arm PEGs was successful and that β-
mecaptoethanol could be used as a model molucule for conjugation. The 1H-NMR spectra of 
cysteine conjugates did not show the characteristic peak for PEG at 3.3-3.9 ppm as the 
cysteine conjugated did not solve in CDCl3. 
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A 
 
B 
 
C 
 
Figure 6.4: NMR spectra of 20 kDa 8arm PEG (A), 20 kDa 8arm PEG-β-mercaptoethanol conjugate (B) and 
20 kDa 8arm PEG-cysteine conjugate (C).  
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A 
 
B 
 
C 
 
Figure 6.5: NMR spectra of 40 kDa 8arm PEG (A), 40 kDa 8arm PEG-β-mercaptoethanol conjugate (B) and 
40 kDa 8arm PEG-cysteine conjugate (C). 
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Unspecific manipulation of mitochondrial fusion in vitro  
A first step towards an enhancement of mitochondrial fusion in vitro was the treatment with a 
50 % PEG 1500 solution to stimulate mitochondrial fusion unspecifically. PEG 1500 treated 
fusion samples were analyzed qualitatively by CLSM (Figure 6.7) in comparison to 
conventional mitochondrial fusion without manipulation (Figure 6.6). In both cases yellow 
mitochondria containing both fluorescent dyes that indicated mitochondrial fusion as well as 
individually labeled green and red mitochondria were detected. This method did not give 
evidence that mitochondrial fusion was enhanced by PEG 1500.  
 
Figure 6.6: CLSM images of fusion without PEG 1500. Single labeled red and green mitochondria and 
mitochondria containing a mixture of GFP and RFP are visible as yellow dots. These fused mitochondria are 
indicated by red arrows. 
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Figure 6.7: CLSM images of fusion enhancement by PEG 1500. Single labeled red and green mitochondria and 
mitochondria containing a mixture of GFP and RFP are visible as yellow dots. These fused mitochondria are 
indicated by red arrows.  
 
The analysis of the fusion samples treated with PEG 1500 by TEM revealed fusion 
intermediates with fused outer and separated adjacent inner membranes (Figure 6.8 and 
Figure 6.9). Completely fused mitochondria with fused outer and inner membrane could not 
be detected with this transmission electron microscopy method. This TEM method also did 
not give evidence that mitochondrial fusion was enhanced by PEG 1500 but it revealed that 
the ultrastructure of mitochondria was still intact after the treatment with PEG 1500. 
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Figure 6.8: TEM image of fusion enhancement by PEG 1500, 12000x magnification. The fusion intermediate with 
separated inner membranes and fused outer membrane is indicated by a red arrow. 
 
 
Figure 6.9: TEM images of fusion enhancement by PEG 1500, 30000x magnification. The fusion intermediates 
with separated inner membranes and fused outer membrane are indicated by red arrows. 
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The quantitative analysis of mitochondrial fusion efficiency after treatment with PEG 1500 by 
flow cytometry revealed that unspecific manipulation of mitochondrial fusion was successful 
(Figure 6.10).  
 
Figure 6.10: Unspecific enhancement of fusion efficiency with PEG 1500 50 %. Data are expressed as means of 
three measurements ± standard deviations (SD). Statistically significant differences are denoted by (°), p < 0.05. 
 
Furthermore, the influence of 50 % PEG solutions with higher molecular weights of 4000 and 
10000 Dalton compared to PEG 1500 was investigated (Figure 6.11). PEG 10000 also 
increased mitochondrial fusion efficiency unspecifically but it emerged that PEG 1500 was 
the most effective one among all investigated PEGs. PEG, thereby, must likely have 
dehydrated the samples [12] and brought mitochondria in close contact to facilitate 
mitochondrial fusion. 
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Figure 6.11: Unspecific manipulation of fusion efficiency with PEG 1500 50 % in comparison to PEG 4000 50 % 
and PEG 10000 50 %. Data are expressed as means of three measurements ± standard deviations (SD). 
Statistically significant differences are denoted by (°), p < 0.05. 
 
The influence of lower concentrated PEG 1500 solutions was investigated in comparison to 
the 50 % solution that corresponded to 0.67 M. The concentrations 100 µM and 1 mM were 
chosen as modified polymers for specific manipulation, described later, were investigated at 
these concentrations. The lower concentrations of PEG 1500 had no influence on 
mitochondrial fusion efficiency (Figure 6.12). The effect of dehydration was apparently too 
low. 
 
Figure 6.12: Unspecific manipulation of fusion efficiency with PEG 1500 50 % in comparison to PEG 1500  
100 µM and 1 mM. Data are expressed as means of three measurements ± standard deviations (SD).Statistically 
significant differences are denoted by (°), p < 0.05. 
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The unspecific effects of highly concentrated 8arm PEGs, dendrimers and Jeffamine® that 
were used for the investigation of specific manipulation of mitochondrial fusion in vitro after 
modification with mitochondria specific peptides were also investigated. The  8arm PEGs 
showed toxicity due to the maleimide groups and the dendrimers showed toxicity due to the 
amine groups on the surface. Jeffamine® did not show toxicity but did also not enhance 
mitochondrial fusion unspecifically (Figure 6.13). 
 
Figure 6.13: Unspecific manipulation of fusion efficiency with 8arm PEG 20 kDa 25 %, 8arm PEG 40 kDa 25 %, 
PAMAM dendrimers G4-G7 5 % and Jeffamine 50 %. Data are expressed as means of three measurements ± 
standard deviations (SD). 
 
Specific manipulation of mitochondrial fusion in vitro 
For specific manipulation of mitochondrial fusion in vitro, two 8armPEGs, 20 KDa and 40 
kDa; four dendrimers, PAMAM-dendrimers generation 4, 5, 6 and 7 (G4-G7); a 
polyetheramine, Jeffamine® 2 kDa and quantum dots (Qdots) were chosen as carrier 
molecules.  
These carrier molecules were modified with a natural mitochondrial targeting sequence 
(MLS) and a mitochondria penetrating peptide (MPP) that specifically recognized 
mitochondrial protein import pores. For comparison, the carrier molecules were also modified 
with β-mercaptoethanol and cysteine that should not be recognized by mitochondria. The 
influence of all modified carrier systems on mitochondrial fusion efficiency in vitro was 
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determined by flow cytometry. Furthermore, the influence of the carrier systems without 
modification was evaluated. 
Modified 8arm PEGs added to a concentration of 100 µM did not influence mitochondrial 
fusion efficiency significantly (Figure 6.14). 
A 
 
B 
 
Figure 6.14: Specific manipulation of fusion efficiency with differently modified 8arm PEGs 20 kDa 100 µM (A) 
and  8arm PEGs 40 kDa 100 µM (B). Data are expressed as means of three measurements ± standard 
deviations (SD).  
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MPP-modified 8arm PEGs added at a concentration of 1 mM, significantly increased 
mitochondrial fusion efficiency. The MPP-modified 20 kDa 8arm PEG doubled mitochondrial 
fusion efficiency in vitro whereas the MPP-modified 40 kDa 8arm PEG increased 
mitochondrial fusion efficiency in vitro even to a twelvefold extent (Figure 6.15). 
A 
 
B 
 
Figure 6.15: Specific manipulation of fusion efficiency with differently modified 8arm PEGs 20 kDa 1 mM (A) and 
8arm PEGs 40 kDa 1 mM (B). Data are expressed as means of three measurements ± standard deviations (SD). 
Statistically significant differences are denoted by (*), p < 0.01.  
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To verify the results of the first batch of MPP-modified 8arm PEG 40 kDa, a second and a 
third batch were produced. They also increased mitochondrial fusion efficiency significantly 
but they only doubled mitochondrial fusion efficiency (Figure 6.16). The results of the second 
and third batch of the MPP-modified 40 kDa 8arm PEG were comparable to the results of the 
MPP-modified 20 kDa 8arm PEG. 
 
Figure 6.16: Specific manipulation of fusion efficiency with three batches of MPP-modified 8arm PEGs 40 kDa  
1 mM. Data are expressed as means of three or four measurements ± standard deviations (SD). Statistically 
significant differences are denoted by (*), p < 0.01. 
 
The MPP-modified 8arm PEG was additionally labeled with the fluorescence dye BODIPY® 
to make it accessible for TEM analysis after photooxidation and to analyze where it 
accumulated, on the surface of mitochondria or inside mitochondria after it was eventually 
taken up. A mitochondrial fusion sample treated with a BODIPY®-labeled MPP-modified 40 
kDa 8arm PEG (Figure 6.17) was analyzed in comparison to a sample treated with a 
BODIPY®-labeled β-mercaptoethanol-modified 40 kDa 8arm PEG (Figure 6.18) and a 
mitochondrial fusion sample without additional treatment (Figure 6.19). All TEM images 
showed fusion intermediates with fused outer mitochondrial membranes and adjacent but 
separated inner mitochondrial membranes. The black photooxidation product was not visible 
in Figure 6.17 and Figure 6.18 compared to Figure 6.19 that could not contain black 
photooxidation products. Eventually, the photooxidation products were distributed all over the 
samples and did not accumulate at specific sites. 
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Figure 6.17: TEM images of fusion enhancement by MPP-conjugated 40 kDa 8arm PEG labeled with BODIPY
® 
after photooxidation  with DAB, 12000x magnification. The fusion intermediates with separated inner membranes 
and fused outer membrane are indicated by red arrows.  
 
  
Figure 6.18: TEM images of fusion enhancement by β-mercaptoethanol-conjugated 40 kDa 8arm PEG labeled 
with BODIPY
® 
after photooxidation with DAB, 12000x magnification on the left image and 20000x magnification 
on the right image. The fusion intermediates with separated inner membranes and fused outer membrane are 
indicated by a red arrows.  
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Figure 6.19: TEM images of mitochondrial fusion in vitro without manipulation and without BODIPY
®
. The fusion 
intermediates with separated inner membranes and fused outer membrane are indicated by red arrows.  
 
MPP-modified generation 4, 5, 6 and 7 dendrimers slightly increased mitochondrial fusion 
efficiency in vitro at concentrations of 1 µM compared to fusion under normal conditions 
(Figure 6.20). Sometimes, also the control samples, that means dendrimers that were 
modified with cysteine or β-mercaptoethanol, slightly increased mitochondrial fusion 
efficiency. 
A 
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Figure 6.20: Specific manipulation of fusion efficiency with differently modified PAMAM G4 dendrimers 1 µM (A), 
PAMAM G5 dendrimers 1 µM (B), PAMAM G6 dendrimers 1 µM (C) and  PAMAM G7 dendrimers 1 µM (D). 
Data are expressed as means of three or four measurements ± standard deviations (SD). Statistically significant 
differences are denoted by (°), p < 0.05 or by (*), p < 0.01. 
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Only the MLS-modified generation 7 dendrimer slightly increased mitochondrial fusion 
efficiency at a concentration of 1 µM (Figure 6.20 D).  
The MPP-modified generation 4 and 5 dendrimers also increased mitochondrial fusion 
efficiency only slightly at concentrations of 100 µM (Figure 6.21). But the increase of carrier- 
and mitochondrial targeting peptide-concentration did not increase mitochondrial fusion 
efficiency. 
A 
 
B 
 
Figure 6.21: Specific manipulation of fusion efficiency with differently modified PAMAM G4 dendrimers 100 µM 
(A) and PAMAM G5 dendrimers 100 µM (B). Data are expressed as means of three or four measurements ± 
standard deviations (SD). Statistically significant differences are denoted by (°), p < 0.05. 
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Unmodified dendrimers were toxic for isolated mitochondria. The higher the generation with 
more amine groups on the surface, the more toxic was the dendrimer for isolated 
mitochondria (Figure 6.20).  
Modified quantum dots did not show any influence on mitochondrial fusion efficiency in vitro 
(Figure 6.22). The concentrations of quantum dots (Qdots) that were investigated, 10 nM and 
100 nM, were low compared to the concentrations of 8arm PEGs, eventually too low to 
influence mitochondrial fusion in vitro. 
A 
 
B 
 
Figure 6.22: Specific manipulation of fusion efficiency with differently modified Qdots 10 nM (A) and Qdots 100 
nM (B). Data are expressed as means of four measurements ± standard deviations (SD). 
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The MPP-modified polyetheramine Jeffamine® slightly increased mitochondrial fusion 
efficiency at a concentration of 100 µM and doubled mitochondrial fusion efficiency in vitro at 
a concentration of 1 mM (Figure 6.23). The investigated concentrations and observed effects 
were comparable to the 8arm PEGs. 
A 
 
B 
 
Figure 6.23: Specific manipulation of fusion efficiency with differently modified Jeffamine 100 µM (A) and 
Jeffamine 1 mM (B). Data are expressed as means of three or four measurements ± standard deviations (SD). 
Statistically significant differences are denoted by (°), p < 0.05. 
 
MPP-modified Jeffamine®, dendrimers and 8arm PEGs enhanced mitochondrial fusion in 
vitro, in which the MPP modified 8arm PEGs were the most successful ones. Beside the 
influence of the targeting sequence, it seemed that the concentration of the carrier molecule 
Chapter 6 – Affecting mitochondrial fusion efficiency in vitro 
 
- 195 - 
 
influenced on mitochondrial fusion efficiency in vitro. The higher concentrated MPP-modified 
8arm PEGs and Jeffamine® enhanced mitochondrial fusion efficiency more than the lower 
concentrated MPP-modified dendrimers. The size or molecular weight of the carrier molecule 
and the amount of MPP molecules attached to the carrier did not influence on mitochondrial 
fusion efficiency as the results of the 20 kDa and 40 kDa 8arm PEGs with a maximum of 
eight MPP molecules at the surface and the 2 kDa Jeffamine® with a maximum of two MPP 
molecules at the surface were comparable at similar concentrations. 
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The targeting peptides MLS and MPP without carrier did not influence mitochondrial fusion 
efficiency in vitro significantly (Figure 6.24). High concentrations of 1 mM MLS and MPP 
were toxic for isolated mitochondria. A trend, that lower concentrations of peptide increase 
mitochondrial fusion efficiency more than higher concentrations, was observable. However, 
these results were difficult to reproduce.  
A 
 
B 
 
Figure 6.24: Specific manipulation of fusion efficiency with different concentrations of MLS without carrier (A) 
and MPP without carrier (B), reduced and not reduced. Data are expressed as means of three measurements ± 
standard deviations (SD). 
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6.4 Conclusions 
It was shown that mitochondrial fusion could be enhanced by unspecific and specific 
approaches. PEG 1500 at a concentration of 50 % was the most effective additive for 
unspecific enhancement of mitochondrial fusion in vitro by dehydration. PEGs with higher 
molecular weights were not more effective. TEM studies revealed that the short term 
treatment with a highly concentrated PEG 1500 did not affect mitochondrial ultrastructure. 
The MPP modified 8arm PEGs, dendrimers and Jeffamine® were effective additives for 
specific enhancement of mitochondrial fusion in vitro. MPP modified 8arm PEGs at a 
concentration of 1 mM were the most effective enhancer of mitochondrial fusion in vitro. It 
emerged that carriers with the natural MLS did not enhance mitochondrial fusion efficiency. 
The successful conjugation of thiol containing molecules such as the targeting peptides MLS 
and MPP to maleimides was shown exemplarily in the conjugation of the 8arm PEGs to the 
model molecules β-mercaptoethanol and cysteine.  
Chapter 6 – Affecting mitochondrial fusion efficiency in vitro 
 
- 198 - 
 
6.5 References 
[1] S.A. Detmer, D.C. Chan, Functions and dysfunctions of mitochondrial dynamics, Nat Rev 
Mol Cell Biol 8 (2007) 870–879. 
[2] H. Chen, M. Vermulst, Y.E. Wang, A. Chomyn, T.A. Prolla, J.M. McCaffery, D.C. Chan, 
Mitochondrial Fusion Is Required for mtDNA Stability in Skeletal Muscle and Tolerance of 
mtDNA Mutations, Cell 141 (2010) 280–289. 
[3] D.C. Chan, Mitochondrial Fusion and Fission in Mammals, Annu. Rev. Cell Dev. Biol 22 
(2006) 79–99. 
[4] E.A. Schon, S. DiMauro, M. Hirano, R.W. Gilkerson, Therapeutic prospects for 
mitochondrial disease, Trends in Molecular Medicine 16 (2010) 268–276. 
[5] V. Salnikov, Y. Lukyánenko, C. Frederick, W. Lederer, V. Lukyánenko, Probing the Outer 
Mitochondrial Membrane in Cardiac Mitochondria with Nanoparticles, Biophysical Journal 
92 (2007) 1058–1071. 
[6] M.P. Schwartz, A. Matouschek, The dimensions of the protein import channels in the 
outer and inner mitochondrial membranes, Proceedings of the National Academy of 
Sciences 96 (1999) 13086–13090. 
[7] N. Pfanner, A. Geissler, Versatility of the mitochondrial protein import machinery, Nat. 
Rev. Mol. Cell Biol 2 (2001) 339–349. 
[8] N. Pfanner, M. Meijer, Mitochondrial biogenesis: The Tom and Tim machine, Current 
Biology 7 (1997) R100–103. 
[9] A. Heller, Chapter 5: Mitochondrial fusion in vitro, in: A. Heller (Ed.), Targeting 
mitochondria by mitochondrial fusion, mitochondria-specific peptides and 
nanotechnology: Dissertation. 
[10] R.L. Davidson, K.A. O'Malley, T.B. Wheeler, Polyethylene glycol-induced mammalian 
cell hybridization: effect of polyethylene glycol molecular weight and concentration, 
Somatic Cell Genet 2 (1976) 271–280. 
[11] J. Yang, M.H. Shen, Polyethylene glycol-mediated cell fusion, in: S. Pells (Ed.), Nuclear 
reprogramming: Methods and protocols, Humana Press, Totowa, N.J, 2006, pp. 59–66. 
Chapter 6 – Affecting mitochondrial fusion efficiency in vitro 
 
- 199 - 
 
[12] J.W. Wojcieszyn, R.A. Schlegel, K. Lumley-Sapanski, K.A. Jacobson, Studies on the 
mechanism of polyethylene glycol-mediated cell fusion using fluorescent membrane and 
cytoplasmic probes, J. Cell Biol 96 (1983) 151–159. 
[13] K.L. Horton, K.M. Stewart, S.B. Fonseca, Q. Guo, S.O. Kelley, Mitochondria-Penetrating 
Peptides, Chemistry & Biology 15 (2008) 375–382. 
[14] L.F. Yousif, K.M. Stewart, K.L. Horton, S.O. Kelley, Mitochondria-Penetrating Peptides: 
Sequence Effects and Model Cargo Transport, ChemBioChem 10 (2009) 2081–2088. 
[15] Y. Abe, T. Shodai, T. Muto, K. Mihara, H. Torii, S.-i. Nishikawa, T. Endo, D. Kohda, 
Structural Basis of Presequence Recognition by the Mitochondrial Protein Import 
Receptor Tom20, Cell 100 (2000) 551–560. 
[16] J. Brix, K. Dietmeier, N. Pfanner, Differential Recognition of Preproteins by the Purified 
Cytosolic Domains of the Mitochondrial Import Receptors Tom20, Tom22, and Tom70, 
Journal of Biological Chemistry 272 (1997) 20730–20735. 
[17] P. Rehling, N. Wiedemann, N. Pfanner, K.N. Truscott, The mitochondrial import 
machinery for preproteins, Crit. Rev. Biochem. Mol. Biol 36 (2001) 291–336. 
[18] G.G.M. D’Souza, S.V. Boddapati, V. Weissig, Gene Therapy of the Other Genome: The 
Challenges of Treating Mitochondrial DNA Defects, Pharm Res 24 (2007) 228–238. 
[19] S.H. Medina, M.E.H. El-Sayed, Dendrimers as Carriers for Delivery of Chemotherapeutic 
Agents, Chem. Rev 109 (2009) 3141–3157. 
[20] G.G.M. D'Souza, V. Weissig, Subcellular targeting: a new frontier for drug-loaded 
pharmaceutical nanocarriers and the concept of the magic bullet, Expert Opin. Drug Deliv 
6 (2009) 1135–1148. 
[21] M. Labieniec, O. Ulicna, O. Vancova, J. Kucharska, T. Gabryelak, C. Watala, Effect of 
poly(amido)amine (PAMAM) G4 dendrimer on heart and liver mitochondria in an animal 
model of diabetes, Cell Biology Int 34 (2010) 89–97. 
[22] M.M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities 
of protein utilizing the principle of protein-dye binding, Analytical Biochemistry 72 (1976) 
248–254. 
Chapter 6 – Affecting mitochondrial fusion efficiency in vitro 
 
- 200 - 
 
[23] S. Meeusen, J.M. McCaffery, J. Nunnari, Mitochondrial Fusion Intermediates Revealed 
in Vitro, Science 305 (2004) 1747–1752. 
 
 
 
 
- 201 - 
 
 
 
Chapter 7 
 
Binding behavior of 
mitochondrial targeting 
sequences to isolated 
mitochondria 
Chapter 7 – Binding behavior of mitochondrial targeting sequences to isolated mitochondria 
 
- 202 - 
 
Abstract 
The binding properties of a natural mitochondrial targeting peptide (MLS) and a synthetic 
mitochondria penetrating peptide (MPP) to isolated mitochondria were evaluated. Quantum 
dots and fluorescent dyes were coupled to the mitochondrial targeting peptides to evaluate 
their binding affinity by flow cytometry whereas gold nanoparticles were used to investigate 
the binding affinity by transmission electron microscopy. Thereby, gold nanoparticles were 
successfully synthesized not by conventional exchange of citric acid but by a HEPES 
reduction method. Additionally, the binding behavior of MPP coupled to a BODIPY®-modified 
8arm PEG was investigated by TEM analysis after photooxidation.  
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7.1 Introduction 
Binding behavior and attraction of proteins to mitochondria are closely related to the affinity 
and properties of the targeting sequences. Beside this, the abundance of mitochondrial 
protein import pores that are targeted by these sequences also plays a role in achieving a 
sufficient binding and targeting to mitochondria. Mitochondria import more than a thousand 
different proteins, but a consensus in the amino acid sequence of the different mitochondrial 
targeting signals has not been identified [1]. Although they do not show amino acid sequence 
identity, the targeting signals have common characteristic physicochemical properties as 
they are enriched in positively charged, hydroxylated and hydrophobic residues with the 
ability to form an amphiphilic α-helix [1]. Protein translocation into mitochondria involves the 
targeting signal on the protein with a typical length of 15-50 amino acids [2], and a 
multiprotein translocator complex on the target membrane [3]. Interaction between these two 
components occurs due to the conformation of the targeting signal. The amphiphilic α-helix 
with hydrophobic residues on one side is able to interact with hydrophobic grooves of the 
translocator complex subunits in the mitochondrial outer membrane [3] and the positively 
charged surface on the other side of the α-helix is recognized by another subunit of the 
translocator complex [2]. Following to the interaction of targeting signal and translocator 
complexes, the membrane potential across the inner mitochondrial membrane directs the 
targeting sequences across this membrane, predominantly by an electrophoretic effect [1].  
It is known that mitochondrial protein import is an efficient and rapid process as isolated 
mitochondria are able to import the majority of added protein within 30 seconds [4]. The 
mitochondrial targeting sequence (MLS) that has been examined in this study consists of 17 
amino acids, derived from the targeting sequence of the saccharomyces cerevisiae protein 
cytochrome c oxidase subunit IV (CoxIV) plus an additional cysteine at the C-terminus for 
chemical reactions involving the thiol. This targeting sequence is well investigated and 
exhibits a high binding affinity to the translocator complexes in the mitochondrial membranes 
in comparison to other sequences [5–7]. Additionally, the binding behavior of a synthetic 
Chapter 7 – Binding behavior of mitochondrial targeting sequences to isolated mitochondria 
 
- 204 - 
 
mitochondria penetrating peptide (MPP) that consists of 6 amino acids, according to MPPs 
described by Horton et al. and Yousif et al. [8,9] has been investigated. 
Beside the affinity of the targeting sequence to the protein import pores, the abundance of 
these translocator complexes in the mitochondrial membranes also play a crucial role in 
attaining a sufficient binding and targeting. It is difficult to define an exact number of protein 
pores on mitochondria as they are dynamic organelles that constantly change their size due 
to fusion and fission processes [10]. Only little is known about the distribution of the 
translocator complexes but there are approaches to define the density of protein import 
pores on mitochondria by special high resolution microscopy techniques [11]. It has been 
revealed that the density of the translocator proteins correlates to growth conditions and the 
mitochondrial membrane potential. It has also been detected that there is an intracellular 
gradient from perinuclear to the peripheral mitochondria [11]. The targeting sequence binding 
subunits of the protein import pores form clusters. Number, distribution and density are 
regulated and correlate with the activity of mitochondria and their position in the cell. The 
membrane potential of perinuclear mitochondria is higher than that of peripheral 
mitochondria and perinuclear mitochondria have a higher metabolic activity. This, in turn, 
correlates with a higher density of protein import pores on metabolic active perinuclear 
mitochondria. The molecular mechanisms that regulate the distribution of protein import 
pores are not known [11]. The density of protein import complexes also varies between 
different cell lines but an average number of approximately 100 translocator complex clusters 
per square micrometer has been determined [11]. 
For investigation of the affinity of the mitochondrial targeting sequence (MLS) and the 
mitochondria penetrating peptide (MPP) to mitochondria, it has been necessary to label the 
peptide sequence fluorescently to make it accessible to flow cytometry analysis. Therefore 
quantum dots as well as the fluorescent dyes tetramethylrhodamine (TAMRA) and BODIPY® 
have been conjugated to the MLS and the MPP. 
To study the binding behavior of the MLS by transmission electron microscopy (TEM), MLS 
capped gold nanoparticles were synthesized. Several methods can be applied to cover and 
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stabilize gold nanoparticles with peptides. The success of which depends on the 
physicochemical properties of the peptide sequence. Peptide capped gold nanoparticles are 
conventionally synthesized by reducing tetrachloroaurate ions with citric acid. The addition of 
cysteine containing peptides results in the exchange of capping agents from citric acid to 
peptides.  But it has been demonstrated that peptides that are abundant of basic amino acids 
lead to aggregation of gold nanoparticles during exchange reactions [12]. This may occur 
due to repulsion between adjacent peptides, resulting in less peptide molecules on the 
particle surface that stabilize the gold nanoparticle [12].  Therefore, a method that reduces 
tetrachloroaurate ions with HEPES under mild conditions (pH 7.2, ambient temperature) in 
the presence of a cysteine-terminal peptide [12,13] was applied to synthesize MLS-capped 
gold nanoparticles for TEM studies. Tetrachloroaurate ions are reduced due to oxidation of 
the piperazine ring of HEPES to an N-centered cationic free radical, producing gold 
nanoparticles in the presence of gold binding peptides [12]. Additionally, the binding behavior 
of the mitochondria penetrating peptide (MPP), conjugated to a fluorescently labeled 8arm 
PEG has been investigated by a photoconversion method in a transmission electron 
microscopy study.  
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7.2 Materials and methods 
7.2.1 Materials 
HAM F-12 nutrient mixture and fetal calf serum (FCS) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Trypsin-EDTA 0.25 % was obtained from Gibco-Invitrogen 
(Karlsruhe, Germany). G418 was purchased from Sigma-Aldrich (Steinheim, Germany). 
Purified water was obtained by using a Milli-Q water purification system from Millipore 
(Schwalbach, Germany). All cell culture materials were purchased from Corning (Bodenheim, 
Germany). 
Isolation buffer consisted of 250 mM sucrose (Merck, Darmstadt, Germany), 10 mM Tris 
(USB Corporation, Cleveland, OH USA), 10 mM KCl (Merck, Darmstadt, Germany), 1 mM 
Na2EDTA (Merck, Darmstadt, Germany) and 0.1 % bovine serum albumin (BSA) (Sigma-
Aldrich, Steinheim, Germany). MLS and MPP peptides were synthesized by GeneCust 
(Dudelange, Luxembourg). TCEP Reducing Gel was obtained from Thermo Fisher Scientific 
(Bonn, Germany) and TCEP was purchased from Sigma-Aldrich (Steinheim, Germany). 
Sodium phosphate/sodium chloride buffer consisted of 0.1 M disodium hydrogenphosphate 
dihydrate (Merck, Darmstadt, Germany) and 0.15 M sodium chloride (Merck, Darmstadt, 
Germany). The pH-value was adjusted to 7.2 by TitriPUR® 1 N hydrochloric acid (Merck, 
Darmstadt, Germany). Amicon® Ultra-4 centrifugal filter units 10 kDa (Millipore, Schwalbach, 
Germany) were used for purification by ultrafiltration. 
Qdot 655 ITK amino (PEG) quantum dots were obtained from Invitrogen (Karlsruhe, 
Germany) and quantum dots eFluor 650 NC (amine) nanocrystals were purchased from 
eBioscience (Frankfurt, Germany). Sulfo-SMCC was obtained from Thermo Fisher Scientific 
(Bonn, Germany). β-mercaptoethanol and L-cysteine hydrochloride monohydrate were 
purchased from Sigma-Aldrich (Steinheim, Germany). TAMRA-maleimide was obtained from 
MoBiTec (Göttingen, Germany) and BODIPY® FL SE was purchased from Invitrogen 
(Karlsruhe, Germany). PD-10 columns filled with Sephadex G-25 medium were obtained 
from GE Healthcare (Freiburg, Germany). Gold(III)chloride trihydrate was obtained from 
Sigma-Aldrich (Steinheim, Germany) and HEPES  was purchased from Merck (Darmstadt, 
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Germany). The pH-value of 0.1 M HEPES buffer was adjusted to 7.2 by TitriPUR® 1 N 
sodium hydroxide (Merck, Darmstadt, Germany). BODIPY® FL L-cystine was obtained from 
Invitrogen (Karlsruhe, Germany). The 8arm PEG-maleimide 40 kDa was purchased from 
Nanocs Inc. (New York, NY, USA). DPBS without calcium and magnesium was obtained 
from Gibco-Invitrogen (Karlsruhe, Germany). 
0.1 M cacodylate fixation buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany), 40 mM sodium chloride (Merck, 
Darmstadt, Germany) and 2 % glutaraldehyde (Serva, Heidelberg, Germany). 0.1 M 
cacodylate washing buffer consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, 
Germany), 2 mM magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM 
calcium chloride dihydrate (Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, 
Darmstadt, Germany). Diaminobenzidine was purchased from Sigma-Aldrich (Steinheim, 
Germany) and agarose was obtained from Biozym (Hessisch Oldendorf, Germany). Osmium 
tetroxide (ScienceServices, Munich, Germany) was dissolved to 1 % in 0.1 M cacodylate 
buffer that consisted of 100 mM sodium cacodylate (Roth, Karlsruhe, Germany), 2 mM 
magnesium chloride hexahydrate (Merck, Darmstadt, Germany), 1 mM calcium chloride 
dihydrate (Merck, Darmstadt, Germany) and 40 mM sodium chloride (Merck, Darmstadt, 
Germany). Embedding in Epon was carried out with an Epoxy Embedding Medium Kit (Fluka 
by Sigma-Aldrich, Steinheim, Germany). Propylen oxide was purchased from Sigma-Aldrich 
(Steinheim, Germany). 
 
7.2.2 Binding behavior of MLS- and MPP-modified Qdots to isolated mitochondria 
Quantum dots from Invitrogen (Karlsruhe, Germany) and eBioscience (Frankfurt, Germany) 
were modified with the MLS, MPP, cysteine and β-mercaptoethanol as described in a 
previous study [14]. Long-time cultivation of a CHO-cell line that was stably transfected with 
mitochondria targeted green fluorescent protein (mtGFP) was carried out in selection 
medium HAM-F12 containing 10 % FCS and 400 µg/ml G418. The last cultivation step of 
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CHO-mtGFP cells before binding experiments was carried out in G418-free medium because 
the cells did not lose the plasmid within one week. Cells were cultured in HAM-F12 nutrient 
mixture with 10 % FCS in 150 cm2 culture flasks until confluency, harvested by Trypsin-
EDTA 0.25 % and washed with isolation buffer. The centrifugation steps for the washing 
steps of the cells were carried out in a GS-15R centrifuge (Beckman, Krefeld, Germany). 
Afterwards, mtGFP-containing cells from one culture flask were suspended in 250 µl isolation 
buffer. Then, cells from four flasks were pooled and the resulting one milliliter of cell 
suspension was transferred into a cooled 2-ml Dounce glass homogenizer (Sigma-Aldrich, 
Steinheim, Germany) where the cells were disrupted by 25 strokes. The suspension was 
transferred into a 2-ml safe-lock tube (Eppendorf, Hamburg, Germany) and centrifuged at 
1500 g at 4 °C for 10 min a type 5415 R centrifuge (Eppendorf, Hamburg, Germany) to 
pelletize nuclei as well as remaining intact cells. The first supernatant was kept on ice, while 
the pellet was resuspended in isolation buffer and homogenized by 25 Dounce strokes for a 
second time to break remaining intact cells. A second centrifugation step at 1500 g at 4 °C 
for 10 min yielded a pellet that was the nuclei enriched fraction. The first and the second 
supernatant were mixed and centrifuged at 16000 g at 4 °C for 15 min to obtain a pellet 
enriched with mtGFP-containing isolated mitochondria. The amount of cells used for the 
isolation of mitochondria depended on the required amount for the different experiments. 
Mitochondrial protein concentration was determined by a Bradford-Assay [15]. 
Isolated mitochondria were mixed with unmodified, MLS-, MPP-, cysteine- and β-
mercaptoethanol-modified quantum dots, in 10 nM and 100 nM concentrations. The mixture 
was either incubated on ice for 1 h or centrifuged at 16000 g, 4 °C for 10min and then 
incubated on ice for 1 h. After incubation, the pellets of the centrifuged samples were 
resuspended again. Analysis of the binding of quantum dots to isolated mitochondria was 
carried out by flow cytometry with a FACSCanto™ (BD Bioscience, Heidelberg, Germany). 
Therefore, the samples were diluted to not exceed the critical count rate of the flow 
cytometer. GFP was excited by a 488 nm blue laser and was detected at 515–545 nm. 
Quantum dots from Invitrogen (Karlsruhe, Germany) were excited by a 405 nm violet laser 
Chapter 7 – Binding behavior of mitochondrial targeting sequences to isolated mitochondria 
 
- 209 - 
 
and detected at 650–670 nm whereas quantum dots from eBioscience (Frankfurt, Germany) 
were excited by a 488 nm blue laser and detected with a 670 nm long pass filter. Plots that 
indicated fluorescence intensity of GFP on the x-axis and fluorescence intensity of quantum 
dots on the y-axis were created. GFP-labeled isolated mitochondria and non-fluorescent 
isolated mitochondria were used to define the quadrants of the plots as follows: the lower left 
quadrant (LL) indicated non fluorescent cell fragments, the upper left quadrant (UL) indicated 
quantum dots that bound non-specifically to non-fluorescent cell fragments as quantum dots 
in solution are too small to be detected by the flow cytometer, the lower right quadrant (LR) 
was determined by single-labeled GFP-mitochondria and the upper right quadrant (UR) was 
positive for quantum dots that bound to GFP-mitochondria (Figure 7.1).  
 
Figure 7.1: Flow cytometry plot for the analysis of the binding of quantum dots to mitochondria. 
 
7.2.3 Binding behavior of MLS-modified TAMRA to isolated mitochondria 
The MLS peptide was reduced by a TCEP-gel at room temperature in the dark for 1 h and 
modified with a tenfold molar excess of TAMRA-maleimide afterwards. Reactions were 
carried out at room temperature for 1-2 h. The conjugate was purified by a PD 10 desalting 
column and stored at -20 °C. Cells were cultured as described previously. The last cultivation 
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step of CHO-mtGFP cells before binding experiments was carried out in G418-free medium 
because the cells did not lose the plasmid within one week. Only long-time cultivation of 
CHO-GFP cells was carried out in selection medium containing 400 µg/ml G418. 
Mitochondria from CHO-mtGFP cells were isolated as described previously. Isolated 
mitochondria were mixed with unmodified or MLS-modified TAMRA, in 1 µM and 5 µM 
concentrations. The mixture was either incubated on ice for 1 h or centrifuged at 16000 g, at 
4 °C for 10min and then incubated on ice for 1 h. After incubation, the pellets of the 
centrifuged samples were resuspended again. 
Analysis of the binding of TAMRA-MLS to isolated mitochondria was carried out by flow 
cytometry with a FACSCanto™ (BD Bioscience, Heidelberg, Germany). Therefore, the 
samples were diluted to not exceed the critical count rate of the flow cytometer. GFP was 
excited by a 488 nm blue laser and detected at 515–545 nm. TAMRA was excited by a 488 
nm blue laser and detected at 564–606 nm. Plots that indicated fluorescence of GFP on the 
x-axis and fluorescence of TAMRA on the y-axis were created. GFP-labeled isolated 
mitochondria and non-fluorescent isolated mitochondria were used to define the quadrants of 
the plots as follows: the lower left quadrant (LL) indicated non fluorescent cell fragments, the 
upper left quadrant (UL) indicated TAMRA that bound non-specifically to non-fluorescent cell 
fragments as TAMRA in solution could not be detected by the flow cytometer, the lower right 
quadrant (LR) was determined by single-labeled GFP-mitochondria and the upper right 
quadrant (UR) was positive for TAMRA that bound to GFP-mitochondria.  
Intact cells, CHO and CHO-mtGFP cells were stained with the unconjugated TAMRA-
maleimide dye in concentrations of 1 µM and 5 µM to determine the intracellular distribution 
of the dye. Analysis was carried out by confocal laser scanning microscopy (CLSM) with a 
Zeiss Axiovert LSM 510 (Carl Zeiss, Oberkochen, Germany) and an AxioCam HRc (Carl 
Zeiss, Oberkochen, Germany). Thereby, GFP was excited at 488 nm and detected at 505–
530 nm whereas TAMRA was excited at 543 nm and detected at 560–615 nm. 
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7.2.4 Binding behavior of BODIPY® to isolated mitochondria 
Before using BODIPY® FL SE as a dye to label the MLS, intact CHO and CHO-RFP cells 
were stained in concentrations of 10 nM and 100 nM to determine the intracellular 
distribution of the dye. Analysis was carried out by confocal laser scanning microscopy 
(CLSM) with a Zeiss Axiovert LSM 510 (Carl Zeiss, Oberkochen, Germany) and an AxioCam 
HRc (Carl Zeiss, Oberkochen, Germany). Thereby, RFP was excited at 488 nm and 
emission was detected at 560–615 nm whereas TAMRA was excited at 488 nm and 
emission was detected at 505–530 nm.  
Afterwards, isolated mitochondria from CHO-cells containing a mitochondria targeted red 
fluorescent protein (mtRFP) were stained with BODIPY® FL SE to investigate the behavior of 
the dye in presence of isolated mitochondria. Therefore, cells were cultured as described 
previously. The last cultivation step of CHO-mtRFP cells before binding experiments was 
carried out in G418-free medium because the cells did not lose the plasmid within one week. 
Only long-time cultivation of CHO-mtRFP cells was carried out in selection medium 
containing 400 µg/ml G418. Mitochondria from CHO-RFP cells were isolated as described 
previously. The dye was added in 10 nM and 100 nM concentrations. The mixture was either 
incubated on ice for 1 h or centrifuged at 16000 g, at 4 °C for 10min and then incubated on 
ice for 1 h. After incubation, the pellets of the centrifuged samples were resuspended again. 
Analysis of the binding of BODIPY® FL SE to isolated mitochondria was carried out by flow 
cytometry with a FACSCanto™ (BD Bioscience, Heidelberg, Germany). Therefore, the 
samples were diluted to not exceed the critical count rate of the flow cytometer. RFP was 
excited by a 488 nm blue laser and was detected at 564–606 nm. BODIPY® FL SE was 
excited by a 488 nm blue laser and was detected at 515–545 nm. Plots that indicate the 
fluorescence of RFP on the x-axis and the fluorescence of BODIPY® FL SE on the y-axis 
were created. RFP-labeled isolated mitochondria and non-fluorescent isolated mitochondria 
were used to define the quadrants of the plots as follows: the lower left quadrant (LL) 
indicated non fluorescent cell fragments, the upper left quadrant (UL) indicated BODIPY® FL 
SE that bound non-specifically to non-fluorescent cell fragments as BODIPY® FL SE in 
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solution could not be detected by the flow cytometer, the lower right quadrant (LR) was 
determined by single-labeled RFP-mitochondria and the upper right quadrant (UR) was 
positive for BODIPY® FL SE that bound to RFP-mitochondria.  
 
7.2.5 Binding behavior of MLS-modified gold nanoparticles to isolated mitochondria 
Gold nanoparticles capped by the targeting peptides MLS and MPP were synthesized using 
a HEPES reduction method according to Slocik et al. [13] and Serizawa et al. [12]. Thereby, 
the peptides were reduced on a TCEP-gel at room temperature in the dark for 1 h. The 
reduced peptides were added in 0.075 mM, 0.15 mM, 0.225, 0.3 mM, 0.45 mM, 0.6 mM or 
0.75 mM concentrations to HEPES buffer 0.1 M in a glass vial. Tetrachloroauric acid was 
added to a 0.5 mM concentration. The mixture was stirred at room temperature for 42 h. 
Gold nanoparticles were purified by three centrifugation steps at 5000 g, 4 °C for 10 min in a 
type 5415 R centrifuge (Eppendorf, Hamburg, Germany) and resuspended in purified water. 
Characterization of the gold nanoparticles was carried out by UV-spectroscopy with a 
Kontron Instruments Uvikon 900 spectrophotometer (Goebel Instrumentelle Analytik, 
Hallertau, Germany). The size of the peptide capped gold nanoparticles was determined by 
photon correlation spectroscopy (PCS) with a Zetasizer nano ZS (Malvern, Herrenberg, 
Germany). The zetapotential of the peptide capped gold nanoparticles also was determined 
with a Zetasizer nano ZS (Malvern, Herrenberg, Germany). All measurements were carried 
at 25 °C in purified water and the concentration of the gold nanoparticles was determined 
according to Haiss et al. [16].  
Cells were cultured and mitochondria were isolated as described previously. Gold 
nanoparticles were added to isolated mitochondria, incubated on ice for 1 h and analyzed by 
TEM.  Therefore, samples were fixed in cacodylate fixation buffer at room temperature for  
5 min and on ice overnight. Afterwards, mitochondria were washed by five washing steps, 
each of them in cacodylate washing buffer for 2 min. Then, isolated mitochondria were 
pelletized in a 1 % agarose solution that was heated to 40 °C. All centrifugation steps were 
carried out in a himac CT15RE (VWR Leuven, Belgium by Hitachi Koki Co. Ltd.). After 
Chapter 7 – Binding behavior of mitochondrial targeting sequences to isolated mitochondria 
 
- 213 - 
 
gelation of the agarose, the gel block was cut and fixed with osmium tetroxide solution 
overnight. Then, the samples were washed in DPBS four times for 15 min. Afterwards, the 
samples were dehydrated in a graded series of ethanol: 50 %, 70 %, 80 %, 90 % and 100 %. 
Each dehydration step was carried out two times for 15 min. Then, the samples were treated 
in an equal mixture of acetone or propylene oxide and ethanol for 20 min and two times in 
acetone or propylene oxide for 20 min. Afterwards, the samples were treated with a mixture 
of acetone or propylene oxide and Epon (2:1) for 2 h, then, in a mixture of acetone or 
propylene oxide and Epon (1:1) for 2 h and subsequently in a mixture of acetone or 
propylene oxide and Epon (1:2) in an open vial overnight. Then, the samples were 
embedded and hardened in Epon at room temperature for 1 h, at 30 °C for 2 h and at 60 °C 
for 2 days. Epon blocks were cut into sections of 50 nm with a microtome Leica EM UC6 
(Leica, Vienna, Austria) and transferred to copper slot grids with a 1.5 % hyaloform foil. They 
were examined either unstained or stained with uranyl acetate and lead citrate in a 
transmission electron microscope Zeiss EM 902 (Carl Zeiss, Oberkochen, Germany), 
operating at 80kV. Digital images were recorded by a slow scan CCD camera (TRS Typ 
7888, Serial No. 321/08). 
 
7.2.6 Binding behavior of MPP-modified BODIPY®-labeled 40kDa 8arm PEG to isolated  
 mitochondria 
BODIPY® FL L-cystine and the MPP were reduced by a thirtyfold molar excess of TCEP in 
the dark for 30 min. The 8arm PEG-maleimid 40 kDa was modified with the reduced 
BODIPY® FL L-cystine in an equal molar ratio and with MPP or β-mercaptoethanol in a 
tenfold molar excess. Therefore, 8arm PEGs were dissolved in sodium phosphate/sodium 
chloride buffer to 1 mM and reduced BODIPY® FL L-cystine and MPP or β-mercaptoethanol 
were added to the 8arm PEG solutions. Reactions were carried out at 4 °C overnight. The 
modified 8arm PEGs were purified by six ultrafiltration steps in ultrafiltration units with a cut-
off of 10 kDa and sodium phosphate/sodium chloride buffer.  
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Cells were cultured and mitochondria were isolated as described previously. The 8arm PEG 
modified with BODIPY® FL L-cystine and MPP or β-mercaptoethanol was added to isolated 
mitochondria, incubated on ice for 1 h and analyzed by TEM after photooxidation. Therefore, 
isolated mitochondria were fixed in cacodylate fixation buffer with glutaraldehyde at room 
temperature for 5 min and on ice overnight. Afterwards, mitochondria were washed by five 
washing steps, each of them in cacodylate washing buffer for 2 min. Then, the buffer solution 
was exchanged by diaminobenzide in cacodylate buffer 0.1 M and photooxidation was 
carried out at an Axiovert 200 (Carl Zeiss, Göttingen, Germany) with an excitation wave 
length of 488 nm and an emission wave length of 515 nm. Afterwards, the diaminobenzidine 
solution was exchange by cacodylate buffer 0.1 M. Then, isolated mitochondria were 
pelletized in a 1 % agarose solution that was heated up to 40 °C. All centrifugation steps 
were carried out in a himac CT15RE (VWR Leuven, Belgium by Hitachi Koki Co. Ltd.). After 
gelation of the agarose, the gel block was cut and fixed with osmium tetroxide solution 
overnight. The samples were washed in DPBS four times for 15 min. Afterwards, the 
samples were dehydrated in a graded series of ethanol: 50 %, 70 %, 80 %, 90 % and 100 %. 
Each dehydration step was carried out two times for 15 min. Then, the samples were treated 
in an equal mixture of acetone or propylene oxide and ethanol for 20 min and two times in 
acetone or propylene oxide for 20 min. Afterwards, the samples were treated with a mixture 
of acetone or propylene oxide and Epon (2:1) for 2 h, then, in a mixture of acetone or 
propylene oxide and Epon (1:1) for 2 h and subsequently in a mixture of acetone or 
propylene oxide and Epon (1:2) in an open vial overnight. Then, the samples were 
embedded and hardened in Epon at room temperature for 1 h, at 30 °C for 2 h and at 60 °C 
for 2 days. Epon blocks were cut into sections of 50 nm with a Leica EM UC6 microtome 
(Leica, Vienna, Austria) and transferred to copper slot grids with a 1.5 % hyaloform foil. They 
were examined either unstained or stained with uranyl acetate and lead citrate in a 
transmission electron microscope Zeiss EM 902 (Carl Zeiss, Oberkochen, Germany), 
operating at 80kV. Digital images were recorded by a slow scan CCD camera (TRS Typ 
7888, Serial No. 321/08).  
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7.3 Results and discussion 
The binding affinity of a natural mitochondrial targeting sequence (MLS) and a synthetic 
mitochondrial targeting peptide (MPP) to isolated mitochondria was investigated by flow 
cytometry. Therefore, the peptides were attached to red fluorescent quantum dots and the 
binding affinity to isolated mitochondria that carried green fluorescent proteins was evaluated 
in comparison to unmodified quantum dots and non-targeting quantum dots that were 
modified with cysteine or β-mercaptoethanol (Figure 7.2). Concentrations of 10 nM and 100 
nM of quantum dots were investigated. Isolated mitochondria and quantum dots were either 
only mixed or centrifuged. The four quadrants of the flow cytometry plots in Figure 7.2 show 
non fluorescent cell fragments in the lower left quadrant, quantum dots that bound non-
specifically to non-fluorescent cell fragments in the upper left quadrant, GFP-containing 
mitochondria in the lower right quadrant and quantum dots that bound to GFP-containing 
mitochondria in the upper right quadrant. Figure 7.2 shows that all kinds of unmodified and 
modified quantum dots bound to isolated mitochondria and cell fragments in the same 
manner. Unmodified and non-targeted quantum dots showed the same binding affinity to 
isolated mitochondria and cell fragments like targeted quantum dots that were modified with 
the MLS or the MPP. In turn, the targeted quantum dots showed the same binding affinity to 
cell fragments like the unmodified and non-targeting quantum dots. The higher the 
concentration of all modified and unmodified quantum dots was, the higher was the binding 
affinity to cell fragments and isolated mitochondria. Centrifugation also increased the binding 
affinity to cell fragments and isolated mitochondria. 
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  10 nM  10 nM  100 nM  100 nM  
    centrifuged    centrifuged 
 unmodified     
  MLS     
  MPP     
  cysteine     
β-mercaptoethanol    
Figure 7.2: Flow cytometry plots showing the binding of unmodified, MLS-, MPP-, cysteine and β-
mercaptoethanol-modified quantum dots to isolated mitochondria. The y-axis indicates red fluorescence intensity 
of the quantum dots whereas the x-axis indicates green fluorescence intensity of isolated mitochondria. 
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As quantum dots showed such a high non-specific binding affinity to isolated mitochondria 
and cell fragments, they were not considered useful for the investigation of the binding 
properties of mitochondrial targeting sequences. Therefore, the natural mitochondrial 
targeting sequence MLS was labeled with the red fluorescent dye TAMRA and the binding 
affinity to green fluorescent isolated mitochondria was investigated by flow cytometry in 
comparison to the binding properties of TAMRA without mitochondrial targeting sequence 
(Figure 7.3). The quadrants of the flow cytometry plots were defined as described previously. 
 
  1 µM  1 µM  5 µM  5 µM 
    centrifuged    centrifuged 
   TAMRA     
           TAMRA-MLS     
 
Figure 7.3: Flow cytometry plots showing the binding of TAMRA and MLS-modified TAMRA to isolated 
mitochondria. 
 
Figure 7.3 shows that TAMRA as well as TAMRA-MLS stained cell fragments and isolated 
mitochondria. To evaluate where TAMRA accumulated in cells predominantly, intact cells 
containing mitochondrial targeted GFP were stained with unmodified TAMRA (Figure 7.4). 
The CLSM image showed that TAMRA accumulated in mitochondria due to the positive 
charge of the molecule that was attracted by the highly negative membrane potential of 
mitochondria [17]. Hence, TAMRA was not useful to study the binding properties of the MLS 
to mitochondria. 
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Figure 7.4: CLSM image of mitochondrial GFP containing cells stained with TAMRA 1 µM. The red fluorescence 
dye colocalized with GFP in mitochondria resulting in a yellow appearance. This panel shows a merge of both 
fluorescence images and the bright field image. 
 
Based on these results, BODIPY® was chosen as an alternative dye as the molecule did not 
carry a charge. To evaluate where BODIPY® accumulated in cells, intact cells were stained 
with unmodified BODIPY®. Figure 7.5 showed that BODIPY® only stained the cytosol of cells 
and was not attracted to mitochondria.  
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Figure 7.5: CLSM image of mitochondrial RFP containing cells stained with BODIPY
® 
100 nM. The green 
fluorescence dye localized in the cytosol and could be distinguished from the red fluorescence in mitochondria. 
This panel shows a merge of both fluorescence images and the bright field image. 
 
To investigate how BODIPY® behaved when it was added to isolated mitochondria, the green 
fluorescent dye BODIPY® was mixed with a RFP-containing isolated mitochondria 
preparation and flow cytometry analysis was carried out. The four quadrants of the flow 
cytometry plots in Figure 7.6 showed non fluorescent cell fragments in the lower left 
quadrant, BODIPY® that stained non-specifically to non-fluorescent cell fragments in the 
upper left quadrant, RFP-containing mitochondria in the lower right quadrant and BODIPY® 
that stained to RFP-containing mitochondria in the upper right quadrant. Concentrations of 
10 nM and 100 nM BODIPY® were investigated. Isolated mitochondria and BODIPY® were 
either only mixed or centrifuged. 
  10 nM  10 nM  100 nM  100 nM  
    centrifuged    centrifuged 
  BODIPY     
 
Figure 7.6: Flow cytometry plots showing the binding of BODIPY to isolated mitochondria. 
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Figure 7.6 showed that BODIPY® stained cell fragments as well as isolated mitochondria 
depending on concentration and additional centrifugation. Therefore, BODIPY® was also not 
suitable for the investigation of the binding properties of mitochondrial targeting peptides. 
Finally, gold nanoparticles were capped with mitochondrial targeting peptides for 
investigation of the binding properties of mitochondrial targeting sequences by TEM. Gold 
nanoparticles that were synthesized by reducing tetrachloroaurate ions with citric acid and 
subsequent exchange by peptides showed aggregation. Aggregation occurred due to the 
physicochemical properties of the MLS and the MPP that were abundant of basic amino 
acids which could lead to aggregation of gold nanoparticles during exchange reactions [12]. 
Therefore, gold nanoparticles were synthesized by reduction of tetrachloroaurate ions with 
HEPES in the presence of the cysteine-containing MLS or MPP. Figure 7.7 showed 
preparations that contained different concentrations of the MLS. The solution without MLS 
appeared black which indicated that large gold aggregates were formed due to the absence 
of a stabilizer. Peptide containing solutions appeared violet which indicated that gold 
nanoparticles were present. 
 
Figure 7.7: Gold nanoparticle solutions, 1 with 0 mM MLS, 3 with 0.45 mM MLS, 4 with 0.6 mM MLS and 5 with 
0.75 mM MLS. 
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Figure 7.8 showed UV-spectra and PCS data of gold nanoparticles that were modified with 
0.45 mM MLS. Only preparations that were modified with 0.45 mM or 0.6 mM MLS showed 
plasmon resonance in the UV-spectra and hence, formed gold nanoparticles. Concentrations 
of 0.075 mM, 0.15 mM, 0.225 mM and 0.3 mM were apparently too low whereas a 
concentration of 0.75 mM MLS was too high. These concentrations did not show the typical 
violet color and plasmon resonance in the UV-spectra. Figure 7.8 also showed that a longer 
incubation time did not lead to aggregation of the gold nanoparticles but rather led to a higher 
concentration of gold nanoparticles as reflected by a higher absorption compared to an 
incubation time of 18 h. 
 
Figure 7.8: UV-spectra of MLS-conjugated gold nanoparticles (AuNP) with 0.45 mM MLS 18 h (left graph) and 42 
h (right graph) after HEPES-reduction. 
 
Figure 7.9 showed gold nanoparticles with 0.45 mM MLS after purification. The size of the 
gold nanoparticles increased to 40-50 nm but was stable over time.  
 
Figure 7.9: UV-spectra of purified MLS-conjugated gold nanoparticles (AuNP) with 0.45 mM MLS after HEPES-
reduction (left graph) and citrate reduced blank gold nanoparticles (right graph). 
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The zetapotential of the MLS-modified gold nanoparticles was 47 mV compared to -40 mV of 
unmodified gold nanoparticles which indicated that the positively charged MLS capped the 
gold nanoparticles. Preparations with 0.6 mM MLS formed gold nanoparticles but showed 
aggregation over time. Hence, 0.45 mM MLS capped gold nanoparticles were used for TEM 
studies.  
Preparations with 0.3 mM and 0.6 mM MPP formed larger gold nanoparticles that showed a 
plasmon resonance at higher wave lengths compared to MLS-modified gold nanoparticles. 
MPP-modified gold nanoparticles could not be purified and showed aggregation over time. 
 
Figure 7.10: UV-spectra of MPP-conjugated gold nanoparticles (AuNP) with 0.3 mM MPP (left graph)  and 0.6 
mM MPP (right graph) after HEPES-reduction. 
 
Therefore, only MLS-modified gold nanoparticles were investigated by TEM in comparison to 
unmodified gold nanoparticles that were synthesized by citric acid reduction (Figure 7.9). The 
concentration of gold nanoparticles that was used for the TEM studies was 3.34 pM, 
determined according to Haiss et al. [16]. 
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Figure 7.11 showed gold nanoparticles modified with 0.45 mM MLS in mitochondria 
suspensions but they were not detected in proximity to isolated mitochondria. 
 
 
 
Figure 7.11: TEM images of the binding of MLS-modified gold nanoparticels to isolated mitochondria, 12000x 
magnification on the upper left image, 20000x magnification on the lower left image and 30000x magnification on 
the lower right image. MLS-modified gold nanoparticles are indicated by red arrows. 
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Figure 7.12 showed unmodified gold nanoparticles that were also not detected in proximity to 
isolated mitochondria. 
  
Figure 7.12: TEM images of the binding of unmodified gold nanoparticels to isolated mitochondria, 12000x 
magnification on the left image and 20000x magnification on the right image. Gold nanoparticles are indicated by 
red arrows. 
 
As it was not possible to produce MPP-modified gold nanoparticles, the binding properties of 
a MPP modified 40 kDa 8arm PEG were investigated by additional labeling with BODIPY® 
that oxidized diaminobenzidine to an insoluble polymer in a photooxidation procedure. The 
insoluble polymer could be stained by osmium tetroxide and appeared in black in TEM 
analysis. Figure 7.13 showed a TEM images of an isolated mitochondria preparation that 
was mixed with the MPP- and BODIPY®-modified 8arm PEG. The black photooxidation 
product was not visible compared to images that did not contain black photooxidation 
products. Maybe the photooxidation products were distributed all over the samples and did 
not accumulate at specific sites. 
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Figure 7.13: TEM images of the binding of MPP-conjugated 40 kDa 8arm PEG labeled with BODIPY
®
 (left image) 
and β-mercaptoethanol-conjugated 40 kDa 8arm PEG labeled with BODIPY
®
 (right image) to isolated 
mitochondria after photooxidation  with DAB, 12000x magnification. Intact isolated mitochondria are indicated by 
red arrows. 
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7.4 Conclusions 
It was not possible to evaluate the binding properties of the mitochondrial targeting peptides 
MLS and MPP by the applied methods. Quantum dots, modified and not modified, bound to 
cell fragments and isolated mitochondria, and it was not possible to distinguish between non-
specific and specific binding mediated by mitochondrial targeting peptides. Fluorescent dyes 
were also not suitable: TAMRA accumulated in mitochondria even without modification due 
to the positive charge of the molecule and BODIPY® stained isolated mitochondria and cell 
fragments non-specifically without modification. MLS-modified gold nanoparticles were 
successfully synthesized by a HEPES reduction method but binding to isolated mitochondria 
could not be detected in a TEM study. The binding of a MPP- and BODIPY®-modified 8arm 
PEG could also not be detected by TEM after photooxidation. 
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This thesis was focused on mitochondria as an intracellular target for drug delivery by the 
reason that mitochondria are becoming of increasing interest in pharmaceutical and medical 
research due to their contribution to several diseases (Chapter 1).  
A protocol for the quick isolation of mitochondria from cultured cells and several methods for 
the characterization of isolated mitochondria were established. Integrity and functionality of 
the mitochondrial preparations were demonstrated by a membrane integrity assay, the 
Cytochrome C Oxidase assay, by staining with a potential sensitive dye, JC-1, and by the 
analysis of mitochondrial ultrastructure by transmission electron microscopy (Chapter 2).  
Additionally, a method for the monitoring of long time functionality of isolated mitochondria in 
terms of their oxygen consumption was established. Typical features of this method included 
the need of only a few microliters of isolated mitochondria and the possibility of using 
microplate sensor technology that allowed for the high throughput screening of large sample 
numbers (Chapter 3).  
Furthermore, several methods to label isolated mitochondria were investigated. Labeling with 
fluorescent dyes was a quick and comfortable method but it was not applicable in further 
studies as the dyes washed out. Therefore, intact cells were transfected with mitochondria 
targeted green or red fluorescent proteins to label mitochondria permanently and to make 
them accessible for fluorescence based analytical methods (Chapter 4). 
To approach the main idea of this thesis, the targeting of mitochondria with nanomaterials by 
utilization of the mitochondrial fusion process, protocols to accomplish and detect fusion of 
isolated mitochondria in vitro were established. Mitochondrial fusion in vitro was detected 
qualitatively by confocal laser scanning microscopy that revealed completely fused 
mitochondria with mixed matrices due to the merged colors of the fluorescent proteins and by 
transmission electron microscopy that revealed fusion intermediates of mitochondria with 
distinct inner membranes and fused outer membranes. Additionally, a protocol for the 
quantitative evaluation and calculation of mitochondrial fusion efficiency based on flow 
cytometry was established. Flow cytometry disclosed several advantages such as the 
capability for high throughput analysis, the possibility to analyze highly diluted samples that 
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did not consume large amounts of isolated mitochondria and an even higher number of 
mitochondria that could be investigated compared to microscopy techniques that would 
accompany with time consuming counting of a comparatively low number of mitochondria 
(Chapter 5). 
One goal of this thesis was to combine targeting strategies by using specific mitochondrial 
targeting peptides and nanomaterials, and to utilize mitochondrial fusion to accomplish an 
uptake of these nanomaterials into mitochondria or to influence on mitochondrial fusion in 
vitro by these mitochondria targeted nanomaterials. To influence on mitochondrial fusion in 
vitro with nanomaterials and mitochondria-specific targeting peptides, several polymers such 
as 8arm PEGs and a polyetheramine, and nanocarriers such as dendrimers and quantum 
dots were conjugated to mitochondrial targeting peptides that were known to be recognized 
by mitochondria, in particular by recognition of the mitochondrial protein import pores. 
Mitochondrial fusion efficiency in vitro was determined by the previously described protocols 
based on confocal laser scanning microscopy, transmission electron microscopy and flow 
cytometry. Thereby, a natural mitochondrial targeting sequence (MLS) and a synthetic 
mitochondria penetrating peptide (MPP) were investigated. Additionally, mitochondrial fusion 
was affected unspecifically by highly concentrated polymer solutions. It was shown that 
mitochondrial fusion could be enhanced by unspecific and specific approaches. PEG 1500 at 
a concentration of 50 % was the most effective additive for unspecific enhancement of 
mitochondrial fusion in vitro by dehydration. PEGs with higher molecular weights were not 
more effective. The MPP modified 8arm PEGs, dendrimers and the polyetheramine 
Jeffamine® were effective additives for specific enhancement of mitochondrial fusion in vitro. 
MPP modified 8arm PEGs at a concentration of 1 mM were the most effective enhancer of 
mitochondrial fusion in vitro. It emerged that carriers with the natural MLS did not enhance 
mitochondrial fusion efficiency (Chapter 6).  
Due to the results of affecting mitochondrial fusion efficiency in vitro, the binding behavior of 
the mitochondrial targeting peptides MLS and MPP to isolated mitochondria was 
investigated. Therefore, quantum dots and fluorescent dyes were coupled to the targeting 
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peptides and the binding to isolated mitochondria was determined by flow cytometry. It was 
not possible to evaluate the binding properties of the mitochondrial targeting peptides MLS 
and MPP as quantum dots, modified and not modified, bound to cell fragments and isolated 
mitochondria. Thereby, it was not possible to distinguish between non-specific and specific 
binding mediated by mitochondrial targeting peptides. The fluorescent dyes TAMRA and 
BODIPY®, coupled to the MLS, were also not suitable as TAMRA accumulated in 
mitochondria even without modification due to the positive charge of the molecule and 
BODIPY® stained isolated mitochondria and cell fragments non-specifically without 
modification. Therefore, MLS capped gold nanoparticles were synthesized for a transmission 
electron microscopy study. MLS-modified gold nanoparticles were successfully synthesized 
by a HEPES reduction method instead of the conventional method of citric acid exchange. 
The binding of these MLS-capped gold nanoparticles to isolated mitochondria could not be 
detected in a TEM study. The binding behavior of the MPP was determined by a 
photoconversion method in transmission electron microscopy using an 8armPEG modified 
with MPP and the fluorescent dye BODIPY®. The binding of the MPP- and BODIPY®-
modified 8arm PEG to isolated mitochondria could also not be detected (Chapter 7). 
Even due to the fact that mitochondria are of increasing interest in pharmaceutical and 
medical research as mitochondrial dysfunction contributes to several severe diseases and 
even though they exhibit a lot of potential targets, mitochondrial drug delivery and drug 
targeting is challenging and still at an early stage. Several barriers have to be crossed to 
achieve a selective targeting and accumulation in mitochondria and there is a need for 
suitable analytical methods to ensure that applied mitochondrial targeting strategies were 
successful. Then, it would eventually be possible to verify one goal of this thesis, the uptake 
of mitochondria targeted nanomaterials into mitochondria by mitochondrial fusion. 
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Abbreviations 
1H-NMR .................. proton nuclear magnetic resonance 
8arm PEG .............. 8arm poly(ethylene glycol) 
ADP ........................ adenosine diphoshate 
AEQ ....................... aequorin 
ANOVA .................. analysis of variance 
ATP ........................ adenosine triphosphate 
AuNP ...................... gold nanoparticle 
b-ME ...................... β-mercaptoethanol 
bp ........................... base pair 
BSA ........................ bovine serum albumin 
CcO ........................ cytochrome c oxidase 
CHO-K1.................. chinese hamster ovarian cell line K1 
CLSM ..................... confocal laser scanning microscopy 
CoxIV ..................... cytochrome c oxidase subunit IV 
CsA ........................ cyclosporin A 
CT .......................... computed tomography 
Cys ......................... cysteine 
DMSO .................... dimethyl sulfoxide 
DNA ....................... deoxyribonucleic acid 
DOPE ..................... 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOTAP ................... dioleoyl-1,2-diacyl-3-trimethylammoniumpropane 
DQA ....................... dequalinium 
Drp1 ....................... dynamin-related protein 1 
dsRed ..................... discosoma red fluorescent protein 
E.coli ...................... Escherichia coli 
EDTA ..................... ethylenediaminetetraacetic acid 
EEG ....................... electroencephalography 
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EMG ....................... electromyography 
EPR ........................ enhanced permeability and retention effect 
FCCP ..................... carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
FCS ........................ fetal calf serum 
Fe-S ....................... iron-sulfide 
FRAP ..................... fluorescence recovery after photobleaching 
FRET ...................... Förster (fluorescence) resonance energy transfer 
FS .......................... freeze substitution 
GFP ........................ green fluorescent protein  
GPCR ..................... G-protein coupled receptor 
GSH ....................... glutathione 
GSSG ..................... glutathione disulfide  
GTP ........................ guanosine triphosphate 
HEPES ................... 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid 
HPF ........................ high pressure freezing 
HR1, 2 .................... heptad repeat region 1, 2 
JC-1 ....................... 5,5′,6,6′-tetrachloro-1,1′,3,3′tetraethylbenzimidazolylcarbocyanine iodide 
LL ........................... lower left quadrant 
LR .......................... lower right quadrant 
MCS ....................... multiple cloning site 
MEND .................... multifunctional envelope-type nano-device 
Mfn 1, 2 .................. mitofusin 1, 2 
mitoKATP ................. mitochondrial potassium channel 
MLS ........................ mitochondrial localization sequence 
MPP ....................... mitochondrial penetrating peptide 
mPTPC .................. mitochondria permeability transition pore complex 
MRI ........................ magnetic resonance imaging 
mRNA .................... messenger RNA 
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mtDNA ................... mitochondrial DNA  
mtGFP .................... mitochondrial green fluorescent protein 
mtRFP .................... mitochondrial red fluorescent protein 
NAD+ ...................... nicotinamide adenine dinucleotide 
NCV ....................... nerve conduction velocity 
nDNA ..................... nuclear DNA 
NO.......................... nitroxide 
NPY ........................ neuropeptide Y 
NSAID .................... non-steroidal anti-inflammatory drug  
OPA1 ..................... optic atrophy type 1 
OXPHOS ................ oxidative phosphorylation 
PAMAM G4-G7 ...... poly(amidoamine) dendrimers generation 4-7 
PEI ......................... poly(ethyleneimine) 
PBR ........................ peripheral benzodiazepine receptor 
PBS ........................ phosphate buffered saline 
PCR ....................... polymerase chain reaction  
PCS ........................ photon correlation spectroscopy 
pDNA ..................... plasmid DNA 
PEG ....................... poly(ethylene glycol) 
pO2 ......................... oxygen partial pressure 
Qdots ..................... quantum dots 
RES ........................ reticuloendothelial system 
RFP ........................ red fluorescent protein 
RNA ....................... ribonucleic acid 
ROS ....................... reactive oxygen species 
rRNA ...................... ribosomal RNA 
tRNA ...................... transfer RNA 
SD .......................... standard deviation 
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Sir........................... silent information regulator protein, sirtuin 
siRNA ..................... small interfering RNA  
SOD ....................... superoxidedismutase  
SS-peptide ............. Szeto-Schiller-peptide 
STPP ...................... stearyl triphenyl phosponium  
sulfo-SMCC ............ 4-(N-Maleimidomethyl)cyclohexane-1-carboxylic acid 3-sulfo-N- 
  hydroxysuccinimide ester sodium salt 
TAMRA .................. tetramethylrhodamine 
TCEP ..................... Tris(2-carboxyethyl)phosphine hydrochloride 
TEM ....................... transmission electron microscopy 
TIM ......................... translocase of the inner mitochondrial membrane  
TOM ....................... translocase of the outer mitochondrial membrane 
TMAEC-Chol .......... trimethyl aminoethane carbamoyl cholesterol iodide 
TPP ........................ triphenylphosphonium 
Tris ......................... 2-Amino-2-(hydroxymethyl)-1,3-propanediol 
tRNA ...................... transfer RNA 
UL .......................... upper left quadrant 
UR .......................... upper right quadrant 
UV .......................... ultraviolett 
VDAC ..................... voltage dependent anion channel 
X-ray ...................... Röntgen radiation 
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MLS 
NH2-M-L-S-L-R-Q-S-I-R-F-F-K-P-A-T-R-T-C-COOH 
M (Met, methionine)   hydrophobic 
L (Leu, leucine)   hydrophobic 
S (Ser, serine)   hydrophilic 
L (Leu, leucine)   hydrophobic 
R (Arg, arginine)   basic 
Q (Gln, glutamine)   hydrophilic 
S (Ser, serine)   hydrophilic 
I (Ile, isoleucine)  hydrophobic 
R (Arg, arginine)   basic 
F (Phe, phenylalanine)   hydrophobic 
F (Phe, phenylalanine)   hydrophobic  
K (Lys, lysine)   basic 
P (Pro, proline)   hydrophobic 
A (Ala, alanine)   hydrophobic 
T (Thr, threonine)   hydrophilic 
R (Arg, arginine)   basic 
T (Thr, threonine)   hydrophilic 
C (Cys, cysteine)   nucleophilic 
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MPP 
NH2-L-Cha-dR-Cha-F-C-COOH 
L (Lys, lysine)   hydrophobic 
Cha (cyclohexylalanine)   hydrophobic 
dR (D-Arg, arginine)   basic 
Cha (cyclohexylalanine)   hydrophobic 
F (Phe, phenylalanine)   hydrophobic 
C (Cys, cysteine)   nucleophilic 
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